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Chronic kidney disease is an important public health problem worldwide. The prevalence of 
chronic kidney disease has been estimated around 13% in the United States and around 
10% in the Netherlands.1,2 A progressive loss in over a period of months or years leading to 
inadequate removal of fluid and waste products is characteristic for chronic kidney disease. 
The diagnosis of chronic kidney disease is often made in patients who are known to be at risk 
of kidney problems, such as those with hypertension or diabetes mellitus.3 
Chronic kidney disease is defined as persistent renal damage (detected by a renal biopsy or 
albuminuria) or a glomerular filtration rate below the 60 ml/min for three months or longer.4 The 
diagnosis of chronic kidney disease is irrespective of the underlying type of kidney disease 
and can be classified into five clinical stages according to the guidelines of the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) (Table 1).4 Patients 
with stage 5 chronic kidney disease are often considered for renal replacement therapy in 
the form of dialysis (hemodialysis or peritoneal dialysis) or transplantation. For hemodialysis, 
vascular access, i.e., a catheter, fistula or graft, is needed for dialysis. For peritoneal dialysis, 
a catheter is implanted in the abdominal cavity of the patient.
Table	1.	Classification	of	chronic	kidney	disease		






3 30-60 Not necessary for diagnosis
4 15-30 Not necessary for diagnosis
5 <15 Not necessary for diagnosis
1.1 Vascular complications in patients with kidney disease
Vascular complications such as arterial thrombosis (myocardial infarction or ischemic stroke), 
venous thrombosis (deep vein thrombosis or pulmonary embolism) and vascular access 
(fistula, graft or catheter) related complications in patients on hemodialysis are important 
threats for chronic kidney disease patients. Many hospitalizations and deaths in chronic 
kidney disease patients, especially in dialysis patients, are consequences of vascular related 
problems.5-11   
1.1.1 Venous and arterial thrombosis
Venous thrombosis is a collective term for deep vein thrombosis and pulmonary embolism, 










































thrombosis include immobilization, surgery, pregnancy, malignancy, hormone replacement 
therapy, oral contraceptive use and genetic risk factors (including factor V Leiden).12 Arterial 
thrombosis, including coronary heart disease and ischemic stroke, is mostly secondary to 
atherosclerosis due to hypertension, hyperlipidemia, diabetes, smoking and obesity.13 Chronic 
kidney disease is an established risk factor for arterial thrombosis.14-16 Until recently, it has 
been unclear whether chronic kidney disease also increases the risk of venous thrombosis. 
The Longitudinal Investigation of Thromboembolism Etiology (LITE) study was the first study 
that showed an increased risk of venous thrombosis for patients with a chronic kidney disease 
in individuals older than 45 years of age.17 
The LITE study focused on patients with stage 3 chronic kidney. However, studies that 
investigated the risk of venous thrombosis in the early stages of chronic kidney disease were 
lacking as well as studies that investigate the risk of venous and arterial thrombosis in dialysis 
patients. Furthermore, the association between kidney disease and venous thrombosis was 
not explained and no studies were available that investigated high-risk groups of patients with 
chronic kidney disease that may benefit from thromboprophylaxis.
1.1.2 Vascular accesses in patient on hemodialysis
Hemodialysis patients require vascular accesses for hemodialysis therapy. The options to gain 
vascular access are fistulas, grafts or catheters. While evidence from randomized-controlled 
trials is lacking, there is a broad consensus that fistulas and grafts are superior to central 
venous catheters. Catheter use for hemodialysis has been associated with increased risk of 
thrombotic complications,18,19 short access survival,19,20 and increased risk of infections.21-24 
Therefore, the National Kidney Foundation Kidney Disease Outcome Quality Initiative (NKF 
K/DOQI) guidelines25 recommend the use of fistulas or grafts instead of catheters for vascular 
access in hemodialysis patients. 
Despite this preference and recommendation for graft or fistula use instead of catheters, 
only few studies have investigated the association between catheter use and mortality in 
hemodialysis patients.27-29 Furthermore, a limited number of studies have investigated the 
association between fistula use versus graft use and mortality.29,30 
1.2 Objective and outline of this thesis
The main objective of this thesis was to investigate vascular complications in patients with 
kidney disease. Specifically, our aims were to:
•	 investigate the association between kidney disease and venous and arterial thrombosis












































•	 investigate the mortality risks for hemodialysis patients with catheter, fistula  or graft 
vascular accesses
•	 investigate the association between genetic risk factors for arterial and venous thrombosis 
and mortality in dialysis patients
These results may help to define new treatment strategies in the prevention of venous 
thrombosis and in the treatment of hemodialysis patients.
1.3 Clinical data used in this thesis
In this thesis, data from the MEGA (Multiple Environmental and Genetic Assessment of risk 
factors for venous thrombosis) study, the PREVEND (Prevention of Renal and Vascular 
Disease) study, the NECOSAD (Netherlands Cooperative Study on the Adequacy of Dialysis) 
study, the ERA-EDTA (European Renal Association-European Dialysis and Transplant 
Association) Registry, and the 4D (German Diabetes Dialysis) study were used.
1.3.1 MEGA study
The studies described in chapter 2, 4, and 5 are based on data collected from the MEGA 
study. The MEGA study is a large, population-based case-control study on risk factors for 
venous thrombosis. Between March 1999 and September 2004, consecutive patients aged 18 
to 70 years with a first objectively confirmed episode of deep venous thrombosis or pulmonary 
embolism were included from six participating anticoagulation clinics in the Netherlands. As 
control persons, initially partners of patients aged <70 years without venous thrombosis were 
included. Later on persons without venous thrombosis were approached via a random-digit-
dialing method.
In chapter 2, we investigated the risk of venous thrombosis for several self-reported major 
illnesses, including kidney disease, liver disease, rheumatoid arthritis, multiple sclerosis, heart 
failure, hemorrhagic stroke, and arterial thrombosis. In chapter 4, we investigated whether 
the association between kidney disease and venous thrombosis could be explained by body 
mass index, immobilization, surgery, corticosteroid use, diabetes mellitus, malignancy, arterial 
disorders, factor V Leiden, prothrombin G20210A, and coagulation factor levels. Based on 
our studies in chapter 2 and 3 in which we found an increased risk of venous thrombosis in 
kidney disease patients, we set out to identify kidney disease patients who were at high risk of 
venous thrombosis. Therefore, in chapter 5, we investigated joint effects of decreased kidney 
function with one or more other risk factors for thrombosis to identify high-risk groups that may 











































For the study described in chapter 3, we collaborated with the Prevention of Renal and 
Vascular Disease (PREVEND) study group from the University Medical Center Groningen. The 
PREVEND study is a prospective cohort study in which all inhabitants of the city of Groningen, 
The Netherlands, aged 28–75 years (n = 85 421) were invited to send a morning urine sample 
to be screened for albuminuria. Of the responders, the PREVEND cohort was selected and 
tested for renal function and proteinuria in 24-hours urine samples. The study participants (n 
= 8 495) were followed for the occurrence of several outcomes, including venous thrombosis. 
In the PREVEND cohort, we determined the absolute and relative risks of venous thrombosis 
for patients with chronic kidney disease stages 1, 2, and 3.
1.3.3 NECOSAD study
For the studies described in chapters 6, 8, 9 and 10, we used data from the NECOSAD study. 
The NECOSAD is a prospective multicenter cohort study in which incident adult end-stage 
renal disease patients in the Netherlands were included from 38 dialysis centers. Outcome 
measures used in our study were patency loss, venous and arterial thrombosis, and death.  
Chapters 2, 3 and 5 focused on the risk of venous thrombosis in kidney disease patients in 
earlier stages. In chapter 6, we explored the risk of venous and arterial thrombosis associated 
with dialysis. To that end, we assessed the absolute risk of deep vein thrombosis, pulmonary 
embolism, myocardial infarction and ischemic stroke in a cohort of end-stage renal disease 
patients receiving dialysis treatment. 
In chapter 8, we investigated death risks in hemodialysis patients comparing catheter use with 
arteriovenous access use. In chapter 9, we compared patency loss and mortality between 
graft users and fistula users.
In the previous studies, we showed that dialysis patients were at increased risk of vascular 
access complications, and of venous and arterial thrombosis. Therefore, in chapter 10, we 
investigated whether polymorphisms in genes within the protein C pathway, which plays an 
important role in endothelial barrier function, anticoagulant processes and thrombosis, were 
associated with mortality in dialysis patients.
1.3.4 4D-study
For independent replication of the results of the NECOSAD study in chapter 10, we 
collaborated with the 4D-study group. The 4D-study was a double-blind, randomized trial 
on the effect of atorvastatin in hemodialysis patients with type 2 diabetes mellitus who had 











































a composite of cardiac death, non-fatal myocardial infarction and stroke, whichever occurred 
first. Patients were randomly assigned to either 20 mg of atorvastatin or placebo once daily 
until the date of death, censoring, or the end of study in March 2004.
1.3.5 ERA-EDTA Registry
For the study described in chapter 7, we collaborated with the ERA-EDTA Registry. The ERA-
EDTA Registry collects data on renal replacement therapy, including date of birth, sex, primary 
kidney disease, date of start of renal replacement therapy, dialysis modality at baseline and 
during follow-up, and date and cause of death. We used a cohort of dialysis patients from 11 
European countries: Austria, Belgium, Denmark, Finland, Greece, Iceland, Calabria (Italy), 
the Netherlands, Norway, Sweden and the autonomous communities of Andalusia, Asturias, 
Basque country, Catalonia, Castile-La Mancha, Castile and Leon, Extremadura, and Valencian 
region in Spain.
In chapter 7, we assessed the rates of death from myocardial infarction, stroke, and pulmonary 
embolism in an ERA EDTA cohort of incident dialysis patients and compared them with those 
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Background: The risk of venous thrombosis associated with major illnesses is not well 
known, as is the combined effect of immobilization, and thrombophilia. The aim of this study 
was to assess the effect on the development of venous thrombosis of several major illnesses 
in combination with immobilization, BMI, and thrombophilia to identify high-risk groups that 
may provide a basis for personalized prevention. 
Methods: This study included 4311 consecutive patients with a first episode of venous 
thrombosis and 5768 controls from a case-control study (MEGA study). We calculated odds 
ratios (ORs) for venous thrombosis for patients with a self-reported history of major illnesses. 
Results: Venous thrombosis risk was increased for all investigated major illnesses: liver 
disease (OR) 1.7 (95%CI 1.0-2.9), kidney disease 3.7 (95%CI 2.3-5.9), rheumatoid arthritis 
1.5 (95%CI 1.2-1.9), multiple sclerosis 2.4 (95%CI 1.3-4.3), heart failure 1.7 (95%CI 1.2-2.3), 
hemorrhagic stroke 4.9 (95%CI 2.4-9.9), arterial thrombosis 1.5 (95%CI 1.2-1.8), and in the 
presence of any of the above major illnesses 1.7 (95%CI 1.5-1.9). Combinations of major 
illnesses with immobilization and increased factor VIII (odds ratio 79.9; 95%CI 33.2-192.2), 
increased factor IX (35.3; 95%CI 14.2-87.8), increased von Willebrand factor (88.0; 95%CI 
33.9-228.3), factor V Leiden (84.2; 95%CI 19.5-363.6), and blood group non-O (53.1; 95%CI 
30.9-91.4) were associated with increased venous thrombosis risks.
Conclusion: All major illnesses reported here were associated with an increased risk of 













































Venous thrombosis occurs in 1-2 per 1000 persons annually.1 Although venous thrombosis is 
a preventable disease, only a few provoking risk factors, such as surgery and hospitalization, 
are currently considered harmful enough to warrant prophylactic measures.2 
A number of studies have reported on the risk of venous thrombosis in patients with a history 
of major illnesses including liver disease,3-5 kidney disease,6-9 rheumatoid arthritis,4,10 multiple 
sclerosis,11 heart failure,4,12,13 hemorrhagic stroke,14 and arterial thrombosis.4,15-18 Some of these 
studies found a positive association between major illnesses and venous thrombosis,4-15,18 
whereas other studies did not.3,16,17 The use of different definitions of major illnesses, together 
with variation in the studied populations, may explain this discrepancy. Studies on the 
association between kidney disease and venous thrombosis,6-9 however, found consistent 
increased risks of venous thrombosis ranging from a 1.3-fold increased risk for patients with 
a mildly decreased kidney function9 to an 8-fold in increased risk for patients with a nephrotic 
syndrome.6 Even if these major illnesses were to be considered as risk factors for venous 
thrombosis, the risk may not be sufficiently high to justify the use of prophylaxis in all these 
situations, due to the increased risk of bleeding associated with most prophylactic measures 
(i.e. anticoagulant therapy).19 The risk-benefit ratio may favor the use of such prophylactic 
measures only in persons at particularly increased risk of venous thrombosis. Patients with a 
major illness in combination with other risk factors, like immobilization or thrombophilia, who 
have high risks of venous thrombosis could benefit from prophylaxis during periods of high 
risks. Thus far, no studies have reported on the risk for venous thrombosis in persons with 
such combinations of prothrombotic conditions. Nor are there studies available that calculated 
the risk for venous thrombosis in patients with a major illness who are immobilized or have a 
genetic or acquired thrombophilia, such as factor (F) V Leiden or elevated levels of factor (F) 
VIII. 
The aim of our study was to investigate the association between major illnesses (liver disease, 
kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, and 
arterial thrombosis) and risk of venous thrombosis.
METHODS
Study design
The MEGA study (Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis study) is a large case-control study on risk factors for venous thrombosis, of which 










































2004, consecutive patients aged 18 to 70 years with a first objectively confirmed episode 
of deep venous thrombosis or pulmonary embolism were included from six participating 
anticoagulation clinics in the Netherlands. Information on the diagnostic procedure was 
obtained from hospital records and general practitioners.
 
Patients
Only patients with a diagnosis of venous thrombosis that was confirmed with objective 
techniques were included in the analyses.20,21 Exclusion criteria were severe psychiatric 
problems and inability to speak Dutch. Of the 6567 eligible patients, 5184 participated (79%). 
For the present analysis, questionnaire data on major illnesses were available from 4311 
patients and 5768 controls, after exclusion of patients with a deep vein thrombosis of the arm 
(n=227). 
Controls
As control persons, partners of patients aged <70 years without venous thrombosis were 
included, as well as persons without venous thrombosis obtained via a random-digit-dialing 
(RDD) method. Of the 5184 participating patients, 3735 had an eligible partner. Of the 3735 
eligible partners, 2979 participated (80%) and completed a questionnaire including questions 
about the presence of major illnesses. The RDD control persons were recruited from the same 
geographical area as the patients, and were frequency matched to the patients on age and 
sex. Of the 4350 eligible random controls, four died before they were able to participate. Of the 
remaining 4346 individuals, 3000 participated (69%). Of the nonparticipants, 15 were in the 
end stage of disease and 1331 refused to participate or could not be located. A questionnaire 
was returned by 2789 of the participating random controls. This resulted in a total of 5768 
control persons without venous thrombosis. 
Data collection
All persons were asked to complete an extensive questionnaire on many potential risk 
factors for venous thrombosis. Of particular interest for this study question are items on 
general health characteristics (age, sex, body weight, height, and immobilization (defined as 
bedridden at home for at least 4 days, hospitalization, or surgery within three months prior to 
the index date)). Body mass index was calculated by dividing self-reported body weight (kg) 
by squared self-reported height (m2). The index date was the date of the thrombotic event 
for patients and their partners, and the date of filling in the questionnaire for the random 
controls. The questionnaire also included questions about the presence of liver disease, 
kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, and 
arterial thrombosis (myocardial infarction, angina, ischemic stroke, transient ischemic attack, 












































Approximately 3 months after discontinuation of oral anticoagulant therapy, patients and 
their partners were invited for collection of a blood sample. In patients who were still on 
anticoagulant therapy 1 year after their event, blood was drawn during anticoagulant therapy. 
All assays were performed by automated coagulation assays by laboratory technicians who 
were unaware of the case-control status of the samples. For logistic reasons, blood sampling 
was performed for patients up to June 2002; after this date only DNA was collected via buccal 
swabs. Plasma samples were available for 2134 of 4311 (50%) cases and 2812 of 5768 (49%) 
control persons. Since we stopped taking blood after June 2002 for logistic reasons only, this 
could not have introduced bias. FVIII activity was measured with a mechanical clot detection 
method on a STA-R coagulation analyzer following the instructions of the manufacturer 
(Diagnostica Stago, Asnieres, France). Levels of FIX antigen were determined by enzyme-
linked immunosorbent assay (ELISA). Von Willebrand factor (VWF) antigen was measured 
with the immunoturbidimetric method, using the STA Liatest kit (rabbit anti–human VWF 
antibodies), following the instructions of the manufacturer (Diagnostica Stago).21,22 The mean 
intra-assay and inter-assay coefficients of variation were 3.7% and 8.9% for factor VIII activity 
levels, respectively, 4.3% and 2.7% for factor IX antigen levels,  respectively,  and 3.6% and 
2.6% for von Willebrand factor antigen levels, respectively.
DNA samples were available for 3957 of 4311 (92%) cases and 4680 of 5768 (81%) control 
persons. Common genetic risk factors were assessed, including the FV Leiden mutation and 
ABO-blood group, by polymerase chain reactions using the TaqMan assay.21 To genotype ABO-
blood group, we determined the 20146G/- (rs8176719), 21463C/G (rs7853989), 21867A/G 
(rs8176749), and 21996C/- (rs8176750) blood group polymorphisms by a 5’nuclease assay 
(Taqman; Applied Biosystems, Foster City, CA, USA) using a standard PCR reaction mix 
(Eurogentec, Seraing, Belgium) and an allele-specific fluorescent probe equipped with a 
minorgroove binding moiety (Applied Biosystems). FV Leiden and blood group non-O, and 
increased levels of VWF, FVIII, and FIX were specifically chosen as thrombophilic conditions, 
because these are either prevalent genetic risk factors, or coagulation factors associated with 
highest venous thrombosis risks.23
Statistical analysis
To determine whether the presence of one or more major illnesses was associated with an 
increased risk for venous thrombosis as compared with persons without a major illness, odds 
ratios with 95% confidence intervals (95% CIs) adjusted for age and sex (the matching factors) 
were calculated. We made cut-off points for FVIII (155 IU/dL), FIX (119 IU/dL), and VWF levels 
(142 IU/dL) that correspond with the 80th percentiles in the control population. Persons who 










































of the effect of vitamin K–dependent coagulation FIX. Odds ratios for venous thrombosis 
were calculated for the combination of major illness and immobilization, increased body mass 
index (≥25 kg/m2), or thrombophilia (FV Leiden, non-O blood group, and elevated levels of 
FVIII, FIX, and VWF) to identify high-risk groups that could benefit from thromboprophylaxis. 
Addressing the causal relation between major illness and risk of venous thrombosis was not 
the aim of this study.22 Therefore, we only adjusted for the matching factors, i.e. age and sex.24 
Malignancy was not considered as a major illness as a previous report of the MEGA study 
already published about malignancy and risk of venous thrombosis.21 Statistical analyses 




4311 patients with venous thrombosis and 5768 control persons without venous thrombosis 
were included in the current analysis. Table 1 shows the general characteristics of the study 
population. Of the patients, 2477 (57%) had a deep vein thrombosis of the leg only, and 
1834 (43%) had a pulmonary embolism with or without deep vein thrombosis. Patients, as 
expected, had a higher BMI, were more often immobilized, were more likely to have FV Leiden 
and non-O blood group, and had higher levels of coagulation factors than control persons.
Odds ratios for venous thrombosis
Odds ratios for venous thrombosis associated with major illnesses all pointed in the same 
direction and were of similar magnitude, regardless of whether partners or RDD control persons 
were used as the control group (Table 2). Therefore, we combined these control groups for 
the further analyses. The prevalence of a history of a major illness was 14% in patients and 
8% in controls. Presence of liver disease (odds ratio 1.7; 95% CI 1.0-2.9), rheumatoid arthritis 
(odds ratio 1.5; 95% CI 1.2-1.9), heart failure (odds ratio 1.7; 95% CI 1.2-2.3), and arterial 
thrombosis (odds ratio 1.5; 95% CI 1.2-1.8) were associated with an increased risk of venous 
thrombosis after adjustment for age and sex. Kidney disease (odds ratio 3.7; 95% CI 2.3-5.9), 
history of hemorrhagic stroke (odds ratio 4.9; 95% CI 2.4-9.9), and multiple sclerosis (odds 
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Odds ratios for deep vein thrombosis and pulmonary embolism
As shown by the point estimates, the odds ratios for deep vein thrombosis alone were higher 
than the odds ratios for pulmonary embolism with or without deep vein thrombosis in patients 
with liver disease and multiple sclerosis. All other major illnesses yielded a similar or lower 
odds ratio for deep vein thrombosis alone than for pulmonary embolism with or without deep 
vein thrombosis. 
Combined major illnesses
The odds ratio of venous thrombosis was 2.2 (95% CI 1.5-3.1) in the presence of two or more 
major illnesses and was 1.6 (95% CI 1.4-1.8) in the presence of only one major illness as 
compared to the absence of a major illness.
Immobilization, body mass index and thrombophilia
In Table 3, the combined effects of immobilization, increased body mass index (≥25 kg/m2) or 
thrombophilia with major illnesses on venous thrombotic risk are shown. The odds ratio for 
immobilization in the absence of major illnesses was 6.2 (95% CI 5.4-7.0). The combination 
of immobilization with a major illness yielded an odds ratio of 10.4 (95% CI 7.5-14.4). 
Participants with liver disease, kidney disease, rheumatoid arthritis, and arterial thrombosis 
had odds ratios in combination with immobilization of 8.3 (95% CI 2.8-24.4), 31.7 (95% CI 
7.6-132.1), 11.7 (95% CI 5.8-23.6) and 11.6 (95% CI 7.1-19.2), respectively. The odds ratio of 
venous thrombosis for a major illness was 2.3 (95% CI 1.9-2.9) in the absence of an increased 
body mass index and 2.3 (95% CI 2.0-2.8) in the presence of an increased body mass index. 
The odds ratio of venous thrombosis for a major illness was 1.7 (95% CI 1.5-2.0) without FV 
Leiden and 4.0 (95% CI 2.5-6.5) in FV Leiden carriers. The odds ratio of venous thrombosis 
for a major illness in the presence of blood group non-O was 3.3 (95% CI 2.7-4.0) and the 
odds ratio in the absence of blood group non-O was 1.9 (95% CI 1.5-2.4). A major illness 
combined with a normal level of FVIII, FIX, or VWF led to odds ratios of 1.6 (95% 1.2-2.1), 1.4 
(95% 1.1-1.8), and 1.6 (95% 1.2-2.0), respectively. These odds ratios were 5.5 (95% CI 4.1-
7.3), 2.3 (95% CI 1.7-3.2), and 5.4 (95% CI 4.1-7.3) in the presence of elevated levels of FVIII, 
FIX, or VWF, respectively. Participants with multiple sclerosis in combination with increased 
FVIII levels had a high risk of venous thrombosis (odds ratio 12.5; 95% CI 1.5-107.9), as did 
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Combinations of a major illness with immobilization and increased FVIII levels (odds ratio 
79.9; 95% CI 33.2-192.2), increased FIX levels (odds ratio 35.3; 95% CI 14.2-87.8), increased 
VWF levels (odds ratio 88.0; 95% CI 33.9-228.3), FV Leiden (odds ratio 84.2; 95% CI 19.5-
363.6), and blood group non-O (odds ratio 53.1; 95% CI 30.9-91.4) were associated with the 
highest venous thrombosis risks (Table 4). 
Table 4. Odds ratios for venous thrombosis for combinations of risk factors
Major illness Immobilization Thrombophilia* Age and sex adjusted 
odds	ratio	(95%	CI)	
No major illness No immobilization No Thrombophilia 1 (ref)
Any major illness + immobilization No Thrombophilia 10.9 (4.2-28.2)
Any major illness + immobilization + increased FVIII levels 79.9 (33.2-192.2) 
Any major illness + immobilization + increased FIX levels 35.3 (14.2-87.8)
Any major illness + immobilization + increased VWF levels 88.0 (33.9-228.3)
Any major illness + immobilization + factor V Leiden 84.2 (19.5-363.6)
Any major illness + immobilization + blood group non-O 53.1 (30.9-91.4)
*No thrombophilia defined as the absence of increased FVIII levels (>155 IU/dL), increased FIX levels 
(>119 IU/dL), increased VWF levels (>142 IU/dL), factor V Leiden, and blood group non-O.   
DISCUSSION
In this large case-control study, major illnesses were associated with an overall 1.7-fold (95% 
CI 1.5-1.9) increased risk of venous thrombosis, varying from a 1.4-fold increased risk for a 
history of ischemic stroke, transient ischemic attacks and peripheral vascular disease to a 
4.9-fold increased risk for hemorrhagic stroke. Overall, odds ratios were slightly higher for 
pulmonary embolism with or without deep vein thrombosis than for deep vein thrombosis 
alone. Major illnesses were associated with higher risks of venous thrombosis when the 
patient was additionally immobilized and had thrombophilia. This was not the case for the 
combination of a major illness with an increased body mass index.  
The reason for performing this study was to explore whether risk groups could be identified that 
would benefit from targeted prevention of venous thrombosis with pharmacological agents. 
Therefore, we were not interested in the causal relation between major illnesses and venous 
thrombosis, i.e. we did not adjust for potential confounding factors. From a prediction point of 
view, it is not important whether a major illness has a causal relation with venous thrombosis, 
since these patients could be targeted for thromboprophylaxis if there is a high risk of venous 










































On the whole, based on the point estimates, our study suggests that the risk of venous 
thrombosis was increased when more major illnesses were present or when a major illness was 
present in combination with immobilization and thrombophilia. This is in line with the concept 
of venous thrombosis as a multicausal disease.25 The presence of more major illnesses could 
have increased coagulation factor levels in MEGA participants. In addition, immobilization may 
be a good marker for severity of disease. As we had no information on disease severity, we 
could not investigate whether the underlying major illness itself, or immobilization associated 
with major illness, increased the risk of venous thrombosis. However, for prediction of high-
risk groups, the causal path leading to venous thrombosis is not important as, either way, 
preventive measures can be initiated when the risk is deemed to outweigh the side-effects. 
Overall, our study suggests that many major illnesses in association with immobilization 
increase the risk of venous thrombosis. 
That the risk for venous thrombosis was higher in participants with a history of hemorrhagic 
stroke (odds ratio 4.9; 95% CI 2.4-9.9) than in participants with a history of ischemic stroke 
(odds ratio 1.4; 95% CI 0.9-2.3) deserves additional comment. This finding might represent 
the less frequent use of thromboprophylaxis in patients with hemorrhagic stroke. In most 
epidemiological studies, hemorrhagic and ischemic stroke are combined.4,18 However, one 
other study also found an higher risk of venous thrombosis in patients with hemorrhagic stroke 
than in patients with ischemic stroke.14
We defined immobilization as being bedridden at home for at least 4 days, being hospitalized, 
or having surgery within three months prior to the index date. We found high odds ratios 
for venous thrombosis for immobilization in combination with liver disease (odds ratio 8.3; 
95% CI 2.8-24.4), kidney disease (odds ratio 31.7; 95% CI 7.6-132.1), rheumatoid arthritis 
(odds ratio 11.7; 95% CI 5.8-23.6) and arterial thrombosis (odds ratio 11.6; 95% CI 7.1-19.2). 
ACCP guidelines currently do not consider thromboprophylaxis for immobilized patients with 
these conditions. If other studies confirm our new findings, intervention trials for weighing the 
benefits and risks of thromboprophylaxis are recommended for these high-risk groups with a 
major illness. 
It is important to note that the baseline risk of venous thrombosis in absence of immobilization 
is low (less than 1.4 per 1000 persons per year).7 Therefore odds ratios of 2.1 (for kidney 
disease in the absence of immobilization), 2.5 (for multiple sclerosis in the absence of 
immobilization), 1.7 (for heart failure in the absence of immobilization), 3.3 (for hemorrhagic 
stroke in the absence of immobilization), and 1.2 (for arterial thrombosis in the absence of 
immobilization) would probably result in an absolute risk of venous thrombosis of less than 
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patients with any of these major illnesses were treated with long term thromboprophylaxis, 
the number needed to treat would be excessively high, while introducing a considerable risk 
of major bleeding. For this reason, thromboprophylaxis in patients with a major illness seems 
unjustified when no additional risk situations, such as hospitalization or surgery, are present. 
An intriguing observation in our study was that myocardial infarction and angina were more 
clearly associated with pulmonary embolism than with deep vein thrombosis. Other studies 
also showed that the risk of pulmonary embolism was higher than for deep vein thrombosis in 
persons with such comorbidity.4,18 This observation may be due to misclassification, which is 
possible as signs and symptoms of arterial thrombosis can be similar to pulmonary embolism. 
Alternatively, it may also be a causal observation as angina or myocardial infarction reflect 
local inflammatory effects in the lungs, which may lead to an increased risk of pulmonary 
embolism.26
The strengths of this study include the large patient sample, the detailed information about 
immobilization in both patients and controls, and the combination with data on thrombophilia. 
A limitation of this study is that major illnesses were assessed via self-report and the exact 
diagnoses of these major illnesses were not available. In addition, no specific questions were 
asked about the (severity of) major illnesses. However, since these are major diseases with 
a large impact, we expect that both patients and control persons reported their illnesses to a 
similar extent, thus limiting recall bias. Any resulting random misclassification would lead to an 
underestimation of our odds ratios. A second limitation of this study is that the blood sample 
was collected after the thrombotic event. Therefore, we cannot exclude the possibility that 
differences in plasma levels of the coagulation factors between cases and control persons 
were the result of the thrombotic event itself. However, the blood draw was performed at 
least 3 months after the thrombotic event, diminishing the possibility that the thrombotic event 
itself caused abnormalities in coagulation factor levels through acute phase reactions. A third 
limitation was that, as we had no data on the time between major illness and the subsequent 
venous thrombotic event in our study, we could not calculate specific risk estimates for different 
time frames. Not many previous studies were able to calculate a risk of venous thrombosis 
after major illness diagnosis, specified on time. However, the one that could showed that the 
risk was highest shortly after the major illness was diagnosed.18 Therefore, our relative risk 
estimates would probably have been higher if we could have taken this time aspect into close 
consideration. A fourth limitation was that for participation as a case in MEGA, those who died 
soon after a first venous thrombotic event (4% of the patient population) were excluded.20 
This probably has led to an underestimation of our risk estimates, since patients with a major 
illness are more likely to die from venous thrombosis than patients without a major illness. 
A fifth limitation of our study was that we had limited power for several analyses. This low 










































thrombosis among participants with angina than among participants with prior ischemic 
stroke. This finding should therefore be interpreted with caution. A sixth limitation is that we 
had no information about thromboprophylaxis during immobilization. This probably led to an 
underestimation of our risk estimates, as it is likely that patients with a major illness receive 
more thromboprophylaxis than other persons. Another aspect was that the risk of venous 
thrombosis could be especially increased for particular conditions causing liver disease, 
kidney disease, or heart failure. However, we did not have this information in our study. Future 
studies are needed on this topic. A final aspect of our study was that we had two separate 
control groups. However, by having a control group partly consisting of partners of patients, 
we probably have conservative estimates as partners will be more likely to resemble the 
cases than random controls. Therefore, we would expect higher odds ratios when comparing 
to RDD controls than to partners. Nevertheless, results pointed in the same direction and were 
roughly similar when both control groups were analyzed separately. Therefore, we do not think 
that our results are affected by the two different control groups.   
In summary, we have reported a detailed epidemiological analysis on the risk of first venous 
thrombosis in patients with a major illness. All major illnesses reported here were associated 
with an increased risk of venous thrombosis ranging from an odds ratio of 1.5 for rheumatoid 
arthritis and arterial thrombosis to 4.9 for hemorrhagic stroke. These risks were most 
pronounced at time of immobilization and in the presence of thrombophilia. These results 
could be a guide for future thromboprophylaxis decisions.
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Chronic kidney disease stage 1-3 increases  
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Background: End-stage renal disease has been associated with venous thrombosis (VT). 
However, the risk of VT in early stages of chronic kidney disease (CKD) has not yet been 
investigated. The aim of this study was to investigate whether CKD patients with stage 1-3 are 
at increased risk of VT.
Methods: 8 495 subjects were included in a prospective cohort study, in which renal function 
and albuminuria was assessed, starting in 1997-1998, and were followed for the occurrence of 
VT until 1 June 2007. CKD patients were staged according to the Kidney Disease Outcomes 
Quality Initiative (K/DOQI) guidelines, on the basis of 24-h urine albumin excretion and 
estimated glomerular filtration rates. Objectively verified symptomatic VT was considered as 
endpoint. 
Results: Of the 8 495 subjects, 243 had CKD stage 1, 856 CKD stage 2, and 491 CKD stage 
3. During a median follow-up period of 9.2 years, 128 individuals developed VT. The hazard 
ratios (HRs) for CKD stages 1, 2, and 3 were, respectively, 2.2 (95% CI 0.9-5.1), 1.9 (95% CI 
1.1-3.1), and 1.6 (95% CI 0.9-2.8) relative to those without CKD after adjustment for age, sex, 
BMI, hypertension, diabetes, malignancy, and high-sensitivity C-reactive protein. Subjects 
with CKD stage 3 and albuminuria (≥30 mg per day) had an adjusted HR of 3.0 and subjects 
with stage 3 without albuminuria had an adjusted HR of 1.0. 
Conclusion: CKD stages 1 and 2, and CKD stage 3 in presence of albuminuria are risk factors 












































Patients with severe chronic kidney disease (CKD) have increased risks of both arterial 
cardiovascular disease as well as for venous thrombosis (VT). The Kidney Disease Outcome 
Quality Initiative (K/DOQI) guidelines defined CKD as either kidney damage (albuminuria 
≥30 mg per day) or decreased kidney function and categorized CKD in five stages.1,2 The 
prevalence of CKD in the US is now 13% and is increasing, predominantly as a result of the 
type II diabetes epidemic.3 
The increased risk of arterial cardiovascular disease in CKD has been known for a long time 
and has been studied extensively for different CKD stages.4-8 Recent studies have also shown 
an association between overt CKD and VT.9,10 A study of the PREVEND cohort showed that 
the presence of micro-albuminuria (albuminuria 30-300 mg per day) was a risk factor for VT.9 
Another study of the LITE cohort showed that patients with estimated glomerular filtration 
rates (eGFR) between 15 and 60 ml/min (CKD stage 3-4) had a two-fold increased risk of 
VT as compared to subjects with a normal kidney function (eGFR >90 ml/min).10 However, 
information on albuminuria was not available in this study. To our knowledge, there is no 
study on the risk of VT in the different CKD stages taking into account albuminuria which is a 
prerequisite for staging CKD and for defining patients without CKD. 
Therefore, we investigated whether patients with CKD stage 1, 2, and 3 had an increased risk 
of VT in a large population-based cohort, and set out to determine absolute and relative risks 
for various stages of CKD.
METHODS
Study population and design
For this study, we used data of PREVEND study, which was designed to investigate the 
association between albuminuria and renal and cardiovascular outcomes in the general 
population. Details of the study have been published elsewhere11-13 and can be found at http://
www.prevend.org. The study outline is presented in Figure 1. In summary, all inhabitants of 
the city of Groningen, the Netherlands, aged 28-75 years (n= 85 421) were invited to send 
a morning urine sample to screen for albuminuria. Of these subjects, 40 856 responded. 
From these responders, the PREVEND cohort was selected aiming for a cohort enriched for 
the presence of albuminuria. Pregnant women and subjects with insulin-dependent diabetes 
mellitus were excluded. All participants with an urinary albumin concentration (UAC) of ≥10 
mg/L were invited (N=9 966), of whom 6 000 subjects participated. Furthermore, a randomly 










































2 592 subjects selected from 30 890 respondents with UAC of <10 mg/L participated. These 
8 592 subjects formed the baseline PREVEND cohort. These participants twice visited an 
outpatient clinic for measurements concerning their health. For the current study, subjects 
were excluded because of missing data on 24-h urinary albumin excretion or creatinine 
(n=86). Furthermore, subjects with CKD stage 4 (n=8) or stage 5 (n=3) were excluded, one of 
whom had a VT event, leaving 8 495 subjects for the present analysis. The PREVEND study 
has been approved by the local medical ethics committee and is conducted in accordance 
with the guidelines of the Declaration of Helsinki.
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Invited by mailed questionnaire for spot urine test 
N=85421 
Responded to questionnaire 
N=40856 
UAC < 10 mg/L 
N=30890 
UAC ≥ 10 mg/L 
N=9966 
Randomly selected  
Completed screening protocol 
N= 2592 
 
Completed screening protocol 
N= 6000 
Baseline PREVEND cohort 
N=8592 




Excluded          N=3966 
Did not consent  N=1800 
Pregnant  N=    60 
Insulin-dependent N=  167 
Declined to participate N=1768 
Other   N=  171 
Excluded          N=28298 
Did not consent  N=  7332 
Pregnant  N=    223 
Insulin-dependent N=    212 
Declined to participate N=    803 
Other   N=    631 
Not selected (random) N=19097 
Excluded          N=97 
Missing creatinine or  N=86 
24-hour urine collection  
CKD stage 4   N=  8 
CKD stage 5  N=  3 
  
Figure 1. Outline of the PREVEND study












































Serum creatinine, total cholesterol, and plasma glucose were measured by dry chemistry 
(Eastman Kodak, Rochester, New York). The high-sensitivity C-reactive protein (hsCRP) level 
was determined by nephelometry (BN II, Dade Behring, Marburg, Germany). Participants 
collected two 24-h urine samples, in which UAC was determined by nephelometry (BN II, 
Dade Behring, Marburg, Germany). The amount of albuminuria was measured as the mean 
of the two 24-hour urine samples.
 
Hypertension was defined as systolic blood pressure of ≥140 mm Hg, diastolic blood 
pressure of ≥90 mm Hg, or the use of antihypertensive drugs. Diabetes was defined as a 
fasting glucose level of ≥126 mg/dL, a non-fasting plasma glucose levels of ≥200 mg/dL, 
or the use of oral antidiabetic drugs. Hypercholesterolemia was defined as a total serum 
cholesterol concentration ≥250 mg/dL, or in case of a previous myocardial infarction or stroke 
a concentration of ≥193 mg/dL, or the use of lipid-lowering drugs. Body mass index (BMI) was 
calculated as weight in kilograms divided by height in meters squared. GFR was estimated by 
the Modification of Diet in Renal Disease (MDRD) study equation14 taking into account sex, 
age, race, and serum creatinine level. In an additional analysis, the newly developed but less 
often used Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) study equation15 
was used to estimate eGFR to compare these results with the results of the MDRD-equation. 
The CKD-EPI equation has been shown to outperform the MDRD equation in estimating the 
GFR above the 60 ml/min.15
Chronic kidney disease
CKD was staged according to the K/DOQI guidelines.1,2 CKD stage 1 was defined as eGFR 
>90 ml/min and albuminuria (urinary albumin excretion ≥30 mg per 24-hour urine collection), 
CKD stage 2 as eGFR between 60 and 90 ml/min and albuminuria, and CKD stage 3 as eGFR 
between 30 and 60 ml/min.
Venous thrombosis
The regional anticoagulation clinic database was used to identify participants who developed 
VT between January 1997 and June 2007. In the Netherlands, all outpatient treatment with 
vitamin K antagonists is monitored by regional anticoagulation clinics. Therefore, all VT events 
in treated outpatients are recorded by anticoagulation clinics. Moreover, as a secondary 
check for outpatient VT cases and identification of within hospital (fatal) cases, all study 
participants were searched for VT events in the national registry of death certificates and the 
national registry of hospital discharge diagnoses datasets. With the use of three independent 
sources, it is unlikely that VT events will be missed. The investigators who collected these 










































to the three sources were validated by reviewing medical records of these patients. Only 
objectively verified symptomatic VT events were considered. Deep vein thrombosis (DVT) 
was confirmed by compression ultrasound and pulmonary embolism (PE) by ventilation-
perfusion lung scanning, spiral computed tomography, or at autopsy. The observation time of 
each participant was calculated as a time elapsed between the testing of albuminuria (1997-
1998) and the first episode of VT or a censoring event (withdrawal from the study, moving 
out of the city, death, or June 2007), whichever occurred first. Incidence rates for VT were 
calculated by dividing the number of patients with a VT by the total observation time at risk. VT 
was considered to be unprovoked in the absence of major surgery, trauma, immobilization for 
>7 days, oral contraceptives, hormone therapy, pregnancy, malignant disease, long-distance 
travel for >4 hours, active infectious disease, paresis/paralysis of the leg, or heart failure at 
or within three months before the development of VT. Medical records were viewed with a 
checklist including these well-defined and well-documented variables to categorize VT into 
provoked or unprovoked.  
Statistical analyses 
Baseline characteristics of the participants were compared between subjects without CKD and 
subjects with CKD stages 1-3. Continuous data were reported as medians with interquartile 
ranges. Kaplan-Meier life-tables were used to estimate cumulative survival for CKD stages 
1-3 and no CKD. To investigate whether patients with CKD stages 1-3 had an increased risk 
of VT, proportional hazard regression was used to calculate hazard ratios (HRs) with 95% 
confidence intervals (CIs) as compared to participants without CKD (reference group). All 
analyses were performed for CKD stages 1, 2, and 3 combined and separately. In contrast 
to CKD stages 1 and 2, CKD stage 3 is only defined by decreased eGFR (between 30 and 
60 ml/min) and not by the presence of albuminuria, according to the K/DOQI guidelines. We 
also calculated HRs for CKD stage 3 stratified for the presence of albuminuria. We adjusted 
the HRs for age, sex, and BMI and additional for hypertension, diabetes, malignancy, and 
hsCRP. HRs were not adjusted for other cardiovascular risk factors such as hyperlipidemia 
and smoking, since these were not associated with VT in the PREVEND cohort.9 We repeated 
the same analyses for provoked and unprovoked VT separately.
 
To investigate whether eGFR is a risk factor for VT apart from albuminuria, we calculated HRs 
with 95% CIs for eGFR adjusted for albuminuria and for albuminuria adjusted for eGFR to 
evaluate the associations of level of eGFR and albuminuria with risk of VT. Furthermore, we 
divided subjects in six categories based on albuminuria and eGFR (>90 ml/min, between 60 
and 90 ml/min, and between 30 and 60 ml/min). HRs with 95% CIs were calculated for eGFR 
in absence or presence of albuminuria as compared with subjects with eGFR >90 ml/min 
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Finally, we calculated HRs with 95% CIs for CKD stages 1-3 as compared to participants 
without CKD, using the CKD-EPI formula for staging CKD. STATA software version 10.1 
(StataCorp LP, College Station, Tx) was used for the statistical analyses.     
RESULTS
The baseline characteristics of the 8 495 subjects are shown in Table 1. Of the 6 905 subjects 
without CKD, 26.4% had an eGFR >90 ml/min and 73.6% had an eGFR between 60 and 90 
ml/min. Of the 1 590 with CKD, 243 were in stage 1, 856 in stage 2, and 491 in stage 3. Of the 
491 subjects with stage 3 CKD, 164 had albuminuria (≥30 mg per day). Subjects with CKD 
stages 1-3 were older, were more often male, more often had diabetes, hypertension and 
malignancy, and had a higher BMI and higher CRP levels than subjects without CKD. The age 
of CKD patients increased with the CKD stage.
Overall, 128 subjects developed VT during a median observation period of 9.2 years (ranging 
from 0 to 10 years). Of the 128 patients with VT, 72 (56%) had DVT only, 44 had PE only 
(34%), and 12 (9%) had a combination of both. Of the 1590 subjects with CKD stage 1-3, 
49 developed VT as compared with 79 of the 6905 subjects without CKD. Seven of the 
243 patients with CKD stage 1, 26 of the 856 patients with CKD stage 2, and sixteen of 
491 patients with CKD stage 3 developed VT. Four patients died because of a PE (three in 
CKD stage 3 and one without CKD). Furthermore, there was no significant difference in the 
distribution of PE and DVT in CKD stage 3 (63% of VT patients had a PE) as compared to 
CKD stages 1 and 2 (36% had a PE) (P=0.09) or as compared to no CKD (43% had a PE) 
(P=0.16). The cumulative incidences for VT at eight years of follow-up were 3.2% for CKD 
stage 1, 3.0% for stage CKD 2, 3.3% for CKD stage 3, 3.1% for CKD stages 1-3, and 1.1% for 
no CKD. The number needed to treat to prevent one VT event in patients with CKD stage 1-3 
was approximately 400 patients per year. Figure 2 shows the Kaplan-Meier risk curves for VT 





















































Age* (years) 46 (37-56) 59 (48-67) 47 (39-56) 58 (48-66) 65 (58-70)
Male, % 49 56 66 64 38
Caucasians, % 95 96 93 97 97
Diabetes, % 2.4 9.8 12.8 11.2 5.9
Hypertension, % 27 65 50 65 72
Hypercholesterolemia, % 28 46 36 44 54
BMI* (kg/m2) 25 (23-28) 27 (24-30) 27 (24-30) 27 (25-30) 27 (25-30)
hsCRP* (mg/L) 1.1 (0.5-2.7) 2.2 (1.0-4.6) 2.1 (0.9-4.9) 2.3 (1.0-4.4) 2.2 (1.1-4.8)
Malignancy, % 1.4 2.3 1.6 2.2 2.8
eGFR* (ml/min) 81 (73-91) 72 (59-83) 97 (93-104) 76 (69-82) 55 (51-58)
UAE* (mg per day) 8 (6-12) 47 (33-93) 57 (39-101) 59 (39-107) 14 (7-47)
CKD, chronic kidney disease; BMI, body mass index; hsCRP, high-sensitivity c-reactive protein; eGFR, 
estimated glomerular filtration rate; UAE, urinary albumin excretion. *median (interquartile range)
Figure 2. Kaplan-Meier estimates of the risk of venous thrombosis according to stages of chronic 
kidney disease
CKD, chronic kidney disease; prs-yrs, person-years; yrs, years. *Adjusted for age, sex, body mass index, 
hypertension, diabetes, malignancy, and hsCRP
The incidence rate for VT in subjects without CKD was 1.3 (95% CI 1.1-1.7) per 1000 person-
years and 3.7 (95% CI 2.8-4.0) for subjects with CKD stages 1-3 with a corresponding 
HR for VT of 2.8 (95% CI 2.0-7.3) for CKD stages 1-3 as compared with no CKD. The HR 
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The crude HRs were 2.6 (95% CI 1.2-5.6), 2.8 (95% CI 1.8-4.3), and 3.0 (95% CI 1.8-5.2) 
for respectively CKD stages 1, 2, and 3. Figure 3 shows adjusted HRs with 95% CIs for CKD 
stages 1, 2, and 3, the last with or without the presence of albuminuria as compared with no 
CKD. The HRs were 2.2 (95% CI 0.9 -5.1), 1.9 (95% CI 1.1 -3.1), and 1.6 (95% CI 0.9 -2.8). 
For CKD stage 3 with and without albuminuria, the HRs were, respectively, 5.5 (95% CI 2.8-
11.0) and 1.9 (95% CI 0.9-4.2) without adjustment, and 3.0 (95% CI 1.4-6.5) and 1.0 (95% CI 
0.4-2.4) after full adjustment. 
 
Of the 128 VT events, 66 were unprovoked (51.6%) and 62 (48.4%) were provoked (Table 
2). For unprovoked VT, the HRs after adjustment for age, sex, BMI, hypertension, diabetes, 
malignancy, and hsCRP were 2.1 (95% CI 1.2-3.6) for CKD stages 1-3, 2.5 (95% CI 0.8-7.4) 
for CKD stage 1, 2.4 (95% CI 1.3-4.4) for CKD stage 2, and 1.4 (95% CI 0.6-3.3) for CKD 
stage 3. For provoked VT, the HRs after adjustment were 1.2 (95% CI 0.6-2.3) for CKD stages 
1-3, 1.4 (95% CI 0.3-5.9) for CKD stage 1, 0.8 (95% CI 0.3-2.2) for CKD stage 2, and 1.7 (95% 
CI 0.8-3.9) for CKD stage 3.
 
Albuminuria was associated with a 2.1-fold increased risk of VT after adjustment for age, sex, 
BMI, hypertension, diabetes, malignancy, hsCRP, and eGFR (Table 3). As compared with 
subjects with an eGFR >90 ml/min, subjects with an eGFR between 30 and 60 ml/min had 
50% increased risk of VT after adjustment for after adjustment for age, sex, BMI, hypertension, 








































Figure 3. Adjusted hazard ratios for venous thrombosis by CKD stage
CKD, chronic kidney disease; HR, hazard ratio; eGFR, estimated glomerular filtration rate; CKD 3 Alb 
+, CKD stage 3 and urinary albumin excretion ≥30 mg per day; CKD 3 Alb -, CKD stage 3 and urinary 























































No. of venous thrombosis 35 31 5 19 7
Incidence rate per 1000 person-years 0.6 (0.4-0.8) 2.4 (1.7-3.4) 2.5 (1.0-5.9) 2.7 (1.7-4.2) 1.7 (0.8-3.7)
Crude hazard ratios (95% CI) 1.0 4.0 (2.5-6.5) 4.2 (1.6-10.6) 4.5 (2.6-7.9) 3.0 (1.3-6.7)
Adjusted* hazard ratios (95% CI) 1.0 2.1 (1.5-3.5) 3.0 (1.1-.8.0) 2.3 (1.3-4.2) 1.4 (0.6-3.2)
Adjusted† hazard ratios (95% CI) 1.0 2.1 (1.2-3.6) 2.5 (0.8-.7.4) 2.4 (1.3-4.4) 1.4 (0.6-3.3)
Provoked venous thrombosis
No. of venous thrombosis 44 18 2 7 9
Incidence rate per 1000 person-years 0.7 (0.5-1.0) 1.4 (0.9-2.2) 1.0 (0.2-3.9) 1.0 (0.5-2.1) 2.3 (1.2-4.4)
Crude hazard ratios (95% CI) 1.0 1.9 (1.1-3.2) 1.3 (0.3-5.5) 1.3 (0.6-3.0) 3.1 (1.5-6.3)
Adjusted* hazard ratios (95% CI) 1.0 1.2 (0.7-2.2) 1.2 (0.3-4.9) 1.0 (0.4-2.2) 1.7 (0.8-3.6)
Adjusted† hazard ratios (95% CI) 1.0 1.2 (0.6-2.3) 1.4 (0.3-5.9) 0.8 (0.3-2.2) 1.7 (0.8-3.9)
CKD, chronic kidney disease. *Adjusted for age, sex, and body mass index. †Adjusted for age, sex, body 
mass index, hypertension, diabetes, malignancy, and hsCRP 
Table 4 shows HRs for VT for decreased eGFR (between 60 and 90 ml/min and between 30 
and 60 ml/min) in absence and presence of albuminuria as compared with subjects with eGFR 
>90ml/min without albuminuria. The adjusted HRs for subjects without albuminuria and an 
eGFR between 60 and 90 ml/min or an eGFR between 30 and 60 ml/min were, respectively, 
1.5 (95% CI 0.7-3.1) and 1.4 (95% CI 0.5-4.1). HRs for VT were increased in the presence of 
albuminuria in all eGFR categories. The adjusted HRs were 3.1 (95% CI 1.1-8.9), 2.7 (95% CI 
1.2-6.1), and 4.1 (95% CI 1.5-11.0) for subjects with albuminuria and, respectively, eGFR >90 
ml/min, eGFR between 60 and 90 ml/min, and eGFR between 30 and 60 ml/min. 
 
The HRs for VT in CKD stages 1, 2, and 3 were, respectively, 1.6 (95% CI, 0.7-3.8), 1.9 (95% 
CI, 1.2-3.0), and 1.5 (95% CI, 0.9-2.7) using the CKD-EPI formula after adjustment for age, 
sex, and BMI. HRs for subjects with CKD stage 3 and albuminuria and subjects with CKD 
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Table 3. Association between eGFR, albuminuria, and risk for venous thrombosis 
Adjusted* hazard ratios
eGFR
> 90 ml/min 1.0 (reference)
60-90 ml/min 1.3 (0.7-2.3)





eGFR, estimated glomerular filtration rate. *Adjusted for age, sex, body mass index, hypertension, 
diabetes, malignancy, and hsCRP, and albuminuria (continuous). †Adjusted for age, sex, body mass 
index, hypertension, diabetes, malignancy, and hsCRP, and eGFR (continuous). ‡Albuminuria defined as 
urinary albumin excretion ≥30 mg per day
Table	 4.	 Hazard	 ratios	 for	 venous	 thrombosis	 by	 decreased	 glomerular	 filtration	 rates	 and	
albuminuria
Crude hazard ratios Adjusted* hazard ratios
No albuminuria Albuminuria† No albuminuria Albuminuria†
eGFR > 90 ml/min HR (95% CI) 1.0 (reference) 4.8 (1.9-12.4) 1.0 (reference) 3.1 (1.1-8.9)
eGFR    60-90 ml/min HR (95% CI) 2.2 (1.2-4.1) 5.2 (2.6-10.5) 1.5 (0.7-3.1) 2.7 (1.2-6.1)
eGFR    30-60 ml/min HR (95% CI) 3.6 (1.4-9.3) 10.3 (4.2-24.7) 1.4 (0.5-4.1) 4.1 (1.5-11.0)
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion 
per day. *Adjusted for age, sex, body mass index, hypertension, diabetes, malignancy, and hsCRP. 
†Albuminuria defined as urinary albumin excretion ≥30 mg per day
DISCUSSION
In this study including 8 495 subjects followed for over 8 years, we found a 2.2-fold (95% CI 
0.9 -5.1) increased risk of VT in patients with CKD stage 1 and a 1.9-fold (95% CI 1.1 -3.1) 
increased risk of VT in patients with CKD stage 2 as compared with subjects without CKD 
according to the K/DOQI guidelines. CKD stage 3 patients with albuminuria had 3.0-fold (95% 
CI 1.4-6.5) increased risk of VT, and CKD stage 3 patients without albuminuria had a HR of 
1.0 (95% CI 0.4-2.4). The risk of VT associated with CKD seemed to be related to albuminuria 
rather than to impaired eGFR. Furthermore, our findings showed that CKD stages 1-3 were 
mainly associated with unprovoked VT. Using the CKD-EPI formula instead of the MDRD 











































Previous studies have investigated the association between eGFR on the basis of MDRD and 
VT.10,16 In the study of the LITE cohort, HRs for VT were 1.3 (95% CI 1.0-1.6) for subjects with 
eGFR between 60 and 90 ml/min and 2.1 (95% CI 1.5-3.0) for subjects with eGFR between 
15 and 60 ml/min (CKD stage 3-4) as compared with subjects with eGFR >90 ml/min.10 
However, information on albuminuria was not available in this study and formal classification 
into CKD stages was therefore not possible. In our study, we found a HR of 1.5 for VT for 
CKD stage 3 after adjustment for age, sex, and BMI; we showed that the risk of VT was 
only increased in the presence of albuminuria. Recent findings from the LITE study group 
contrast their earlier findings: eGFR based on cystatin was associated with an approximately 
1.6-fold increased risk of VTE, while eGFR based on creatinine was not associated with an 
increased risk of VT.16 The authors could not explain the discrepancy between the earlier 
and the current finding. Furthermore, albuminuria was not a risk factor for VT in their study, 
in contrast to our study. An explanation for this discrepancy could be that the relatively low 
prevalence of albuminuria may have limited their power to detect an association between VT 
and albuminuria, whereas our cohort was enriched for the presence of albuminuria. Moreover, 
in our study albuminuria was assessed in 24-h urine samples (gold standard) that were not 
frozen before assessment, whereas in their study albuminuria was assessed by albumin-
creatinine ratio in frozen samples. Frozen storage is known to induce a systematic decrease 
and more variability in albuminuria concentration.17 Furthermore, subjects with albuminuria are 
probably mainly diabetics in their study, while in PREVEND these are mainly non-diabetics, as 
per protocol insulin-using diabetic patients were excluded. This may have influenced the risk 
estimates, as diabetic subjects are usually on statin therapy and more frequently treated with 
anti-platelet medication for their cardiovascular morbidity. New findings indicate that statin use 
may reduce the risk of VT.18 
Although the seemingly higher risk of VT in CKD stages 1 and 2 as compared with stage 3 
might be surprising, the same pattern in the association between CKD and cardiovascular 
disease was previously found in the PREVEND study.4 Patients with CKD stages 1 and 2 were 
at higher risk of cardiovascular disease than those with CKD stage 3. A plausible explanation 
for this might be the difference in staging of CKD stage 3 and CKD stages 1 and 2. Albuminuria 
is necessary to define CKD stages 1 and 2, whereas only GFR is needed to define CKD stage 
3 to 5. Therefore, CKD stage 3 is a heterogeneous category, with subjects with and without 
evident kidney damage (albuminuria). We found that CKD stage 3 patients with albuminuria 
were at higher risk of VT than CKD stage 3 patients without albuminuria. These findings 
are in line with several other studies suggesting a higher risk for CKD stage 3 subjects with 
albuminuria than for CKD stage 3 subjects without albuminuria for different adverse outcomes, 
such as cardiovascular disease and the development of end-stage renal disease.19-21 Taken 
together, these data suggest that information on albuminuria could be added to CKD stage 3 
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There are several possible mechanisms for the increased risk of VT in CKD. First, endothelial 
damage could explain the increased risk of VT. It is remarkable that the association between 
CKD stages 1-3 and VT was comparable with the previously reported association between 
CKD stages 1-3 and cardiovascular disease in the PREVEND study.4 Therefore, it is tempting 
to hypothesize that a common risk factor for CKD leads to both VT and arterial cardiovascular 
disease. In our analysis, hypertension, BMI, and diabetes did not explain the increased risk 
of VT. Second, the increased risk of VT could be attributable to procoagulant changes in 
CKD patients which may be predominantly present in subgroups of CKD patients such as 
patients with nephrotic syndrome.22 CKD and nephrotic syndrome have been associated 
with elevated levels of D-dimer, CRP, fibrinogen, factor VII, factor VIII, and von Willebrand 
factor,23,24 which are important proteins in the development of VT. Third, inflammation may 
explain the increased risk of VT in CKD. It has been suggested that inflammation leads to VT.25 
However, additional adjustment of the HRs for hsCRP, which is currently the most widely used 
biomarker of inflammation,26 did not alter the HRs in our study. 
This study has several limitations. First, the K/DOQI guidelines require impaired GFR or 
albuminuria for at least three months. As in most studies, repeated measurements for a period 
of at least three months were not available in our study, and some subjects may therefore 
have been falsely classified as having CKD. Second, VT events were identified through 
anticoagulation clinic databases and registries for hospital discharge diagnoses and death 
certificates, which could lead to an underestimation of the incidence rates of VT. However, the 
incidence rates for VT in the PREVEND cohort (i.e. 1.4 per 1000 person-years) correspond 
well to those found in studies that had a complete case-finding procedure of objectively 
confirmed VT events.27 Third, we may have underestimated renal function in subjects with a 
GFR >60 ml/min, because we used the MDRD study equation.28,29 However, use of the CKD-
EPI formula did not result in large differences in the HRs. Fourth, there are studies suggesting 
that risk of adverse events increases when GFR drops below 45 ml/min.7,20 Our study did not 
include enough subjects with an eGFR <45 ml/min (n=52) to investigate this. Despite these 
limitations, PREVEND is a unique cohort in its large population-based prospective setting in 
which albuminuria was assessed in two 24-h urine samples. 
We showed that CKD stages 1, 2, and 3 in the presence of albuminuria are risk factors for 
VT. The relative risk of VT for those with CKD stage 1-3 was 1.8-fold increased relative to 
those without CKD. Although these relative risk estimates may be considered to be weak 
as compared with, for example, relative risk estimates for venous thrombosis that have 
been reported for genetic thrombophilia,30 on a population level CKD may be an important 
contributor to VT, because of the high prevalence of CKD, i.e. 12.7% for CKD stages 1-3 in the 










































prothrombin gene mutation.31 Clinicians should be aware of the increased risk of VT in these 
patients. Further studies are needed to show whether VT prophylaxis in subgroups of these 
patients will be safe and cost-effective, especially as the high risk of anticoagulant treatment-
related major bleeding episodes applies to CKD stage 4 and 5, and not CKD stage 1-3.32 
 
In conclusion, CKD stages 1 and 2, and CKD stage 3 in presence of albuminuria were
risk factors for VT. The risk of VT is more related to albuminuria than to impaired eGFR.
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Background: Factors explaining the association between impaired kidney function and 
venous thrombosis have not been identified so far. The aim of our study was to  determine 
whether the association between impaired kidney function and venous thrombosis can be 
explained by the concurrent presence of genetic or acquired venous thrombosis risk factors.
Methods: The glomerular filtration rate was estimated (eGFR) in 2473 venous thrombosis 
patients and 2936 controls from a population-based case-control study. Kidney function was 
grouped into 6 categories based on percentiles of the eGFR in the controls (>50th percentile 
[reference], 10th-50th percentile, 5th-10th percentile, 2.5th-5th percentile, 1st-2.5th percentile, 
and <1st percentile). 
Results: Several hemostatic factors showed a procoagulant shift with decreasing kidney 
function in controls, most notably factor VIII and von Willebrand factor (VWF). Compared 
with eGFR >50th percentile, factor VIII levels (adjusted mean difference of 60 IU/dl for the 
<1st eGFR percentile category) and VWF levels (adjusted mean difference of 60 IU/dl for the 
<1st eGFR percentile category) increased with each percentile category. The ORs for venous 
thrombosis similarly increased across the categories from 1.1 (95%CI 0.9-1.3) for the 10th-
50th percentile to 3.7 (95%CI 2.4-5.7) for the <1st percentile category. Adjustment for factor 
VIII or von Willebrand factor attenuated these ORs indicating an effect of eGFR on thrombosis 
through these factors. Adjustments for other risk factors for venous thrombosis did not affect 
the ORs. 
Conclusion: Impaired kidney function affects venous thrombosis risk via concurrently raised 












































The overall incidence of venous thrombosis is 1-2 per 1000 persons each year which rises 
exponentially with age, from 0.005% in children to 1% per year in the elderly.1 The prevalence 
of kidney disease is increasing due to ageing and a concurrent rise in prevalence of diabetes,2 
which explains the growing interest in the role of kidney disease as a risk factor for venous 
thrombosis.3 Several population-based studies have shown that chronic kidney disease 
increases the risk of venous thrombosis.4,5 
Unfortunately, studies that described this association were limited in providing information 
on explanatory factors. Knowledge of these mechanisms is important, both from a clinical 
and from a scientific viewpoint. The association between chronic kidney disease and venous 
thrombosis might be explained by the presence of common risk factors (confounders) that are 
associated with both venous thrombosis and chronic kidney disease, such as an increased 
body mass index,6,7 factor V Leiden,8,9 prothrombin G20210A,8,9 diabetes mellitus,6,10 
malignancy,9,11 and arterial thrombosis.12,13 The association might also be explained by factors 
that are a consequence of chronic kidney disease (mediators), that in their turn increase the 
risk of venous thrombosis such as immobilization,9 surgery,9 corticosteroid use,14 or changes 
in hemostatic factors.9 
 
Therefore, the aim of our study was to investigate whether the association between impaired 
kidney function and venous thrombosis can be explained by potential confounders and 
mediators. To this aim, we measured the estimated glomerular filtration rates (eGFRs) in 2473 
patients with a recent venous thrombosis and 2936 matched control subjects participating in a 
large population-based case-control study (Multiple Environmental and Genetic Assessment 
of risk factors for venous thrombosis study [MEGA study]). 
METHODS
Study design
MEGA is a large, population-based case-control study of risk factors for venous thrombosis. 
Between March 1999 and September 2004, consecutive patients aged 18 to 70 years with 
a first objectively confirmed episode of deep venous thrombosis or pulmonary embolism 
were included from six participating anticoagulation clinics in the Netherlands. Information 
on the diagnostic procedure was obtained from hospital records and general practitioners.15 
This study was approved by the Ethics Committee of the Leiden University Medical Center 
and written informed consent was obtained from all participants. The investigation has been 











































Only patients with a diagnosis of venous thrombosis that was confirmed with objective 
techniques were included in the analyses, as previously described.15 Exclusion criteria were 
severe psychiatric problems and inability to speak Dutch. Of the 6567 eligible thrombosis 
patients, 5183 participated (79%). For logistic reasons, blood sampling was performed for 
participants included up to June 2002 (n=2473) (Figure 1). Two sets of controls were gathered; 
partners of patients and subjects from the general population reached by random-digit dialing 
(RDD). Of the 3735 partner controls (age <70 years without venous thrombosis), 3297 
participated and 1480 provided blood samples (Figure 1). Of 5183 RDD controls (frequency 
matched to patients on age and sex) without venous thrombosis who were approached via 
an RDD method (recruited from the same geographical area as the patients), 4350 were 
eligible, 3000 participated and 1456 provided blood (Figure 1). Of the 1480 partner controls, 
1316 partner controls could be matched with a thrombosis patient, that is, of 164 partners, the 
corresponding patient originally participated, but was later found not to be eligible (age >70 
years, not objectivated thrombosis, or not a first thrombotic event). These control subjects 
were included in the overall analyses but not in the matched patient-partner analysis.
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Figure 1. Flow chart of the MEGA study 
 
 

















All persons were asked to complete an extensive questionnaire on many potential risk 
factors for venous thrombosis. Of interest for the current analysis are the items on 
general health characteristics, immobilization, surgery, history of arterial thrombosis 
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All persons were asked to complete an extensive questionnaire on many potential risk factors 
for venous thrombosis. Of interest for the current analysis are the items on general health 
characteristics, immobilization, surgery, history of arterial thrombosis (angina, myocardial 
infarction, ischemic stroke, peripheral vascular disease, or transient ischemic attack), 
malignancy, diabetes mellitus, and corticosteroid use. The index date was the date of the 
thrombotic event for patients and their partners, and the date of completing the questionnaire 
for the random controls.
Laboratory assays
Approximately 3 months after discontinuation of oral anticoagulant therapy, thrombosis patients 
and their partners were invited for collection of a blood sample. In patients who were still on 
anticoagulant therapy 1 year after their event, blood was drawn during anticoagulant therapy. 
Serum creatinine was measured enzymatically (Roche Diagnostics, Mannheim, Germany). 
Glomerular filtration rate was estimated by the Modification of Diet in Renal Disease (MDRD) 
study equation.16 The common genetic risk factors factor V Leiden and prothrombin G20210A 
were determined with the TaqMan assay.17 Levels of natural anticoagulants (antithrombin, 
protein S and protein C levels) and procoagulant factors (fibrinogen, factor II, factor VII, factor 
VIII, von Willebrand factor, factor IX, factor X, and factor XI) were also assessed. All assays 
were performed in automated machines by laboratory technicians who were unaware of the 
case-control status of the samples. A detailed description of how these laboratory markers 
were analyzed has been published previously.17-20
Statistical analysis
Hemostatic factor levels in controls in relation to kidney function
We investigated whether impaired kidney function was associated with changes in hemostatic 
factors in controls. Kidney function was grouped into 6 categories based on percentiles 
of the eGFR of the controls (>50th percentile (reference), 10th -50th percentile, 5th -10th 
percentile, 2.5th – 5th percentile, 1st – 2.5th percentile, and <1st percentile). The reason for 
using these 6 percentile groups was to investigate a wide range of eGFR values, particularly 
for the abnormal levels. We calculated age- and sex-adjusted mean differences with 95% 
confidence intervals (95% CIs) in levels of hemostatic factors for 10th -50th percentile, 5th 
-10th percentile, 2.5th – 5th percentile, 1st – 2.5th percentile, and <1st percentile of the kidney 
function in control persons as compared with the >50th percentile using linear regression. 
Furthermore, we used linear regression to calculate the decrease or increase in levels of 
hemostatic factors in control persons for every increase of 10 ml/min in eGFR after adjustment 










































Case-control comparisons: risk of venous thrombosis and eGFR
To determine whether an impaired kidney function was associated with an increased risk 
for venous thrombosis, age- and sex-adjusted odds ratios with 95% CIs were calculated 
as estimates of the relative risk for the different levels of eGFR. In addition, we adjusted 
for potential confounding and mediating factors to explore whether an increased risk was 
explained by these factors. The following potential confounders were included in the model: 
body mass index, factor V Leiden, prothrombin G20210A, diabetes mellitus, malignancy, and 
arterial thrombosis including angina, myocardial infarction, ischemic stroke, transient ischemic 
attack, and peripheral vascular disease. We subsequently included factors that might mediate 
the increased risk of VT associated with chronic kidney disease, that is, immobilization, 
surgery, and corticosteroid use. We also adjusted for hemostatic factors (as continuous 
variables) (Figure 2). Lastly, we reanalyzed the data using clinical cutoff points instead of 
percentiles for kidney function (normal kidney function [eGFR>90 ml/min], mildly decreased 
kidney function [eGFR 60-90 ml/min], and moderately to severely decreased kidney function 
[eGFR <60 ml/min]). As a sensitivity analyses, we applied the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) instead of the MDRD equation. We ran three parallel 
analyses to determine the direction of the precision of the association, (1) patients compared 
with the pooled control groups, (2) patients compared with partner controls (conditional logistic 
regression), and (3) patients compared with RDD controls (unconditional logistic regression). 
The first analysis used nonconservative estimates of the standard errors, whereas the second 
and third analyses provide overly conservative estimates when applied to the pooled analysis.
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Figure 2. Causal diagram on the association between kidney function and venous thrombosis 
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*Hemostatic factors could be both confounders and mediators in the association between kidney function and venous 
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Case-case comparisons: effect of time between venous thrombosis and blood sampling 
on eGFR mean levels 
In addition, we compared mean eGFRs of patients who were tested within 3 to 6 months, 
6 to 12 months, or >12 months after their first venous thrombosis (ANOVA test). 
Statistical analyses were performed with statistical package SPSS Windows version 17.0 
(SPSS, Chicago, IL, USA). 
Figure 2. Causal diagram on the association between kidney function and venous thrombosis
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Case-case comparisons: effect of time between venous thrombosis and blood sampling on 
eGFR mean levels
In addition, we compared mean eGFRs of patients who were tested within 3 to 6 months, 
6 to 12 months, or >12 months after their first venous thrombosis (ANOVA test). Statistical 
analyses were performed with statistical package SPSS Windows version 17.0 (SPSS, 
Chicago, IL, USA).
RESULTS
Table 1 shows the baseline characteristics of the study population. In total, 5183 patients 
and 6297 control persons (3297 partner controls and 3000 RDD controls) participated in the 
MEGA study. Of the patients, 2473 provided blood samples. Of the control subjects, 2936 
provided blood samples. There were no substantial differences in the baseline characteristics 
in all participants compared with participants who provided blood samples (Table 1). Of the 
2473 thrombosis patients, 1473 (59.6%) had a deep vein thrombosis only, and 1000 (40.4%) 
had a pulmonary embolism with or without deep vein thrombosis. There were negligible age 
or sex differences between patients and controls. Body mass index was higher in patients 
with thrombosis than in controls. Furthermore, compared with controls, patients with venous 
thrombosis more often used corticosteroids, more often were carriers of factor V Leiden 
or prothrombin G20210A and more often had a history of arterial thrombosis, malignancy, 
diabetes mellitus, immobilization or surgery. There were no substantial differences between 
the partner and RDD controls in the baseline characteristics. 
Hemostatic factor levels in controls in relation to kidney function
In controls, several hemostatic factors showed a shift towards a procoagulant state with 
decreasing kidney function (Table 2). Compared with subjects with an eGFR >50th percentile, 
the adjusted mean factor levels were significantly different from  subjects with an eGFR <1st 
percentile for fibrinogen (adjusted mean difference 0.7 g/L; 95% CI 0.5-0.9), factor VII (31 IU/
dL; 95% CI 22-40), factor IX (12 IU/dL; 95% CI 5-19), and factor XI (10 IU/dL; 95% CI 3-17), 
with a most pronounced increase in factor VIII (60 IU/dL; 95%CI 44 to 76) and von Willebrand 
factor (60 IU/dL; 95%CI 43 to 77). A 10 ml/min decrease in eGFR was associated with a an 
increase of 3 IU/dL (95% CI 2 to 4) in factor VIII levels and an increase of 2 IU/dL (95% CI 1 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The results were the same when clinical cut-off points were used to categorize kidney function 
instead of percentiles. Persons with moderately to severely decreased kidney function (eGFR 
<60 ml/min) had procoagulant changes compared with subjects with normal kidney function 
(eGFR >90 ml/min), most notably in levels of factor VIII (41 IU/dL; 95% CI 31-51) and von 
Willebrand factor (32 IU/dL; 95% CI 21-43) (Table 3). These results were in the same range for 
partner controls and for RDD controls. factor VIII (41 IU/dL; 95% CI 31-51) and von Willebrand 
factor (32 IU/dL; 95% CI 21-43) (Table 3). These results were in the same range for partner 
controls and for RDD controls.
Case-control comparisons: risk of venous thrombosis and eGFR
Table 4 shows the risk of venous thrombosis for categories of eGFR. Compared with subjects 
in the >50th percentile, decreasing eGFR was associated with a steadily increasing risk, that 
is, from a 1.1-fold (95% CI 0.9-1.2) increased risk for subjects in the 10th – 50th percentile to a 
3.7-fold (95% CI 2.4-5.7) increased risk in subjects with an eGFR <1st percentile. Adjustment 
for potential confounders (body mass index, diabetes mellitus, arterial thrombosis, malignancy, 
prothrombin G20210A, and factor V Leiden) slightly attenuated these risk estimates. Additional 
adjustment for potential mediators between impaired kidney function and venous thrombosis 
(immobilization, surgery, and corticosteroid use) further decreased the risk slightly. After 
additional adjustment for factor VIII and von Willebrand factor levels, i.e. the two hemostatic 
factors that showed the strongest relation with impaired kidney function, the odds ratios 
attenuated to almost unity in all percentiles. Additional adjustment for other hemostatic factors 
did not further alter the odds ratios. Figure 3 shows the risk of venous thrombosis for different 
percentiles of kidney function after adjustment for factor VIII and von Willebrand factor levels 
only (without adjustment for the other possible mediators and confounders). For factor VIII 
levels, participants with levels >150 IU/dL had an 8.0-fold (95% CI 6.7-9.5) increased risk of 
venous thrombosis compared with participants with levels <100 IU/dL. Results were in the 
same direction and risks were similarly attenuated after adjustment for the coagulation factors 
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Figure 3. Percentiles of kidney function and risk of venous thrombosis
The results were the same when clinical cut-off points were used to categorize kidney function 
instead of percentiles. Moderately to severely decreased kidney function was associated 
with a 2.6-fold (95% CI 2.0-3.5) increased risk of venous thrombosis compared with normal 
kidney function in the pooled results, with a 3.8-fold (95% CI 2.4-6.0) increased risk versus 
the partner controls and a 2.2-fold (95% CI 1.6-3.2) increased risk versus the RDD controls 
after adjustment for age and sex. Odds ratios for moderately to severely decreased kidney 
function were again attenuated to the null after adjustment for von Willebrand factor and factor 
VIII levels (odds ratio 1.2 [95% CI 0.8-1.7] for the combination of both coagulation proteins, 
odds ratio of 1.4 [95% CI 0.9-2.0] for von Willebrand factor only, and odds ratio of 1.2 [95% CI 
0.8-1.7] for factor VIII only). In both the partner controls and RDD controls, odds ratios were 
attenuated for moderately to severely decreased kidney function and venous thrombosis after 
adjustment for von Willebrand factor and factor VIII levels (Table 5).
Results were in the same direction and risks attenuated after adjustment for the coagulation 
factors when both control groups were analyzed separately (Table 5). Furthermore, because 
the MDRD equation may underestimate glomerular filtration rates at borderline abnormal 
levels (i.e., 60mL/minute ), although most of the participants with reduced kidney function 
were close to this level, it is possible that reclassification of kidney function by the CKD-EPI 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Case-case comparisons: effect of the time between venous thrombosis and blood 
sampling on eGFR mean levels
No major differences in mean eGFRs were observed when patients were tested within 3 to 6 
months (mean 87 ml/min), 6 to12 months (mean 86 ml/min), or >12 months (mean 86 ml/min) 
after their first venous thrombosis.     
DISCUSSION
In this large, population-based case-control study, an association was found between 
impaired kidney function and levels of fibrinogen, factor VII, factor IX, factor XI, factor VIII, 
and von Willebrand factor levels. Furthermore, the increased risk of venous thrombosis with 
decreasing kidney function seemed fully explained by concurrently raised levels of factor VIII 
or von Willebrand factor. 
In both the Longitudinal Investigation of Thromboembolism Etiology (LITE)4 and Prevention 
of Renal and Vascular End-Stage Disease (PREVEND)5 study, chronic kidney disease was 
associated with an increased risk of venous thrombosis. However, in neither study were factors 
that might explain the association between chronic kidney disease and venous thrombosis 
identified. Our analyses showed that the presence of common risk factors for chronic kidney 
disease and venous thrombosis, such as body mass index,6,7 factor V Leiden,8,9 prothrombin 
G20210A,8,9 diabetes mellitus,6,10 malignancy,9,11 and arterial thrombosis12,13 could not explain 
the association. In our attempt to explain the increased risk of venous thrombosis in chronic 
kidney disease, we also adjusted for risk factors that are a consequence of chronic kidney 
disease and in turn increase the risk of venous thrombosis (mediators), such as immobilization,9 
surgery,9 corticosteroid use,14 and changes in hemostatic factors.9 Immobilization, surgery, 
and corticosteroid use only slightly changed the odds ratio. However, factor VIII and von 
Willebrand factor could fully explain the increased risk of venous thrombosis associated with 
impaired kidney function.
In previous studies, patients with end-stage renal disease and nephrotic syndrome (defined 
as proteinuria of >3 grams per 24 hours) were shown to have elevated levels of fibrinogen, 
factor VIII and von Willebrand factor.21-23 In addition, patients with nephrotic syndrome have 
decreased antithrombin levels as a result of urinary loss of antithrombin.24 Increased levels 
of fibrinogen,25,26 factor VIII,27 factor IX,9 factor XI,9 and von Willebrand factor28 have been 
associated with an increased risk of venous thrombosis in the general population, whereas 
factor VII was not associated with venous thrombosis in previous studies.27,29 In our study, 
we observed a procoagulant shift in subjects with an impaired kidney function <1st percentile 
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XI, and especially levels of factor VIII and von Willebrand factor were increased. We did not 
find an association between antithrombin levels and impaired kidney function.
We showed that impaired kidney function, estimated with either the MDRD equation or the 
CKD-EPI equation, affects venous thrombosis risk via concurrently raised factor VIII and von 
Willebrand factor levels. However, the exact mechanism through which chronic kidney disease 
leads to venous thrombosis via procoagulant changes (especially increases in factor VIII and 
von Willebrand factor levels) cannot be determined from these data with certainty. Because 
von Willebrand factor and factor VIII are markers of endothelial damage,30 it might be that 
endothelial damage, which is associated with chronic kidney disease, leads to increased factor 
VIII and von Willebrand factor levels and eventually to venous thrombosis. According to this 
view, chronic kidney disease would be an epiphenomenon to the risk of venous thrombosis, 
and the endothelial damage that leads to a procoagulant shift would be the underlying cause. 
Alternatively, the endothelial damage could be caused by the chronic kidney disease, which 
leads to a procoagulant state and finally to venous thrombosis. 
The strengths of this study include the large patient sample and the detailed information about 
genetic and acquired risk factors for venous thrombosis, medication use, and comorbidities 
in both patients and controls in combination with hemostatic factor level information. In our 
study, blood was collected after the thrombotic events as a consequence of our study design 
(case-control study), minimizing the time frame between event and measurements (eGFR 
and hemostatic factors). A drawback of cohort studies is that they usually assess indicators at 
baseline, long before the occurrence of the disease, resulting in a possible dilution of the effect, 
especially when we take into account that kidney function and hemostatic factors levels could 
change in the years before the disease. Because there is a time lag in cohort studies between 
the event and assessments (kidney function), case–control studies might be better for showing 
the association between kidney function and the risk of venous thrombosis. Furthermore, it 
is unlikely that differences in creatinine levels between cases and control persons were the 
result of the thrombotic event itself. No major differences in mean eGFRs were observed 
when patients were tested within 3 to 6 months, 6 to12 months, or >12 months after their first 
venous thrombosis suggesting that these levels were not influenced by a temporarily raised 
effect. In addition, it is not likely that our results are explained by acute-phase reactions from 
the thrombotic event itself, because the clear dose-response relationship between decreased 
kidney function and increased factor VIII and von Willebrand factor was observed in subjects 
without venous thrombosis. Furthermore, it is not likely that an acute-phase reaction results 
in higher levels of factor VIII and von Willebrand factor in patients with venous thrombosis 
and chronic kidney disease than in subjects with venous thrombosis and a normal kidney 










































after the venous thrombotic event occurred in patients, thereby minimizing any acute-phase 
reactions.31 Another potential limitation in our study was that blood was provided in a subset 
of the participating patients and controls in the MEGA study. However, because we stopped 
taking blood after June 2002 for logistic reasons only and since baseline characteristics were 
similar, it is unlikely that this has introduced bias. Additionally, we had no information about 
proteinuria. It would be useful to explore whether proteinuria is associated with an increased 
risk of venous thrombosis and whether such an association can be explained by changes 
in hemostatic factors. Proteinuria, especially in the nephrotic range (defined as proteinuria 
of >3 grams per 24 hours), has been associated with venous thrombosis.23-25 It has been 
suggested that nephrotic syndrome leads to venous thrombosis through loss of antithrombin 
in the urine. This, however, was beyond the scope of our study. Our aim was to relate eGFR 
levels to venous thrombosis risk, taking potential confounding and mediation into account. 
Furthermore, we did not find an association between decreased kidney function and low levels 
of antithrombin. Another limitation of our study was that we cannot provide risk estimates by 
the primary kidney disease. The reason is that most of the subjects with impaired kidney 
function in our study had no symptoms and were never, or had not yet been diagnosed with 
impaired kidney function. It would certainly be useful to study the risks of thrombosis for the 
various types of primary kidney disease. Rather than comparing patients with thrombosis with 
controls, patients with specific kidney disorders should be followed for the development of 
thrombosis, because these various diseases are too rare to differentiate in a thrombosis case-
control study. A final aspect of our study was that we had two separate control groups. The 
analysis that pooled controls does not easily generalize to a known population. Nevertheless, 
results pointed in the same direction and were roughly similar when both control groups 
were analyzed separately. Therefore, our results were not affected by the use of two different 
control groups. 
In summary, we have reported a detailed epidemiological analysis into the risk of first venous 
thrombosis in individuals with reduced kidney function. We showed that the increased risk of 
venous thrombosis can be explained by concurrently raised factor VIII and von Willebrand 
factor levels. 
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Background: Although an association between venous thrombosis and chronic kidney 
disease has recently been established, it is unknown which patients with chronic kidney 
disease are most likely to benefit from thromboprophylaxis. The aim of this study was to assess 
the association between venous thrombosis and chronic kidney disease in combination with 
arterial thrombosis, malignancy, surgery, and thrombophilia to identify high-risk groups as a 
basis for personalized prevention. 
Methods: This study included 2473 consecutive patients with first venous thrombosis and 
2936 controls from a case-control study (the MEGA study). 
Results: Moderately decreased kidney function (eGFR 30-60 ml/min) was associated with 
a 2.5-fold (95%CI 1.9-3.4) increased risk and severely decreased kidney function (eGFR 
<30 ml/min) was associated with a 5.5-fold (95%CI 1.8-16.7) increased risk, compared with 
those with normal kidney function (eGFR >90 ml/min). The risk of venous thrombosis was 
additionally increased for moderately and severely reduced kidney function in combination 
with arterial thrombosis (odds ratio 4.9; 95%CI 2.2-10.9), malignancy (5.8; 95%CI 2.8-12.1), 
surgery (14.0; 95%CI 5.0-39.4), immobilization (17.1; 95%CI 6.8-43.0), or thrombophilia (odds 
ratios 4.3-9.5), with particularly high risks when three or more risk factors were present (odds 
ratio 56.3; 95% CI 7.6-419.3). 
Conclusion: Decreased kidney function is associated with an increased risk of venous 













































Chronic kidney disease is an established risk factor for arterial thrombosis.1-3 Until recently, it 
has been unclear whether chronic kidney diseases also increase the risk of venous thrombosis. 
In the Longitudinal Investigation of Thromboembolism Etiology (LITE) study, chronic kidney 
disease was associated with venous thrombosis in individuals older than 45 years of age.4 This 
study reported that individuals with an estimated glomerular filtration rate between 15-60 ml/
min had a 2.1-fold increased risk of venous thrombosis as compared with those with a normal 
kidney function. Recently, we confirmed these results in the Prevention of Renal and Vascular 
Disease (PREVEND) cohort study.5 The moderately increased risk found in the above studies 
for chronic kidney disease probably does not justify the use of thromboprophylaxis when 
weighed against the thromboprophylaxis-related risk of major bleeding episodes.6 Having 
chronic kidney disease in combination with other risk factors or high risk situations, such as 
immobilization, the presence of prothrombotic genes or other comorbidities, might increase 
the risk to such an extent that thromboprophylaxis would be recommendable. However, no 
studies have reported on the risk of venous thrombosis in persons with such combinations of 
risk factors.
We therefore calculated the estimated glomerular filtration rate in 2473 patients with a recent 
venous thrombosis and 2936 control subjects participating in a case-control (MEGA) study. 
The size of the study enabled us to investigate the risk for various glomerular filtration rates as 
well as the effects of combination with one or more other risk factors for thrombosis, with the 
aim of identifying high-risk groups that may benefit from thromboprophylaxis.
METHODS
Study design
The MEGA study (Multiple Environmental and Genetic Assessment of risk factors for venous 
thrombosis study) is a large case-control study on risk factors for venous thrombosis. Between 
March 1999 and September 2004, consecutive patients aged 18 to 70 years with a first 
objectively confirmed episode of deep venous thrombosis (leg or arm) or pulmonary embolism 
were included from six participating anticoagulation clinics in the Netherlands. Information on 
the diagnostic procedure was obtained from hospital records and general practitioners.7
Patients
Only patients with a diagnosis of venous thrombosis that was confirmed with objective 
techniques were included in the analyses, as previously described.7 Exclusion criteria were 










































participated (79%). For logistic reasons, blood sampling was performed for patients included 
up to June 2002.Therefore, in the current analyses 2473 patients out of the 5184 patients 
(48%) who had their blood drawn were included. 
Controls
As control individuals, partners of patients aged <70 years without venous thrombosis were 
included, as well as individuals without venous thrombosis obtained via a random-digit-dialing 
(RDD) method. Of the 5184 participating patients, 3735 had an eligible partner. Of the 3735 
eligible partners, 3039 participated (81%). The RDD control individuals were recruited from 
the same geographical area as the patients, and were frequency matched to the patients on 
age and sex. Of the 4350 eligible random controls, 2789 participated (64%). This resulted in 
a total of 5828 control individuals without venous thrombosis. Blood was drawn in participants 
included until June 2002, again for the same logistic reasons, which included 2936 control 
individuals (50%).
Data collection
All individuals were asked to complete an extensive questionnaire on many potential risk 
factors for venous thrombosis. Of particular interest for the current analysis are items on 
demographics (including age and sex), immobilization (defined as being bedridden for more 
than 4 days or hospitalization within 3 months prior to the index date), surgery within 3 months 
prior to the index date, history of arterial thrombosis (myocardial infarction, angina pectoris, 
ischemic stroke, transient ischemic attack, and peripheral vascular disease) (self-reported) 
and malignancy (validated for participating patients with cancer by reviewing discharge letters 
from their primary physician or from the hospital in which they were being treated).8 The index 
date was the date of the thrombotic event for patients and their partners and the date of filling 
in the questionnaire for the random controls. 
Laboratory assays
Approximately 3 months after discontinuation of oral anticoagulant therapy, thrombosis 
patients and their partners were invited for collection of a blood sample. In patients who were 
still on anticoagulant therapy 1 year after their event, blood was drawn during anticoagulant 
therapy. All assays were performed in an automated machine by laboratory technicians who 
were unaware of the case-control status of the samples. Serum creatinine was measured 
enzymatically (Roche Diagnostics, Mannheim, Germany). Glomerular filtration rate was 
estimated by the Modification of Diet in Renal Disease (MDRD) study equation.9 Common 
genetic risk factors were assessed, including the factor V Leiden mutation and the prothrombin 












































To determine whether chronic kidney disease was associated with an increased risk for venous 
thrombosis, odds ratios (ORs) with 95% confidence intervals (95% CIs) adjusted for age and 
sex were calculated using unconditional logistic regression as estimates of the relative risk 
for mildly decreased kidney function (glomerular filtration rate 60-90 ml/min), moderately 
decreased kidney function (glomerular filtration rate 30-60 ml/min), and severely decreased 
kidney function (glomerular filtration rate <30 ml/min), as compared with normal kidney 
function. In our study, partner controls were matched on time to cases and random controls 
were selected from a stable, dynamic population.10 We also investigated the association 
with venous thrombosis for glomerular filtration rate categories based on percentiles instead 
of using these clinical cut-off points for kidney function. In addition, odds ratios for venous 
thrombosis were calculated in order to identify high-risk groups, combining moderately to 
severely decreased kidney function (estimated glomerular filtration rate of <60 ml/min) with a 
priori specified risk factors (i.e. arterial thrombosis, malignancy, surgery, immobilization), and 
thrombophilia (factor V Leiden and prothrombin G20210A). As we were primarily interested 
in establishing high-risk groups that may benefit from thromboprophylaxis, we only adjusted 
for the matching factors, i.e. age and sex.11,12 Adjusting for other factors when determining the 
association between chronic kidney disease and venous thrombosis is only of interest when 
determining the causal relationship. However, from a prediction point of view it is preferable 
to only determine the association between the predictive marker (chronic kidney disease) and 
the outcome (venous thrombosis), because adjustment could lead to false conclusions with 
respect to identifying high-risk groups. Statistical analyses were performed with statistical 
package SPSS Windows version 17.0 (SPSS Inc., Chicago, IL).
RESULTS
Table 1 shows the baseline characteristics of the study population. Of the 2473 thrombosis 
patients, 1473 (59.6%) had a deep vein thrombosis only and 1000 (40.4%) had a pulmonary 
embolism with or without deep vein thrombosis. Venous thrombosis patients had, as expected, 
more often arterial thrombosis, malignancy, surgery, immobilization, factor V Leiden mutation, 















































Median age, years (5-95th %) 49.1 (25.9-67.5) 49.8 (27.1-67.0)
Women, n (%) 1346 (54.4%) 1543 (52.6%)
Arterial thrombosis, n (%) 147 (6.7%) 133 (4.8%)
Malignancy, n (%) 201 (8.2%) 107 (3.7%)
Surgery, n (%) 413 (16.7%) 85 (2.9%)
Immobilization, n (%) 663 (27.0%) 170 (5.8%)
Factor V Leiden, n (%) 390 (15.8%) 145 (4.9%)
Prothrombin G20210A, n (%) 117 (4.7%) 52 (1.8%)
Type of venous thrombosis, n (%)
Deep vein thrombosis only 1473 (59.6%)
Pulmonary embolism 1000 (40.4%)
No major differences in mean glomerular filtration rates were observed when patients were 
tested on glomerular filtration rate within 3-6 months (mean 87 ml/min), 6-12 months (mean 86 
ml/min), or >12 months (mean 86 ml/min) after their first venous thrombosis, suggesting that 
glomerular filtration rates were not influenced by a temporarily raised effect. 
As shown in Table 2, the age- and sex-adjusted odds ratios of venous thrombosis increased 
with increasing severity of kidney disease compared with normal kidney function (glomerular 
filtration rate >90 ml/min): the odds ratio was 1.1 (95% CI 1.0-1.2) for mildly decreased kidney 
function (estimated glomerular filtration rate 60-90 ml/min), 2.5 (95% CI 1.9-3.4) for moderately 
decreased kidney function (estimated glomerular filtration rate 30-60 ml/min), and 5.5 (95% 
CI 1.8-16.7) for severely decreased kidney function (estimated glomerular filtration rate <30 
ml/min). The odds ratios were similar for deep vein thrombosis and pulmonary embolism as 
separate outcomes. 
When defining glomerular filtration rate categories based on percentiles instead of clinical 
cut-off points for kidney function, we also found, beside an increase in venous thrombosis risk 
with decreasing estimated glomerular filtration rate (Figure 1), an increased risk of venous 
thrombosis (odds ratio 1.4; 95% CI 1.0-1.9) for participants with glomerular hyperfiltration (i.e. 
those with the highest 2.5 percentile of the kidney function, corresponding to an estimated 
glomerular filtration rate of more than 125 ml/min). 
To investigate joint effects of reduced kidney function and common risk factors for venous 
thrombosis, we categorized kidney function into two groups: reduced kidney function 
(moderately to severely decreased; estimated glomerular filtration rate <60 ml/min) and normal 
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glomerular filtration rate of more than 125 ml/min were excluded from this analysis because 
their risk of venous thrombosis was also increased. Surgery in the absence of reduced kidney 
function increased the risk of venous thrombosis 6.9-fold (95% CI 5.3-8.8), while surgery 
combined with reduced kidney function increased the risk of venous thrombosis 14-fold (95% 
CI 5.0-39.4) (Table 3). Immobilization in the absence of reduced kidney function increased 
the risk of venous thrombosis 5.7-fold (95% CI 4.8-6.9), while immobilization combined with 
reduced kidney function increased the risk of venous thrombosis 17.1-fold (95% CI 6.8-43.0) 
(Table 3). The presence of all other risk factors, including malignancy, factor V Leiden mutation, 
or prothrombin G20210A, also additionally increased the risk for patients with reduced kidney 
function (Table 3).
 107
Table 2. Association between chronic kidney disease and venous thrombosis 





odds ratio for 
Adjusted*† 
odds ratio for  
Adjusted*‡ 
odds ratio for  
 Function N (%) N (%) venous thrombosis DVT  PE  
eGFR > 90  Normal 
 
937 (37.9) 1179 (40.2) 1 (reference) 1 (reference) 1 (reference) 
eGFR 60- 90  Mildly 
decreased 
1376 (55.6) 1672 (56.9) 1.1 (1.0-1.2) 1.1 (0.9-1.2) 1.1 (1.0-1.3) 
eGFR 30-60  Moderately 
decreased 
144 (5.8) 81 (2.8) 2.5 (1.9-3.4) 2.2 (1.6-3.1) 2.9 (2.0-4.2) 
eGFR < 30  Severely 
decreased 
16 (0.6) 4 (0.1) 5.5 (1.8-16.7) 7.0 (2.2-21.8) 3.4 (0.8-13.7) 




























Figure 1. Percentiles of kidney function and risk of venous thrombosis
The risk of venous thrombosis further increased when more than one risk factor was present 
(Table 4). In the absence of immobilization, surgery, malignancy, arterial thrombosis, factor V 
Leiden, and prothrombin gene mutation, a reduced estimated glomerular filtration rate <60 ml/
min was still associated with a two-fold increased risk of venous thrombosis (odds ratio 2.0, 
95% CI 1.3-3.0). The presence of three or more of the six risk factors for venous thrombosis 
was associated with 56.3-fold (95% 7.6-419.3) increased risk of venous thrombosis.
 
There was a high risk of venous thrombosis for patients with chronic kidney disease patients 
with concomitant arterial thrombosis with surgery (odds ratio 17.9; 95% CI 2.2-146.2) or 
immobilization (odds ratio 16.8; 95% CI 3.8-75.1). In addition, chronic kidney disease patients 
with concomitant malignancy in combination with immobilization had a high risk of venous 
thrombosis (odds ratio 52.3; 95% CI 7.0-390.4). Also, the combination of chronic kidney 
disease with prothrombin G20210A or factor V Leiden in the presence of immobilization 
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Table 3. Joint effects on venous thrombosis of chronic kidney disease and surgery, immobilization, 
malignancy, factor V Leiden, and prothrombin G20210A
Decreased 
kidney function* 
Acquired or genetic 
risk factor 
Thrombosis patients Controls Adjusted†
odds ratio (95% CI)
N (%) N (%)
Arterial thrombosis
No No 1878 (87.8) 2524 (92.4) 1 (reference)
Yes No 114 (5.3) 75 (2.7) 2.2 (1.6-3.0)
No Yes 120 (5.6) 124 (4.5) 1.4 (1.1-1.8)
Yes Yes 26 (1.2) 8 (0.3) 4.9 (2.2-10.9)
Malignancy
No No 2053 (86.6) 2674 (93.6) 1 (reference)
Yes No 124 (5.2) 76 (2.7) 2.3 (1.7-3.1)
No Yes 159 (6.7) 98 (3.4) 2.3 (1.8-3.0)
Yes Yes 36 (1.5) 9 (0.3) 5.8 (2.8-12.1)
Surgery 
No No 1845 (72.8) 2681 (94.3) 1 (reference)
Yes No 124 (4.4) 79 (2.8) 2.4 (1.8-3.3)
No Yes 366 (20.6) 78 (2.7) 6.9 (5.3-8.8)
Yes Yes 36 (2.2) 4 (0.1) 14.0 (5.0-39.4)
Immobilization
No No 1633 (68.9) 2600 (91.5) 1 (reference)
Yes No 107 (4.5) 76 (2.7) 2.3 (1.7-3.2)
No Yes 579 (24.4) 160 (5.6) 5.7 (4.8-6.9)
Yes Yes 52 (2.2) 5 (0.2) 17.1 (6.8-43.0)
Factor V Leiden
No No 1871 (78.4) 2642 (92.3) 1 (reference)
Yes No 136 (5.7) 77 (2.7) 2.6 (2.0-3.5)
No Yes 358 (15.0) 134 (4.7) 3.8 (3.1-4.6)
Yes Yes 23 (1.0) 8 (0.3) 4.3 (1.9-9.7)
Prothrombin G20210A
No No 2120 (88.8) 2726 (95.3) 1 (reference)
Yes No 152 (6.4) 84 (2.9) 2.5 (1.9-3.3)
No Yes 109 (4.6) 50 (1.7) 2.8 (2.0-3.9)
Yes Yes 7 (0.3) 1 (0.0) 9.5 (1.2-77.4)
*Decreased kidney function defined as eGFR<60 ml/min as compared with eGFR 60-125 ml/min; 











































Table 4. Odds ratios for venous thrombosis for total number of risk factors present per person
Chronic kidney disease* Number	of	genetic/acquired	
risk factors†
Age and sex adjusted 
odds	ratio	(95%	CI) 
No 0 1 (reference) 
Yes 0 2.0 (1.3-3.0) 
No 1 3.2 (2.8-3.7)
Yes 1 7.8 (4.4-13.8)
No 2 9.6 (7.3-12.5)
Yes 2 7.6 (3.0-19.2)
No ≥ 3 13.2 (7.7-22.6)
Yes ≥ 3 56.3 (7.6-419.3) 
*Chronic kidney disease eGFR<60ml/min (Yes) as compared with eGFR 60-125 ml/min; †Risk factors: 
arterial thrombosis, malignancy, surgery, immobilization, factor V Leiden, or prothrombin G20210A
DISCUSSION
In this large case-control study, kidney function showed an inverse association with venous 
thrombosis risk with a nearly 6-fold increased risk for those with severely decreased kidney 
function (estimated glomerular filtration rate <30 ml/min). Those with additional risk factors had 
an even higher risk of thrombosis, particularly patients who were immobilized or underwent 
surgery (around 15-fold increased risk). Furthermore, there was a cumulative effect when 
several risk factors were present simultaneously with renal function impairment, with up to 56-
fold increased risks. Since these involve common medical circumstances, these findings may 
offer a tool for targeted thromboprophylaxis in vulnerable patients.  
In line with our results, both the LITE4 and PREVEND5 study found an increased risk of 
venous thrombosis for chronic kidney disease. Interestingly, we showed that a high glomerular 
filtration rate of more than 125 ml/min was also associated with an increased risk of venous 
thrombosis (odds ratio 1.4; 95% CI 1.0-1.9). A high glomerular filtration rate has been shown 
to be an indicator for early kidney disease and a predictor of cardiovascular disease.13-16 
Based on the odds ratios of venous thrombosis for decreased kidney function ranging from 
1.1 for mildly decreased kidney function (estimated glomerular filtration rate 60-90 ml/min) to 
5.5 for severely decreased kidney function (estimated glomerular filtration rate <30 ml/min), 
thromboprophylaxis is probably not justified in all patients with decreased kidney function since 
it does not seem to outweigh the increased bleeding risk associated with decreased kidney 
function.17,18 However, our data imply that chronic kidney disease is especially relevant when 
it is present in combination with other risk factors for venous thrombosis, because we found 
a 4- to 17-fold increased risk when chronic kidney disease was jointly present with arterial 








































Risk of venous thrombosis in patients with chronic kidney disease: Identification of high-risk groups
83
5
The risk of venous thrombosis was 56.3-fold increased in the presence of chronic kidney 
disease and three or more of the six risk factors (arterial thrombosis, malignancy, surgery, 
immobilization, factor V Leiden, and prothrombin G20210A). These observations could have 
clinical implications. The American College of Chest Physicians (ACCP) currently recommends 
pharmacologic thromboprophylaxis for several hospitalized groups at high risk for venous 
thrombosis, including patients with a major trauma, spinal cord injury, or heart failure,6 but not 
including patients with chronic kidney disease. Our study results suggest, however, that these 
patients are also at increased risk of venous thrombosis, especially in combination with one or 
more other risk factors. In patients with arterial thrombosis or malignancy who are immobilized 
or will undergo surgery, creatinine measurements are often routinely performed (for example 
before diagnostic testing with contrast agents, for medication dosing, or to identify concurrent 
kidney damage) and can therefore be easily taken into account when deciding on thrombosis 
prophylaxis. However, a potential problem in patients with a chronic kidney disease is the 
increased bleeding risk associated with anticoagulation use.17,18 Therefore, each person’s 
risks and benefits need to be weighed individually until there are randomized clinical trials 
answering these questions. Furthermore, screening for thrombophilia in patients with chronic 
kidney disease is probably not justified given the low prevalence of thrombophilia (factor V 
Leiden and prothrombin gene mutation) and given the moderately increased risks of venous 
thrombosis.
Decreased glomerular filtration has been associated with endothelial dysfunction and 
subsequent arterial thrombosis.1-3,19 Endothelial dysfunction has also been associated with 
changes in the levels of several coagulation proteins and with an increased venous thrombosis 
risk.20 Hence, in theory, the association between chronic kidney disease and venous 
thrombosis could be causally explained through endothelial dysfunction. However, these 
assumptions are merely based on literature,21 and we did not assess endothelial dysfunction 
in this study. Addressing the mechanism through which chronic kidney disease increases the 
risk of venous thrombosis was not the aim of this study, as we were primarily interested in 
establishing high-risk groups that may benefit from thromboprophylaxis, irrespective of the 
underlying causal relation. Research into this relation has yet to be conducted.
A limitation of this study is that we had no information about proteinuria. It would be useful to 
explore whether proteinuria in combination with decreased kidney function is associated with a 
more increased risk of venous thrombosis than decreased kidney function alone. Proteinuria, 
especially in the nephrotic range, has been associated with venous thrombosis.22-24 Another 
limitation was that arterial thrombosis was self-reported. However, we expect that patients 
and control persons misreported arterial thrombosis similarly and infrequently, because these 










































result in an underestimation of our odds ratios. Of note, we used the cut-off levels for the 
glomerular filtration rate of the National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI) guidelines to define kidney disease.25 Nevertheless, it would have 
been interesting to identify risk of venous thrombosis in, for example, kidney-transplanted 
patients or patients who had hemodialysis or peritoneal dialysis treatment, but this information 
was not available in our study. Strengths of this study include the large patient sample and 
detailed information about other risk factors for venous thrombosis such as history of arterial 
thrombosis, malignancy, surgery, immobilization, and genetic risk factors. Nevertheless in 
some subgroups numbers became small, which may have led to slightly inflated risk estimates.
In summary, in a large case-control population we found that a decreasing kidney function 
was associated with an increasing risk of venous thrombosis. The risk of venous thrombosis 
in individuals with chronic kidney disease was further increased in the presence of additional 
risk factors for venous thrombosis. These high-risk groups could be considered for future 
intervention trials into the effectiveness of thromboprophylaxis.
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Background: Whether the risk of both venous and arterial thrombosis is increased in dialysis 
patients as compared to the general population is unknown. In addition, it is unknown which 
subgroups are at highest risk. Furthermore, it is unknown whether having a history of venous 
thrombosis or arterial thrombosis prior to dialysis treatment increases mortality risk. 
Methods: A total of 455 dialysis patients were followed for objectively verified symptomatic 
thrombotic events between January 1997 and June 2009. 
Results: The incidence rates in dialysis patients as compared to the general population 
was 5.6-fold (95% CI 3.1-8.9) increased for venous thrombosis, 11.9-fold (95% CI 9.3-14.9) 
increased for myocardial infarction, and 8.4-fold (95% CI 5.7-11.5) increased for ischemic 
stroke. The combination of hemodialysis, lowest tertile of albumin, history of venous 
thrombosis, and malignancy was associated with subsequent venous thrombosis. Increased 
age, renal vascular disease, diabetes, high cholesterol levels, history of venous thrombosis, 
and history of arterial thrombosis were associated with subsequent arterial thrombosis. The 
all-cause mortality risk was 1.9-fold (95% CI 1.1-3.3) increased for patients with a history of 
venous thrombosis and 1.9-fold (95% CI 1.4-2.6) increased for patients with a history of arterial 
thrombosis. A potential limitation of this study was that in some risk categories associations 
with venous thrombosis did not reach statistical significance due to small numbers.
Conclusion: Dialysis patients have clearly elevated risks of venous thrombosis and arterial 
thrombosis and occurrence of venous thrombosis or arterial thrombosis prior to the start of 












































In the past, venous and arterial thrombosis have been regarded as separate diseases with 
different causes.1 In the last decade, however, several investigators suggested that venous 
and arterial thrombosis might not be fully separate entities as several studies have shown 
that patients with venous thrombosis have an increased risk of arterial thrombosis and vice 
versa.2-6 Additional studies have shown that arterial and venous thrombosis share some risk 
factors, although this has only consistently been shown for obesity.7-11 
Early stages of chronic kidney disease have been associated with both venous and arterial 
thrombosis.12,13 However, end-stage renal disease has only been associated with arterial 
thrombosis,14-20 and not with venous thrombosis including deep vein thrombosis and pulmonary 
embolism. One study in the US Renal Data System (USRDS) showed that dialysis patients 
had an age-adjusted 2.3-fold increased risk of for a primary discharge diagnosis of pulmonary 
embolism occurring within the first year of dialysis treatment as compared to the general 
population.21 However, deep vein thrombosis was not assessed in this study. 
Therefore, the primary aim of this study was to assess the absolute risk of deep vein 
thrombosis and pulmonary embolism (venous thrombosis) and myocardial infarction and 
ischemic stroke (arterial thrombosis) in a cohort of end-stage renal disease patients receiving 
dialysis treatment. We also assessed whether venous thrombosis and arterial thrombosis 
shared risk factors in dialysis patients. Finally, we determined whether having a history of 
venous and arterial thrombosis prior to start of dialysis treatment increased the mortality risk.
METHODS
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospective 
multicenter cohort study in which incident adult end-stage renal disease patients in the 
Netherlands were included. Eligibility included age older than 18 years, and no previous 
renal replacement therapy. All patients gave informed consent and the study was approved 
by all local medical ethics committees. We followed 455 patients, from January 1997 in 
three dialysis centers that participated in NECOSAD, until a thrombotic event (venous 
thrombosis, myocardial infarction, and ischemic stroke), death, or censoring, i.e. transfer to 
a nonparticipating dialysis center, withdrawal from the study, transplantation, or end of the 
follow-up period (June 2009). These three centers were chosen for logistic reasons, i.e. they 










































Demographic and clinical data
Data on age, sex, primary kidney disease, smoking status, diabetes, medication, and history 
of thromboembolic events (venous thrombosis, myocardial infarction, or ischemic stroke) 
were collected at the start of dialysis treatment. Primary kidney disease was classified 
according to the codes of the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA).22 We grouped patients into four classes of primary kidney disease: 
glomerulonephritis, diabetes mellitus, renal vascular disease, and other kidney diseases. 
Other kidney diseases consisted of patients with interstitial nephritis, polycystic kidney 
diseases, other multisystem diseases and unknown diseases. 
Serum albumin, hemoglobin, creatinine, urea, total cholesterol, and triglycerides were routinely 
measured in the dialysis centers at 3 months after start of dialysis. Total protein, urea, and 
creatinine levels were also routinely measured in 24-hour urine samples. Renal function, 
expressed as glomerular filtration rate (GFR), was calculated as the mean of creatinine and 
urea clearance corrected for body surface area (ml/min per 1.73 m2). 
Venous thrombosis and arterial thrombosis 
Symptomatic venous thrombosis (deep vein thrombosis of the leg and pulmonary embolism) 
and symptomatic arterial thrombosis (myocardial infarction and ischemic stroke) during 
follow-up were identified from hospital diagnosis registration systems and from chart review 
of all 455 patients. Moreover, we used medical records to validate the thrombotic events. 
Peripheral vascular atherosclerotic diseases were not considered as arterial events due to 
lack of detailed information of these disease entities in our patients charts.
Venous thrombosis was considered confirmed when diagnosed by compression ultrasound 
for deep vein thrombosis of the leg and/or when diagnosed by spiral computed tomography 
or ventilation-perfusion lung scanning for pulmonary embolism. Venous thrombosis 
was considered unprovoked in the absence of surgery, trauma, presence of a catheter, 
immobilization for >7 days or hospitalization, oral contraceptives, hormone therapy, pregnancy, 
malignant disease, or long-distance travel for >4 hours at or within one month before the 
development of venous thrombosis. Medical records were reviewed with a standardized 
check-list to categorize venous thrombosis into provoked or unprovoked.
Myocardial infarction had to be confirmed by typical symptoms, electrocardiogram features, 
elevated levels of cardiac enzymes, radionuclide imaging techniques, or coronary angiography. 













































We classified causes of death according to the codes of the European Renal Association-
European Dialysis and Transplantation Association (ERA-EDTA) which is a standardized 
classification of death causes in dialysis patients.22 We grouped death causes into 
cardiovascular and non-cardiovascular. Cardiovascular mortality was defined as death due to 
myocardial ischemia and infarction (code 11); cardiac arrest/ sudden death (code 15); cardiac 
failure/ fluid overload/ pulmonary edema (codes 14,16,18); hyperkalemia /hypokalemia (code 
12,17); pulmonary embolism (code 21); cerebrovascular accident (code 22); hemorrhage 
from ruptured vascular aneurysm (code 26); mesenteric infarction (code 29); cause of death 
uncertain/unknown (code 0). Non-cardiovascular mortality was defined as death caused by 
pulmonary infection (code 31-33); infections elsewhere (code 34); septicemia (code 35); 
tuberculosis (code 36-37); generalized viral infection (code 38); peritonitis (code 39); suicide 
(code 52); treatment cessation (code 51, 53-54) ; cachexia (code 64) ; malignancies (codes 
66-68); miscellaneous (codes 13, 23-28, 41-46, 61-63, 69-73, 81-82, 99-102).
Statistical analysis
Continuous variables are presented as mean with standard deviation (SD) or as median 
and interquartile rage (IQR) depending on the normality of the data. Categorical variables 
are presented as counts with corresponding percentages. The observation time for venous 
thrombosis in each participant was calculated as the time elapsed between the start of 
dialysis and a censoring event (withdrawal from the study, transplantation, death, or June 
2009), or the first episode of venous thrombosis during dialysis. The observation time for 
arterial thrombosis in each participant was calculated as the time elapsed between the start 
of dialysis and a censoring event (withdrawal from the study, transplantation, death, or June 
2009), or the first episode of arterial thrombosis during dialysis. Incidence rates for arterial 
and venous thrombosis were calculated by dividing the number of patients with a venous 
thrombosis or arterial thrombosis by the total observation time at risk. When calculating the 
incidence rates for venous thrombosis, we ignored the occurrence of arterial thrombosis 
and vice versa. Incidence rates and 95% confidence intervals (95% CIs) were calculated 
with Poisson regression models for venous thrombosis, myocardial infarction, and ischemic 
stroke in dialysis patients. We used indirect standardization to compare these incidence rates 
to the age- and sex-weighted incidence rates in the general population obtained from the 
HUNT2 study for venous thrombosis23 and the Framingham study for myocardial infarction24 
and ischemic stroke.25 The presented incidence rates in the general population are based on 
the age- and sex-distribution of the dialysis patients in our study. Cumulative incidences for 
venous thrombosis and arterial thrombosis were analyzed by using time-to-event analyses 
accounting for competing risk of transplantation and death.26 Furthermore, we calculated 










































characteristics on the development of venous thrombosis and arterial thrombosis. Finally, we 
determined whether having a history of venous and arterial thrombosis prior to start of dialysis 
treatment increased the (cardiovascular and non-cardiovascular) mortality. SPSS statistical 
software (version 17.0; SPSS, Chicago, Illinois) was used for the analyses.
RESULTS 
Baseline characteristics of the 455 patients are shown in Table 1. Overall, the mean age 
was 60.4 years, 65.7% were male, 64.6% had hemodialysis treatment at initiation of dialysis 
including 85 patients with a catheter (18.7%) and 209 patients with an arteriovenous access 
(45.9%), and 18.2% of patients had diabetes as primary kidney disease. Of the 455 patients, 23 
(5.1%) had a history of venous thrombosis and 116 (25.5%) had a history of arterial thrombosis 
prior to the start of dialysis therapy. Patients were followed for a median observation period of 
2.4 years (range 0.1 to 11.7 years).
During the observation period, 15 patients developed venous thrombosis, of whom seven 
had pulmonary embolism, seven deep vein thrombosis, and one presented with both. Four 
patients (26.7%) with pulmonary embolism died. Of the 15 venous thrombotic events, 5 were 
unprovoked and 10 were provoked (hospitalization, n=4; catheter-related, n=4; surgery, n=2, 
presence of malignancy, n=2). Of the 4 patients who developed venous thrombosis during 
hospitalization, one had an exacerbation of ulcerative colitis, one patient had sepsis, one had 
a pancreatitis, and one had an exacerbation of Wegener’s disease. Of the 4 patients who 
developed catheter associated venous thrombosis, three had a deep vein thrombosis and one 
had a pulmonary embolism. One patient developed venous thrombosis during hospitalization 
after coronary artery bypass grafting and another patient developed venous thrombosis 
shortly after thrombectomy of a thrombosed dialysis shunt. Of note, none of the patients had 
an arteriovenous access in the lower limb. Furthermore, 96 patients developed an arterial 
thrombosis (72 patients developed myocardial infarction of which 15 were fatal (20.8%) and 
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Table 1. Baseline characteristics
N=455






Peritoneal dialysis 161 (35.4%)
Primary kidney disease (%)
Diabetes mellitus 83 (18.2%)
Glomerulonephritis 48 (10.5%)
Renal vascular disease 75 (16.5%)
Other 249 (54.7%)
Body mass index, kg/m2 25.0 ± 5.2
Diabetes mellitus as comorbidity 122 (26.8%)
Malignancy 24 (5.3%)
History of venous thrombosis 23 (5.1%)




Hemoglobin, mmol/L 6.9 ± 1.0
GFR, ml/min 3.3 (1.9-5.6)
Proteinuria, gram per day 1.1 (0.5-2.4)
Anticoagulation use 21 (6.7%)
Erythropoietin use 276 (60.7%)
Erythropoietin dose, IU/week 6000 (4000-8000)
Albumin, g/L 33.0 (29.0-37.0)
Cholesterol, mmol/L 4.4 (3.6-5.4)
Triglycerides, mmol/L 1.9 (1.3-2.6)
Figure 1 shows the incidence rates per 1000 person-years for venous thrombosis (combination 
of deep vein thrombosis and pulmonary embolism), deep vein thrombosis (alone), pulmonary 
embolism (with or without deep vein thrombosis), myocardial infarction, and ischemic stroke 
in dialysis patients as compared to the estimated age- and sex-weighted incidence rates 
in the general population (HUNT2 study23 for venous thrombosis and Framingham study24,25 
for myocardial infarction and ischemic stroke). The incidence rate of venous thrombosis 
(12.3 (95% CI 7.2-19.9) per 1000 person-years) in dialysis patients was 5.6 (95% CI 3.1-
8.9) times higher  than the estimated age- and sex-weighted annual incidence rate in the 
general population (HUNT2 study,23 2.2 per 1000 person-years). The incidence of both 
provoked venous thrombosis (8.2 per 1000 person-years; 95% CI 4.2-14.6) and unprovoked 










































and sex-weighted annual incidence rates of provoked and unprovoked venous thrombosis 
in the general population (HUNT2 study,23 1.1 per 1000 person-years for provoked venous 
thrombosis and 1.1 per 1000 person-years for unprovoked venous thrombosis). The absolute 
risk of myocardial infarction (62.1 (95% CI 49.0-77.8) per 1000 person-years) was 11.9 (95% 
CI 9.3-14.9) times higher in dialysis patients than the estimated age- and sex-weighted 
incidence rate in the general population (the Framingham study,24 5.2 per 1000 person-years). 
Moreover, the absolute risk of ischemic stroke (27.6 (95% CI 19.3-38.4) per 1000 person-
years) was 8.4 (95% CI 5.7-11.5) times higher in dialysis patients than the estimated age- and 
sex-weighted annual incidence rate in the general population (the Framingham study,25 3.3 
per 1000 person-years). The cumulative incidence at eight years of follow-up was 4.1% for 
venous thrombosis and 24.8% for arterial thrombosis. 
 129
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MI indicates myocardial infarction; STROKE, ischemic stroke; VT, venous thrombosis; DVT, deep 
vein thrombosis; PE, pulmonary embolism 
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Figure 1. Incidence rates per 1000 person-years for venous and arterial thrombosis in dialysis 
patients as compared to the age- and sex- weighted incidence rates in the general population
MI indicates myocardial infarction; STROKE, ischemic stroke; VT, venous thrombosis; DVT, deep vein 
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Table 2 shows the risk of venous or arterial thrombosis for different baseline variables after 
adjustment for age and sex. Venous and arterial thrombosis did not share risk factors in these 
dialysis patients, except for history of venous thrombosis which was associated with both 
venous and arterial thrombosis. Hemodialysis therapy, highest tertile of albumin, malignancy, 
and history of venous thrombosis were associated with venous thrombosis after adjustment 
for age and sex, although not significant. The combination of hemodialysis, highest tertile 
of albumin, history of venous thrombosis, and malignancy were associated with a 12.0-fold 
(95% CI 1.7-84.9) increased risk of venous thrombosis as compared with the absence of 
these risk factors. History of arterial thrombosis was not associated with subsequent venous 
thrombosis (hazard ratio 1.0; 95 CI 0.3-3.9). However, after exclusion of vitamin K antagonist 
users (anticoagulation use), the hazard ratio increased to 1.6 (95% CI 0.3-8.0). Increased 
age, diabetic nephropathy, renal vascular disease, history of arterial and venous thrombosis, 
diabetes as comorbidity, and the highest tertile of cholesterol were associated with arterial 
thrombosis. The combination of increased age (≥65 years), renal vascular disease, history of 
arterial and venous thrombosis, diabetes, and the highest tertile of cholesterol was associated 
with an 11.3-fold (95% CI 1.8-72.3) increased risk of arterial thrombosis as compared with the 
absence of these risk factors.
During the observation period, 197 patients died (99 cardiovascular mortality and 98 non-
cardiovascular deaths). Patients with a history of venous or arterial thrombosis before starting 
dialysis had an increased mortality risk while on dialysis after adjustment for age, sex, 
diabetes, and primary kidney disease (Table 3): the all-cause mortality risk was 1.9-fold (95% 
CI 1.1-3.3) increased for patients with a history of venous thrombosis and 1.9-fold (95% CI 
1.4-2.6) increased for patients with a history of arterial thrombosis as compared to patients 
without a history of venous or arterial thrombosis. Patients with a history of venous thrombosis 
had a non-significantly 2.0-fold (95% CI 0.9-4.4) increased risk of cardiovascular mortality and 
a non-significantly 1.8-fold (95% CI 0.8-4.0) increased risk for non-cardiovascular mortality. 
Patients with a history of arterial thrombosis had a 2.4-fold (95% CI 1.6-3.7) increased risk for 











































Table 2. Association of baseline characteristics with subsequent venous and arterial thrombosis 
after adjustment for age and sex





Age, years < 65 1.0 (reference) 1.0 (reference)
65-75 0.3 (0.1-1.6) 1.1 (0.7-1.7)
>75 1.2 (0.3-4.5) 1.6 (1.0-2.8)
Sex Male 0.8 (0.3-2.1) 1.3 (0.9-2.1)
Female 1.0 (reference) 1.0 (reference)
Dialysis modality Hemodialysis 2.6 (0.7-9.7) 0.7 (0.4-1.1)
Peritoneal dialysis 1.0 (reference) 1.0 (reference)
Primary kidney disease Diabetes mellitus 0.5 (0.1-2.2) 2.0 (1.2-3.4)
Glomerulonephritis 0.4 (0.1-2.2) 1.2 (0.5-2.5)
Renal vascular disease NE 2.5 (1.5-4.2)
Other 1.0 (reference) 1.0 (reference)
Body mass index, kg/m2 <30.0 1.0 (reference) 1.0 (reference)
≥30.0 1.6 (0.4-5.8) 0.8 (0.4-1.6)
Diabetes mellitus as comorbidity 1.5 (0.5-4.3) 1.5 (1.0-2.3)
Malignancy 3.0 (0.6-13.8) 0.6 (0.2-1.7)
History of venous thrombosis 3.4 (0.7-15.5) 2.3 (1.1-4.9)
History of arterial thrombosis 1.0 (0.3-3.9) 2.9 (1.9-4.5)
Smoking 1.2 (0.4-3.6) 1.5 (0.9-2.3)
Erythropoietin use 0.8 (0.3-2.3) 1.2 (0.8-1.8)
Hemoglobin, mmol/L <6.5 1.0 (reference) 1.0 (reference)
≥6.5 to 7.2 0.7 (0.2-2.3) 1.0 (0.6-1.7)
>7.2 0.6 (0.2-2.0) 1.3 (0.8-2.1)
GFR, ml/min 0 to 5 1.0 (reference) 1.0 (reference)
>5 to 10 0.9 (0.3-3.3) 1.0 (0.6-1.6)
>10 1.6 (0.2-12.4) 0.9 (0.3-2.3)
Proteinuria, gram per day 0 to 0.3 1.0 (reference) 1.0 (reference)
>0.3 to 3.5 0.3 (0.1-1.1) 1.3 (0.7-2.3)
≥3.5 0.8 (0.2-3.2) 1.2 (0.6-2.6)
Albumin, g/L <30.1 1.0 (reference) 1.0 (reference)
≥30.1 to 35.5 0.8 (0.2-2.5) 0.7 (0.5-1.2)
>35.5 0.4 (0.1-1.6) 0.8 (0.5-1.2)
Cholesterol, mmol/L <3.9 1.0 (reference) 1.0 (reference)
≥3.9 to 5.0 0.9 (0.2-3.6) 1.1 (0.6-1.9)
>5.0 1.6 (0.5-5.7) 1.6 (1.0-2.8)
Triglycerides, mmol/L <1.4 1.0 (reference) 1.0 (0.6-1.7)
≥1.4 to 2.3 1.1 (0.2-5.0) 0.8 (0.5-1.4)
>2.3 1.3 (0.3-5.7) 1.1 (0.7-1.9)
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Table 3. History of venous and arterial thrombosis prior to start of dialysis treatment and mortality 
risk after adjustment for age and sex
All-cause mortality
Hazard ratios* (95% CI)
CV mortality
Hazard ratios* (95% CI)
Non CV mortality
Hazard ratios* (95% CI)
No history venous or arterial 
thrombosis
1.0 (reference) 1.0 (reference) 1.0 (reference)
History of venous thrombosis 1.9 (1.1-3.3) 2.0 (0.9-4.4) 1.8 (0.8-4.0)
History of arterial thrombosis 1.9 (1.4-2.6) 2.4 (1.6-3.7) 1.5 (1.0-2.4)
*hazard ratios adjusted for age, sex, diabetes, and primary kidney disease.
DISCUSSION
In the present study, we observed that dialysis patients had absolute risks of more than one 
percent per year for venous thrombosis, myocardial infarction and ischemic stroke, with 6-fold 
increase of venous thrombosis, 8-fold increase of ischemic stroke, and 12-fold increase of 
myocardial infarction risk as compared to the age- and sex-weighted incidence rates in the 
general population. Finally, our data showed a strong association between a history of venous 
and arterial thrombosis prior to the start of dialysis and mortality during dialysis.
To our knowledge, this the first study that assessed the incidence of both deep vein thrombosis 
and pulmonary embolism in end-stage renal disease patients. One other study has examined 
the incidence of only pulmonary embolisms in end-stage renal disease patients. It showed that 
dialysis patients had a 2.3-fold increased risk for pulmonary embolism,21 which is lower than in 
our study. However, as they only assessed pulmonary embolism in case of primary discharge 
diagnosis in the first year of dialysis, this could have resulted in an underestimation of the 
number of pulmonary embolisms. The observed risk of venous thrombosis in dialysis patients 
in our cohort is in contrast with previous autopsy studies.27-30 These studies showed that 
pulmonary embolism was less common in dialysis patients than in non-dialysis patients.27-30 
However, the incidence of venous thrombosis may be underestimated in these autopsy 
studies, since only a small and selective proportion of dialysis patients undergo postmortem 
examination. Furthermore, postmortem diagnosis often provides little information about the 
clinical significance of thrombotic events. The increased risk for myocardial infarction and 
ischemic stroke in our Dutch cohort of dialysis patients is in line with previous studies.14-20 
Studies revealed that cardiovascular mortality rates were 8 to 20 times higher than in the 
general population.15-17 
A possible explanation for the increased risk of venous thrombosis is the high rate of 
hospitalization, surgery, and immobilization resulting in stasis of the blood and in subsequent 










































thrombosis suggesting that also other factors play a role in the development of venous 
thrombosis in dialysis patients. One of these other factors could be hypercoagulability. 
Several studies have shown that there is a hypercoagulable state in dialysis patients.31,32 
Another explanation for the increased risk of venous thrombosis in dialysis patients could be 
that the high usually rate of thrombus formation in grafts and fistulas in hemodialysis patients 
may cause pulmonary embolisms through dislodgement of thrombi.33 An important finding that 
strengthens this hypothesis was that venous thrombosis was more frequent in hemodialysis 
patients than in peritoneal dialysis patients. Moreover, deep vein thrombosis and pulmonary 
embolism occurred in a similar frequency in this cohort of dialysis patients, whereas in the 
general population deep vein thrombosis is twice as frequent as pulmonary embolism.23 In 
addition, one patient had a symptomatic pulmonary embolism shortly after a thrombectomy of 
a thrombosed dialysis shunt. 
Recent studies have challenged the historical dichotomy of arterial and venous thrombosis as 
two different entities with distinct risk factors.2-6 Indeed, arterial cardiovascular risk factors such 
as hypertension, smoking, and diabetes appeared to be risk factors for venous thrombosis as 
well.7-11 In our study, venous and arterial thrombosis did not share risk factors in these dialysis 
patients, except for a history of venous thrombosis prior to the start of dialysis which was 
associated with both venous and arterial thrombosis. “Classic” cardiovascular risk factors in the 
general population, such as an increased age, diabetic nephropathy, renal vascular disease, 
history of arterial thrombosis, diabetes as comorbidity, and highest tertiles of cholesterol were 
associated with subsequent arterial thrombosis and not with venous thrombosis. Malignancy, 
a “classic” risk factor for venous thrombosis in the general population was associated with a 
non-significantly increased risk of subsequent venous thrombosis. Furthermore, we found a 
non-significant inverse association between serum albumin levels and venous thrombosis. 
Also in patients with nephrotic syndrome, serum albumin has been inversely associated with 
venous thrombosis.34,35
We showed that both a history of arterial thrombosis and venous thrombosis before the start of 
dialysis increased the mortality risk during dialysis. Prior studies also found that dialysis patients 
who had suffered cardiovascular disease had a poor long-term survival.36,37 This finding is in 
agreement with previous studies that showed that venous thrombosis was associated with an 
increased risk for arterial thrombosis3-5 and an increased long-term mortality risk in the general 
population.38 Therefore, it is tempting to suggest that a history of venous thrombosis before the 
start of dialysis could be marker of underlying atherosclerosis which results in an increased risk 
of subsequent arterial thrombosis and an increased mortality risk. Atherosclerosis in patients 
with a history of venous or arterial thrombosis could also explain why the hazard ratios were 
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association between a history of arterial thrombosis and subsequent venous thrombosis. 
This might be explained by the high prevalence of anticoagulation use in patients with a 
history of arterial thrombosis preventing also venous thrombosis. Indeed, after exclusion of 
vitamin K antagonist users, the risk of venous thrombosis for patients with a history of arterial 
thrombosis was 1.6-fold increased, but as numbers in this subgroup analysis became small, 
the results should be handled with caution.
A strength of this study is its prospective design in which objectively confirmed venous and 
arterial thrombotic events were considered as outcome measures. Nevertheless, our study 
has some potential limitations that should be addressed. A limitation of this study was that we 
could not measure levels or activity of coagulation factors or markers of hypercoagulability 
to investigate the role of these factors in the development of thrombotic events in dialysis 
patients. Another limitation of this study was that confidence intervals around the hazard ratios 
were wide for risk factors of venous and arterial thrombosis, indicating a limited power for 
detecting underlying risk factors for venous and arterial thrombosis in dialysis patients. Small 
numbers also restricted us to not perform further analyses of potential risk factors (such as 
hemodialysis or peritoneal dialysis) on mortality in patients with previous venous or arterial 
thrombosis. Nevertheless, this study is the largest to date that analyzed risk factors for both 
venous and arterial thrombosis and subsequent mortality in dialysis patients.
In conclusion, we showed that dialysis patients had high risks for venous and arterial 
thrombosis, while occurrence of these thrombotic diseases prior to the start of dialysis was 
associated with an increased mortality risk in this patient group. Furthermore, we showed that 
venous and arterial thrombosis did not share risk factors in these dialysis patients. 
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Background: It has been suggested that dialysis patients have lower mortality rates for 
pulmonary embolism than the general population, because of platelet dysfunction and bleeding 
tendency. However, there is limited information whether dialysis is indeed associated with a 
decreased mortality risk from pulmonary embolism. The aim of our study was to evaluate 
whether mortality rate ratios for pulmonary embolism were lower than for myocardial infarction 
and stroke in dialysis patients compared with the general population. 
Methods: Cardiovascular causes of death for 130 439 incident dialysis patients registered 
in the ERA-EDTA Registry were compared with the cardiovascular causes of death for the 
European general population. 
Results: The age- and sex-standardized mortality rate (SMR) from pulmonary embolism was 
12.2 (95%CI 10.2-14.6) times higher in dialysis patients than in the general population. The 
SMRs in dialysis patients compared with the general population were 11.0 (95% CI 10.6-11.4) 
for myocardial infarction, 8.4 (95% CI 8.0-8.8) for stroke, and 8.3 (95% CI 8.0-8.5) for other 
cardiovascular diseases. In dialysis patients, primary kidney disease due to diabetes was 
associated with an increased mortality risk due to pulmonary embolism (HR 1.9; 95% CI 1.0-
3.8), myocardial infarction (HR 4.1; 95% CI 3.4-4.9), stroke (HR 3.5; 95% CI 2.8-4.4), and 
other cardiovascular causes of death (HR 3.4; 95% CI 2.9-3.9) compared with patients with 
polycystic kidney disease. 
Conclusion: Dialysis patients were found to have an unexpected highly increased mortality 












































End-stage renal disease patients who receive dialysis treatment have a markedly increased 
risk of death with a cardiovascular mortality risk that is 8-20 times higher than in the general 
population.1-6 However, there is limited information on the contribution of various specific 
causes of cardiovascular death such as pulmonary embolism, myocardial infarction and 
stroke to the excess risk. It has been suggested that dialysis patients have a lower risk for 
pulmonary embolism than the general population, because of platelet dysfunction and bleeding 
tendency.7,8 In support of this notion, autopsy studies have shown pulmonary embolism to be 
less common in dialysis patients than in non-dialysis patients.9-12 However, epidemiological 
studies investigating the risk of mortality due to pulmonary embolism in dialysis patients 
are lacking. While studies in dialysis patients have shown an increased risk for myocardial 
infarction13 and stroke,14,15 the specific mortality risks due to these causes have not been 
adequately dissected. 
Based on the previous autopsy studies on pulmonary embolism, we hypothesized that mortality 
rate ratios for pulmonary embolism would be lower than those for myocardial infarction and 
stroke in dialysis patients compared with the general population. Therefore, our aim was to 
assess the rates of mortality from myocardial infarction, stroke, and pulmonary embolism 
in a large cohort of incident dialysis patients and compare them with those in the general 
population. Finally, we set out to investigate the risk factors for death from these specific 
cardiovascular causes in the dialysis population.
METHODS
Dialysis patients
The study cohort consisted of incident dialysis patients derived from the European Renal 
Association-European Dialysis and Transplant Association (ERA-EDTA) Registry.16 This 
cohort included patients from national and regional registries in 11 European countries: Austria, 
Dutch- and French-speaking Belgium, Denmark, Finland, Greece, Iceland, Calabria (Italy), 
the Netherlands, Norway and the autonomous communities of Andalusia, Asturias, Basque 
country, Catalonia, Castile-La Mancha, Castile and Leon, Extremadura, and Valencian region 
in Spain, and Sweden. The ERA-EDTA Registry collects data on renal replacement therapy, 
including date of birth, sex, primary kidney disease, date of start of renal replacement therapy, 
dialysis modality at baseline and during follow-up, and date and cause of death. Primary kidney 
disease was classified according to the coding system of the ERA-EDTA.17 We grouped patients 
into nine classes of primary kidney disease: polycystic kidney disease, glomerulonephritis, 










































vascular disease due to polyarteritis, granulomatous polyangiitis, glomerulonephritis related 
to liver cirrhosis, cryoglobulinaemic glomerulonephritis, myelomatosis, amyloidosis, systemic 
lupus erythematosus, Henoch-Schoenlein purpura, Goodpasture’s syndrome, and systemic 
sclerosis), miscellaneous, and missing/unknown. Patients were included if they originated 
from registries reporting less than 25% missing or unknown causes of death. We included 
patients who initiated dialysis between January 1, 1994, and December 31, 2005, and followed 
them for a maximum of 3 years from onset of dialysis until December 31, 2008, or until death 
or censoring (i.e. recovery of renal function, kidney transplantation or loss to follow-up).
Mortality in dialysis patients
We classified the causes of death according to the coding system of the ERA-EDTA, which is 
a standardized classification of causes of death in dialysis patients.17 Cardiovascular mortality 
was defined as a death attributable to pulmonary embolism (ERA-EDTA code 21), myocardial 
infarction (ERA-EDTA code 11), stroke (ERA-EDTA code 22), and other cardiovascular causes 
[cardiac arrest / sudden death (ERA-EDTA code 15), fluid overload / pulmonary edema (ERA-
EDTA codes 18), hypertensive cardiac failure (ERA-EDTA codes 16), other causes of cardiac 
failure (ERA-EDTA codes 14)]. Unknown (ERA-EDTA code 0) and missing causes of death 
were defined as unknown. All other causes of death were defined as non-cardiovascular. 
Mortality in the general population
Mortality data obtained from the general population in the corresponding 11 countries (or 
regions) that contributed data on dialysis patients were used as reference. These mortality 
data, derived from the national cause of death statistics, were obtained from the World Health 
Organization (WHO). The WHO provides mortality data coded according to the International 
Statistical Classification of Diseases (ICD), stratified by age categories, sex, and calendar 
year. 
Cardiovascular mortality in the general population was defined as death from diseases of the 
circulatory system (ICD-9 codes 390-459; ICD-10 codes I00-I99),3 i.e. pulmonary embolism 
(ICD-9 codes 415.1; ICD-10 codes I26),18 myocardial infarction (ICD-9 code 410; ICD-10 codes 
I21-I22),19 stroke (ICD-9 codes 430-434, 436; ICD-10 codes I60-I64)20, and other causes of 
cardiovascular death (ICD-9 codes 390-459, except 415.1, 410, 430-434, and 436; ICD-10 
codes I00-I99, except I26, I21-I22, and I60-I64). Ill-defined and unknown causes of mortality 
(ICD-9 codes 797-799; ICD-10 codes R96-R99) were regarded as unknown cause of death 
in the general population, while all other codes (all ICD-9 codes except 390-459 and 797-799 
and all ICD-10 codes except I00-I99 and R96-R99) were regarded as non-cardiovascular 












































Continuous variables are presented as means with standard deviation (SD). Data were 
stratified by age-categories (20-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 
65-74 years, 75-84, and ≥85 years) and sex. 
The rates of mortality from all causes and specific cardiovascular causes (pulmonary embolism, 
myocardial infarction, stroke, and other) in each age category were calculated by dividing the 
number of patients who died due to cardiovascular causes by the total observation time at 
risk in each age stratum, for both the dialysis patients and the general population. The time 
at risk in the general population was calculated using the demographic large-scale method.3 
Using this method, person-time at risk in the general population of the 11 countries from which 
dialysis patients were included, was calculated as the sum of the mean size of the general 
population in the subsequent calendar years. 
Furthermore, we calculated crude mortality rate ratios with 95% CIs by dividing the mortality 
rates in dialysis patients by the mortality rates in the general population. In addition, age- and sex-
standardized mortality rate ratios were calculated using direct standardization with the general 
population as reference. We also did a sensitivity analysis in which age- and sex-standardized 
mortality rate ratios with 95% CIs were calculated for pulmonary embolism, myocardial 
infarction, and stroke after changing all unknown codes of death in the general population into 
pulmonary embolism, myocardial infarction, or stroke, respectively. Finally, among incident 
dialysis patients, we calculated hazard ratios (HRs) with 95% CIs to evaluate the effect of age, 
sex, and primary kidney disease at baseline on death due to pulmonary embolism, myocardial 
infarction, stroke, and other cardiovascular diseases using Cox regression. We also used 
Cox regression to evaluate the effect of dialysis modality (hemodialysis or peritoneal dialysis) 
at 3 months after the beginning of renal replacement therapy on death due to pulmonary 
embolism, myocardial infarction, stroke, and other cardiovascular diseases. SPSS statistical 
software (version 18.0; SPSS, Chicago, Illinois) was used for the analysis.
RESULTS
In this study, we included 130 439 dialysis patients from 11 countries who began dialysis 
between January 1, 1994, and December 31, 2005. The mean age of the dialysis patients 
was 63.1 years, 61.0% were male, in 22.3% diabetes was the cause of kidney disease, and 
84.1% started hemodialysis as the initial dialysis modality (Table 1). The mean follow-up of 
dialysis patients was 2.0 years resulting in a total observation time of 260 772 years. During 
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The general population yielded an observation time of 1140.2 million person-years. The mean 
age of the general population was lower than the mean age of the dialysis patients. There 
were fewer men in the general population than in the dialysis patients.
During follow-up, 50 765 of the 130 439 dialysis patients died (Table 2). Among the deceased 
patients, cardiovascular diseases were the cause of death in 39.8% of cases: pulmonary 
embolism 0.7%, myocardial infarction 11.4%, stroke 7.3%, and other cardiovascular cause 
of death 20.3% (including cardiac arrest/ sudden death 12.3% and other than cardiac arrest/ 
sudden death 8.0%). Death from non-cardiovascular causes occurred in 46.5% of the patients, 
while the cause of death was unknown in 13.8%. There was a similar pattern of cardiovascular 
causes of death (pulmonary embolism, myocardial infarction, stroke, and other cardiovascular 
cause of death) across the age groups. In the general population, 13 739 478 persons died 
during the study period. Of those, 40.1% died from cardiovascular diseases (pulmonary 
embolism 0.5%, myocardial infarction 8.6%, stroke 9.0%, and other cardiovascular cause of 
death 21.9%), 57.9% from non-cardiovascular diseases, and 2.0% from unknown causes. 
Both in the general population and the dialysis population, the mortality rates for pulmonary 
embolism, myocardial infarction, stroke, and other cardiovascular causes of death increased 
with age (Figure 1).
Table 3 shows the mortality rates for total and cause specific (pulmonary embolism, myocardial 
infarction, stroke, and other) cardiovascular mortality in different age categories stratified by 
sex. In both the dialysis patients and the general population, mortality rates due to myocardial 
infarction and due to other cardiovascular causes of death were higher in men than in women, 
while women were at higher risk of death due to stroke and pulmonary embolism than men. 
The total cardiovascular mortality rate was 77.4 per 1000 person-years in dialysis patients 
and 4.8 per 1000 person-years in the general population. The age- and sex-standardized 
cardiovascular mortality rate was 8.9 (95% CI 8.7-9.1) times higher in dialysis patients than in 































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Mortality rates due to pulmonary embolism, myocardial infarction, stroke, and other cardiovascular 















Figure 1. Mortality rates due to pulmonary embolism, myocardial infarction, stroke, and other 
cardiovascular diseases in dialysis patients and in the general population for different age 
categories 
PE, pulmonary embolism; MI, myocardial infarction; CVD, cardiovascular disease; y, years 
Compared with the general population, the age- and sex-standardized mortality rate ratios in 
dialysis patients were 12.2 (95% CI 10.2-14.6) for pulmonary embolism (1.4 among dialysis 
patients versus 0.1 among the general population per 1000 person-years, respectively), 
11.0 (95% CI 10.6-11.4) for myocardial infarction (22.3 versus 1.0 per 1000 person-years, 
respectively), 8.4 (95% CI 8.0-8.8) for stroke (14.2 versus 1.1 per 1000 person-years, 
respectively), and 8.3 (95% CI 8.0-8.5) for other cardiovascular causes of death (39.5 versus 
2.6 per 1000 person-years, respectively). The mortality rates for all cardiovascular causes 
of death were highest in the first 6 months after initiation of dialysis: mortality rate 1.9 per 
1000 person-years for pulmonary embolism, 26.2 per 1000 person-years for myocardial 
infarction, 15.5 per 1000 person-years for stroke, and 51.6 per 1000 person-years for other 
cardiovascular causes of death.
In a worst case scenario, in which we changed all unknown codes of death in the general 
population into pulmonary embolism, myocardial infarction, or stroke, age- and sex-
standardized mortality rate ratios were still increased for respectively pulmonary embolism 











































Table	 3.	 Total	 and	 cause-specific	 mortality	 rates	 per	 1000	 person-years	 in	 dialysis	 patients	
compared with the general population
Age	category,	N	(%)
Characteristic All 20-24 y 25-34 y 35-44 y 45-54 y 55-64 y 65-74 y 75-84 y ≥85	y
Total cardiovascular mortality
Dialysis patients Male 80.5 5.5 9.9 22.9 38.2 60.6 95.6 131.8 176.6
Female 72.6 3.6 12.9 20.9 30.1 48.7 83.5 116.9 164.1
Total 77.4 4.8 11.1 22.1 35.2 56.2 90.7 125.6 171.1
General Male 4.6 0.0 0.1 0.3 1.1 3.2 9.7 28.9 86.0
Population Female 5.0 0.0 0.0 0.1 0.4 1.1 4.7 21.0 82.0
Total 4.8 0.0 0.1 0.2 0.7 2.1 7.0 24.1 83.2
Unstandardized mortality rate ratio 
16.0	(95%	CI	15.8-16.3)
Age- and sex-standardized mortality rate ratio 
8.9	(95%	CI	8.7-9.1)
Pulmonary embolism
Dialysis patients Male 1.1 0.0 0.2 0.2 0.6 0.9 1.4 2.0 1.7
Female 1.8 1.2 0.0 0.9 0.5 1.1 2.2 3.0 2.6
Total 1.4 0.4 0.1 0.4 0.5 1.0 1.7 2.4 2.1
General Male 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.9
Population Female 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.9
Total 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.9
Unstandardized mortality rate ratio 
20.2	(95%	CI	18.3-22.4)
Age- and sex-standardized mortality rate ratio 
12.2	(95%	CI	10.2-14.6)
Myocardial infarction
Dialysis patients Male 25.2 0.0 1.3 5.3 11.8 21.1 30.6 41.0 37.4
Female 17.8 0.0 2.0 5.1 7.2 13.0 22.1 27.9 25.2
Total 22.3 0.0 1.6 5.2 10.1 18.1 27.2 35.5 32.1
General Male 1.2 0.0 0.0 0.1 0.5 1.2 3.1 7.1 14.6
Population Female 0.9 0.0 0.0 0.0 0.1 0.3 1.2 4.0 10.5
Total 1.0 0.0 0.0 0.1 0.3 0.7 2.0 5.2 11.7
Unstandardized mortality rate ratio 
21.5	(95%	CI	21.0-22.1)
Age- and sex-standardized mortality rate ratio 
11.0	(95%	CI	10.6-11.4)
Stroke
Dialysis patients Male 13.2 1.4 3.7 5.6 8.3 9.3 14.7 20.8 33.4
Female 15.7 0.0 4.8 6.0 6.1 10.6 17.2 25.0 42.3
Total 14.2 0.9 4.1 5.8 7.5 9.8 15.7 22.5 37.3
General Male 0.9 0.0 0.0 0.1 0.2 0.5 1.7 6.2 18.4
Population Female 1.3 0.0 0.0 0.0 0.1 0.3 1.2 5.6 19.3
Total 1.1 0.0 0.0 0.0 0.1 0.4 1.4 5.8 19.0
Unstandardized mortality rate ratio 
13.1	(95%	CI	12.7-13.5)
Age- and sex-standardized mortality rate ratio  
8.4	(95%	CI	8.0-8.8)
Other Cardiovascular disease
Dialysis patients Male 41.0 4.1 4.7 11.7 17.4 29.3 48.9 68.0 104.0
Female 37.3 2.4 6.1 9.0 16.3 23.9 42.0 61.1 94.1
Total 39.5 3.5 5.2 10.7 17.0 27.3 46.1 65.2 99.7
General Male 2.4 0.0 0.0 0.1 0.5 1.4 4.7 15.2 52.2
Population Female 2.9 0.0 0.0 0.1 0.2 0.5 2.3 11.0 51.2
Total 2.6 0.0 0.0 0.1 0.3 1.0 3.4 12.7 51.5
Unstandardized mortality rate ratio 
15.0	(95%	CI	14.7-15.3)
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In dialysis patients, older age at the beginning of dialysis (≥85 years) was associated with an 
increased risk of pulmonary embolism (HR 7.8; 95% CI 3.3-18.6), myocardial infarction (HR 
9.6; 95% CI 7.5-12.3), stroke (HR 8.9; 95% CI 7.2-11.2), and other cardiovascular causes of 
death (HR 12.3; 95% 10.6-14.3) when compared with patients who were younger at onset of 
dialysis (20-44 years) (Table 4). Male sex was associated with an increased risk of myocardial 
infarction (HR 1.4; 95% CI 1.3-1.5) and other cardiovascular causes of death (HR 1.1; 95% 
1.1-1.2), whereas males had a decreased risk of death due to pulmonary embolism (HR 
0.6; 95% CI 0.5-0.8) and stroke (HR 0.9; 95% CI 0.8-0.9). Both diabetes and multi-system 
diseases were associated with an increased risk of pulmonary embolism (HR 1.9; 95% CI 1.0-
3.8 and HR 3.2; 95% CI 1.6-6.4, respectively), myocardial infarction (HR 4.1; 95% CI 3.4-4.9 
and HR 2.2; 95% CI 1.7-2.7, respectively), stroke (HR 3.5; 95% CI 2.8-4.4 and HR 2.8; 95% CI 
2.1-3.6, respectively), and other cardiovascular causes of death (HR 3.4; 95% CI 2.9-3.9 and 
HR 3.4; 95% CI 2.9-4.0, respectively), as compared with polycystic kidney disease. Dialysis 
modality was not associated with specific cardiovascular causes of death. Risk factors were 

























































Age categories at onset of dialysis*
20-44 1 (reference) 1 (reference) 1 (reference) 1 (reference)
45-54 1.6 (0.8-3.4) 2.6 (2.1-3.1) 1.5 (1.2-1.8) 1.9 (1.7-2.2)
55-64 3.1 (1.6-5.8) 4.6 (3.8-5.5) 2.2 (1.8-2.6) 3.2 (2.8-3.6)
65-74 5.1 (2.8-9.4) 7.4 (6.2-8.8) 3.4 (2.9-4.0) 5.3 (4.7-6.0)
75-84 8.0 (4.3-14.8) 9.4 (7.9-11.3) 5.0 (4.2-5.9) 7.7 (6.9-8.7)
≥85 7.8 (3.3-18.6) 9.6 (7.5-12.3) 8.9 (7.2-11.2) 12.3 (10.6-14.3)
Sex
Female 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Male 0.6 (0.5-0.8) 1.4 (1.3-1.5) 0.9 (0.8-0.9) 1.1 (1.1-1.2)
Primary kidney disease†
Polycystic kidney disease 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Glomerulonephritis 1.3 (0.7-2.7) 1.3 (1.1-1.7) 1.6 (1.3-2.1) 1.5 (1.3-1.8)
Pyelonephritis 1.7 (0.8-3.5) 1.3 (1.1-1.7) 1.6 (1.2-2.1) 1.6 (1.3-1.9)
Hypertension 1.2 (0.6-2.4) 2.5 (2.1-3.1) 2.3 (1.8-2.9) 2.3 (2.0-2.7)
Renal vascular disease 1.8 (0.9-3.8) 2.9 (2.3-3.5) 2.7 (2.1-3.4) 3.1 (2.7-3.7)
Diabetes 1.9 (1.0-3.8) 4.1 (3.4-4.9) 3.5 (2.8-4.4) 3.4 (2.9-3.9)
Miscellaneous 1.9 (0.9-3.8) 1.6 (1.3-1.9) 2.1 (1.6-2.7) 2.0 (1.7-2.3)
Multisystem disease 3.2 (1.6-6.4) 2.2 (1.7-2.7) 2.8 (2.1-3.6) 3.4 (2.9-4.0)
Unknown 1.6 (0.8-3.1) 1.9 (1.6-2.4) 2.2 (1.8-2.8) 2.3 (2.0-2.7)
Dialysis modality‡
Peritoneal dialysis 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Hemodialysis 0.8 (0.6-1.1) 1.0 (0.9-1.1) 1.0 (0.9-1.1) 1.0 (0.9-1.1)
CV, cardiovascular disease; *Adjusted for sex, calendar year, and country; †Adjusted for age, sex, 
calendar year, and country; ‡Adjusted for age, sex, primary kidney disease, calendar year, and country
DISCUSSION
We found an unexpected highly increased risk of pulmonary embolism in dialysis patients 
as compared with the general population and an elevated risk of myocardial infarction and 
stroke in dialysis patients as compared with the general population. The total cardiovascular 
mortality rate in the 130 439 dialysis patients was 77.4 per 1000 person-years of which 1.4 per 
1000 person-years could be attributed to pulmonary embolism, 22.3 per 1000 person-years to 
myocardial infarction, 14.2 per 1000 person-years to stroke, and 39.5 per 1000 person-years 
to other cardiovascular causes. The age- and sex-standardized mortality rates in dialysis 
patients were 12.2-fold increased for pulmonary embolism, 11.0-fold increased for myocardial 
infarction, 8.9-fold increased for stroke, and 8.3-fold increased for other cardiovascular causes 
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The previous studies have investigated the total cardiovascular mortality risk in dialysis 
patients compared with the general population,1,3,6 but there is limited information on the 
contribution of the various specific causes of cardiovascular death to the excess risk. The 
age- and sex-standardized mortality rates in dialysis patients as compared with the general 
population were comparable to a previous European study.21 While two previous studies 
suggested an increased incidence of pulmonary embolism in the first year of dialysis,22,23 
there is limited information on the mortality associated with pulmonary embolism and whether 
it contributes to the increased cardiovascular mortality risk in dialysis patients. Our results 
contradict the findings of autopsy studies on pulmonary embolism.9-12 These studies showed 
that pulmonary embolism was less common in dialysis patients (prevalences ranging from 0% 
to 6.5%) than in non-dialysis patients (prevalences ranging from 8.2% to 16.0%). In our study, 
0.7% of deaths in dialysis patients were caused by pulmonary embolism compared with 0.5% 
in the general population. Comparison of our findings with those from the aforementioned 
autopsy series is hampered for several reasons. First, the use of autopsy series to investigate 
pulmonary embolism could lead to selection bias caused by different indications for autopsy 
in dialysis patients and non-dialysis patients. Moreover, postmortem diagnosis often provides 
little information about the clinical significance of pulmonary embolism and information on 
whether it contributed to death is often lacking. 
Our finding that the mortality rate ratio was highest for pulmonary embolism was a surprise. 
Although pulmonary embolism as a cause of death is less common, clinicians should be 
aware of the increased risk of this disorder in dialysis patients, since it is the most common 
preventable cause of hospital death.24 In contrast to myocardial infarction and stroke, 
pulmonary embolism can be prevented by administering prophylactic anticoagulation 
therapy in patients considered to be at increased risk.25 Especially high-risk groups, including 
elderly dialysis patients with diabetes or multi-system disease as shown in our study, could 
benefit from thromboprophylaxis. Nevertheless, further studies are needed to show whether 
thromboprophylaxis is cost-effective and safe in high-risk dialysis patients, given the increased 
bleeding risk associated with anticoagulation and given its potential role in the generation 
of vascular calcification. The increased mortality rate for myocardial infarction,2,13,26,27 
stroke,14,15,27,28 and other cardiovascular diseases2,4,5 in our cohort of dialysis patients is in line 
with previous studies that showed an increased incidence of myocardial infarction, stroke, and 
other cardiovascular events.
Our results show that death due to pulmonary embolism was associated with increased age, 
female sex, and diabetes. Female sex and increased age are also important risk factors for 
pulmonary embolism in the general population.29 Studies on the association between diabetes 










































data show that diabetes is a risk factor in dialysis patients. We did not find an association 
between treatment modality (hemodialysis or peritoneal dialysis) and mortality due to 
pulmonary embolism. It could be suggested that the mortality risk of pulmonary embolism 
should be theoretically lower for hemodialysis patients than for peritoneal dialysis patients, 
because of anticoagulation use during hemodialysis sessions to prevent clot formation. 
However, peritoneal dialysis patients could have less comorbidities than hemodialysis 
patients at baseline explaining the similar mortality rates for hemodialysis and peritoneal 
dialysis patients. We had no information about comorbidities to investigate this. Our findings 
that older age, male sex, and diabetes as cause of end-stage renal disease were associated 
with an increased risk of myocardial infarction in dialysis patients is consistent with previous 
studies.1,13 The association between stroke and increased age, female sex, and diabetes as 
cause of end-stage renal disease in our study was also in agreement with previous studies in 
dialysis patients.14,15,27,32
The unexpected increased mortality risk of pulmonary embolism could reflect an increased 
incidence of pulmonary embolism in dialysis patients.22,23 Furthermore, an increased fatality 
rate of pulmonary embolism in dialysis patients could lead to an increased mortality risk due 
to pulmonary embolism.33 A previous study showed that patients with a severely decreased 
kidney function (glomerular filtration rate <30 ml/min) had a 5.5-fold increased mortality risk 
within 2 weeks after an initial pulmonary embolism as compared with persons with a filtration 
rate ≥30 ml/min.33 The investigation of non-fatal events and fatality rates was beyond our 
scope, since we focused on mortality rates. However, based on the higher prevalence of 
pulmonary embolism as a cause of death in dialysis patients (0.7%) than in the general 
population (0.5%), the 12.2-fold increased mortality risk due to pulmonary embolisms is 
probably not only a reflection of higher mortality rates in dialysis patients than in the general 
population. 
Several explanations for an increased incidence of pulmonary embolism in dialysis patients 
are possible. An explanation could be the higher rate of hospitalization, surgery, and 
immobilization in dialysis patients than in the general population. Furthermore, several studies 
have demonstrated a hypercoagulable state in dialysis patients.34,35 Hypercoagulability due 
to vasculitis could also explain the increased risk of pulmonary embolism in patients with 
multi-system disease, including patients with systemic lupus erythematosus or granulomatous 
polyangiitis,36-38 while nephrotic-range proteinuria could explain the increased risk in patients 
with diabetes as both diabetes and pulmonary embolism have been associated with the 
nephrotic syndrome.39 However, the nephrotic syndrome probably plays a less important 
role in the development of pulmonary embolisms in dialysis patients than in other kidney 
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of the fast loss of residual renal function. Another plausible explanation for the increased 
risk of venous thrombosis in dialysis patients could be thrombus formation associated with 
catheters and arteriovenous accesses for dialysis which may cause pulmonary embolisms 
through dislodgement of thrombi.40,41 We had no information about type of access in this study. 
Moreover, anticoagulation could be withheld in dialysis patients, because of the increased 
bleeding risk. We also had no information about anticoagulation use. 
Several explanations for the highly increased mortality risk of myocardial infarction and stroke 
are possible. The high risk of myocardial infarction and stroke could be explained by the much 
higher prevalence of traditional risk factors for cardiovascular diseases, such as diabetes, 
hypertension, and left ventricular hypertrophy in the dialysis population than in the general 
population.14,15,27,32,42 In addition, chronic kidney disease has been shown to be associated 
with inflammation and accelerated atherosclerotic vascular disease that subsequently could 
increase the mortality risk from myocardial infarction or ischemic stroke.43,44 Moreover, 
anticoagulation of patients combined with uremic bleeding diathesis, may cause an increased 
risk of hemorrhagic stroke. Unfortunately, our data did not allow the calculation of mortality 
rate ratios for ischemic and hemorrhagic stroke separately.
 
A potential limitation of our study was that the cause of death was unknown in approximately 
13.8% of the dialysis patients compared with 2.0% of the general population. This difference 
can be explained by the slightly different method for assigning the cause of death in dialysis 
patients as compared with the general population. For example, the autopsy is performed 
less commonly in dialysis patients than in the general population. Causes of death among 
patients on dialysis were recorded by the primary nephrologist. When a patient died at home 
or elsewhere outside the hospital, the nephrologist will have been dependent on information 
from others, and may more likely report a cause of death as unknown. Conversely, causes 
of death within the general population are, according to law, recorded by the physician who 
confirmed the death and thereafter sent the data to the statistics office, resulting in relatively 
fewer missing causes of death. Since the proportion of missing causes of death is greater 
in dialysis patients than in the general population, it is likely that this study underestimated 
the mortality rate ratios for total and specific cardiovascular mortality in dialysis patients as 
compared with the general population due to misclassification of cardiovascular death as 
unknown. Furthermore, misclassification may have become even worse due to the potential 
attribution of the code sudden cardiac death to dialysis patients who in reality may have 
died from pulmonary embolism, myocardial infarction, or stroke. In a highly unlikely worst 
case scenario, in which we change all unknown codes of death in the general population 
into pulmonary embolism, myocardial infarction, or stroke, we would still observe increased 










































and also for myocardial infarction (8.4; 95% CI 8.0-8.8) and stroke (6.8; 95% CI 6.5-7.2), 
respectively. 
In conclusion, dialysis patients have an unexpected highly increased mortality risk due to 
pulmonary embolism, and an increased mortality risk due to myocardial infarction, 
stroke, and other cardiovascular diseases as compared with the general population. 
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Chapter 8
Hemodialysis catheters increase mortality  
as compared to arteriovenous accesses 
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Background: Catheter use has been associated with an increased mortality risk in 
hemodialysis patients. However, differences in the all-cause and cause-specific mortality 
risk between catheter use and arteriovenous access use in young and elderly hemodialysis 
patients has not yet been investigated.
Methods: In this prospective cohort study of 1109 incident hemodialysis patients from 38 
centers in the Netherlands, hazard ratios (HRs) with 95% confidence intervals (95% CIs) were 
calculated for 2-year all-cause, infection-related, and cardiovascular mortality in patients with 
a catheter as compared to patients with an arteriovenous access stratified for age (< 65 years 
and ≥ 65 years). 
Results: Of the 1109 patients, 919 had an arteriovenous access and 190 had a catheter. The 
mortality rate was 76 per 1000 person-years in young patients with an arteriovenous access, 
129 per 1000 person-years in young patients with a catheter, 222 per 1000 person-years 
in elderly patients with an arteriovenous access, and 427 per 1000 person-years in elderly 
patients with a catheter. The adjusted HR was 3.15 (95% CI 2.09-4.75) for elderly patients 
with a catheter as compared to young patients with an arteriovenous access. The adjusted 
HRs in elderly patients with a catheter as compared to elderly patients with an arteriovenous 
access were 1.54 (95% CI 1.13-2.12) for all-cause mortality, 1.60 (95% CI 0.62-4.19) for 
infection-related mortality, and 1.67 (95% CI 1.04-2.68) for cardiovascular mortality.
Conclusion: Especially elderly hemodialysis patients with a catheter have an increased all-













































Dialysis patients require a vascular access for hemodialysis therapy. However, vascular 
access problems are responsible for 25% to 50% of hospitalizations in hemodialysis patients 
and are also associated with high costs.1-6 While evidence from randomized-controlled trials 
is lacking, there is a broad consensus that arteriovenous accesses (fistula or graft) are 
superior to central venous catheters. Catheter use for hemodialysis has been associated 
with an increased risk for thrombosis,7,8 short access survival,8,9 and an increased risk for 
infections.10-13 Therefore, the National Kidney Foundation Kidney Disease Outcome Quality 
Initiative (NKF K/DOQI) guidelines14 and the European Best Practice Guidelines15 recommend 
the use of arteriovenous accesses instead of catheters for vascular access in hemodialysis 
patients. 
Despite this preference and recommendation for arteriovenous access use instead of 
catheters, limited studies have investigated the association between catheter use and 
mortality in elderly hemodialysis patients. Three studies from the United States have reported 
an increased mortality risk in elderly hemodialysis patients (elderly defined as age ≥ 65 years 
in two studies and aged ≥ 67 years in one study)  ranging from a 1.3 to 2.1-fold increased 
risk for mortality in patients with a catheter as compared to patients with an arteriovenous 
access.16-18 Moreover, information about differences in the association between catheter use 
and all-cause and cause-specific mortality in incident hemodialysis patients is limited and 
needs further exploration. This information is important, since the cause-specific and all-cause 
mortality risk could be different in elderly patients as compared to young patients, leading to 
age-specific treatment strategies. 
Therefore, we investigated the association between catheter use versus arteriovenous 
access use and effect on all-cause and cause-specific (infection-related and cardiovascular) 
mortality risk in elderly hemodialysis patients as compared to young hemodialysis patients 
from a Dutch cohort of incident dialysis patients.    
METHODS
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospective 
multicenter cohort study in which incident adult end-stage renal disease patients from 38 
dialysis centers in the Netherlands were included.19 All patients gave informed consent and 
the study was approved by all local medical ethics committees. We followed patients at three 










































or censoring, i.e. transfer to a nonparticipating dialysis center, withdrawal from the study, 
transplantation, or end of the follow-up period (April 2006).
Eligibility included age older than 18 years, no previous renal replacement therapy, and 
survival of the initial three months of dialysis. For the current analyses, we used data from 
hemodialysis patients included between January 1997 and April 2004. The baseline was 
defined at three months after the start of dialysis. This time point of three months was chosen 
because patients’ switch to another therapy or deaths within this period were most probably 
due to their health status before the start of dialysis, rather than to the dialysis modality.
Demographic and clinical data
Data on age, sex, primary kidney disease, comorbidity, predialysis care, diabetes, and 
cardiovascular disease (angina pectoris, myocardial infarction, heart failure, ischemic stroke, 
or claudication) were collected at the start of dialysis treatment. Primary kidney disease was 
classified according to the codes of the European Renal Association-European Dialysis and 
Transplant Association (ERA-EDTA).20 We grouped patients into four classes of primary kidney 
disease: glomerulonephritis, diabetes mellitus, renal vascular disease, and other kidney 
diseases. Other kidney diseases consisted of patients with interstitial nephritis, polycystic 
kidney diseases, other multisystem diseases, and unknown diseases. The comorbidity was 
scored on the basis of the number comorbid conditions according to the comorbidity index 
described by Davies et al.21. The patients were classified as having no, intermediate, or 
severe comorbidity. Since comorbidity is an important confounder for the association between 
arteriovenous access use versus catheter use and mortality, the Davies score is used to adjust 
for comorbidity. The Davies score is based on the presence or absence of seven comorbid 
conditions, producing three risk groups. The Davies score assigns 1 point for each of the 
following conditions: ischemic heart disease (defined as prior myocardial infarction, angina 
pectoris, or ischemic changes on electrocardiogram), left ventricular dysfunction (defined as 
clinical evidence of pulmonary edema not due to errors in fluid balance), peripheral vascular 
disease (includes distal aortic, lower extremity, and cerebrovascular disease), malignancy, 
diabetes, collagen vascular disease, and other significant disorder (e.g. chronic obstructive 
pulmonary disease). Predialysis care was defined as a referral to a nephrologist for at least 
three months before initiation of dialysis to provide patients with adequate medical preparation. 
Data on vascular access, Kt/Vurea delivered by hemodialysis, and body mass index (BMI) 
were collected at 3 months after the start of dialysis. Catheters included both tunneled and 
non-tunneled catheters (jugular and femoral) and arteriovenous accesses included native 
fistulas and grafts; data on native fistula and graft were not available, though. BMI was 
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by hemodialysis was estimated according to the second-generation Daugirdas formula on 
the basis of one plasma urea measurement before and one immediately after the dialysis 
session, the ultrafiltration, and the duration of the session as described previously.22,23 Blood 
and 24-hour urine samples were obtained at 3 months after the start of dialysis. Albumin, 
creatinine, urea, cholesterol, and C-reactive protein (CRP) were determined from the blood 
samples. Urea and creatinine levels were also measured in the urine samples. Renal function, 
expressed as glomerular filtration rate (GFR), was calculated as the mean of creatinine and 
urea clearance corrected for body surface area (ml/min per 1.73 m2). GFR was missing 
in 250 patients and serum albumin in 35 patients. The missing values for GFR and serum 
albumin were imputed with multiple imputation, a recommended technique where missing 
data for a subject are imputed by a value that is predicted by using the subject’s other, known 
characteristics,24,25 i.e. using demographic characteristics, mortality, catheter use and serum 
albumin, creatinine, and GFR at different time points. We used standard imputation methods 
in SPSS statistical software (version 17.0; SPSS, Chicago, Illinois). 
Outcome definition
The endpoint of this study was 2-year mortality. We classified causes of death according to the 
codes of the ERA-EDTA  and grouped death causes into cardiovascular, infection-related, and 
other mortality. The following codes were designated as cardiovascular mortality: myocardial 
ischemia and infarction; cardiac failure/fluid overload/pulmonary edema; cardiac arrest, 
cause unknown; cerebrovascular accident; hemorrhage from ruptured vascular aneurysm; 
mesenteric infarction; hyperkalemia; hypokalemia; cause of death uncertain/unknown. The 
following codes were designated as infection-related mortality: pulmonary infection; infections 
elsewhere except viral hepatitis; septicaemia; tuberculosis; generalized viral infection; 
peritonitis. All other deaths were designated as other.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) or as median and 
interquartile rage (IQR) depending on the normality of the data. Categorical variables are 
presented as number with valid percentages. For continuous data, differences for arteriovenous 
access use versus catheter use were tested with t test or Mann–Whitney–Wilcoxon test, 
depending on the distribution of the data. Chi-square test was used for categorical variables. 
A P value less than 0.05 was considered significant. 
Survival curves were determined with the Kaplan-Meier method and mortality rates per 1000 
person-years were calculated for four categories of hemodialysis patients defined by age 
group and vascular access (elderly arteriovenous access users aged ≥ 65 years, young 










































young catheter users aged < 65 years). We calculated crude and adjusted hazard ratios (HRs) 
with 95% confidence intervals (95% CIs) for all-cause, infection-related, and cardiovascular 
mortality within 2-year of follow-up in young and elderly hemodialysis patients using Cox 
proportional hazard analysis. Furthermore, we calculated HRs for elderly catheter users aged 
≥ 65 years, elderly arteriovenous access users aged ≥ 65 years, and young catheter users 
aged < 65 years as compared to young arteriovenous access users aged < 65 years. In an 
additional analysis, HRs for mortality were calculated for very old patients with a catheter aged 
≥ 75 years as compared to very old patients with an arteriovenous access and as compared 
to young patients with an arteriovenous access aged < 65 years. HRs were adjusted for 
age, sex, primary kidney disease, Davies comorbidity score, predialysis care, GFR, CRP, 
cholesterol, BMI, serum albumin levels, and Kt/Vurea delivered by hemodialysis. The 
association between catheter use and mortality was studied with an intention-to-treat design 
since we were interested in the effect of initial vascular access on mortality. All analysis have 
been done in SPSS statistical software version 17.0; SPSS, Chicago, Illinois.
RESULTS
A total of 1109 patients were included between January 1997 and April 2004 and were 
treated with hemodialysis therapy at 3 months after start of dialysis in the NECOSAD. Of 
these patients, 190 (17.1%) had a catheter and 919 (82.9%) had an arteriovenous access 
for hemodialysis as vascular access. Table 1 shows the baseline characteristics of these 
patients. There were no differences between patients with a catheter or arteriovenous access 
according to age, sex, angina pectoris, myocardial infarction, ischemic stroke, claudication, 
diabetes, Davies comorbidity score, distribution of primary kidney disease, and Kt/Vurea 
delivered by hemodialysis. The patients with a catheter had a lower BMI, received less often 
predialysis care, had more often heart failure, had lower serum albumin levels, had lower 
cholesterol levels, had higher CRP levels, and had a lower GFR as compared to patients with 
an arteriovenous access (p<0.05 for all).
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Age (years) (%) 63.7 ± 13.6 63.2 ± 14.5
< 65 years 51.6  ± 10.6 (44.8) 50.1 ± 11.4 (44.2)
≥ 65 to 75 years 70.0 ± 2.9 (33.1) 70.1 ± 2.8 (33.2)
≥ 75 years 79.0 ± 3.1 (22.1) 78.8 ± 3.1 (22.6)
Sex, male (%) 58.7 55.8
BMI  (kg/m2) 24.7 ± 4.3 24.5± 4.5
Primary kidney disease (%)
Diabetes mellitus 15.6 16.8
Glomerulonephritis 11.1 5.8
Renal vascular disease 21.0 27.4
Others 52.3 50.0
Cardiovascular disease (%)
Angina pectoris 11.9 11.6
Myocardial infarction 13.5 15.3
Heart failure 12.1 20.5
Ischemic stroke 9.7 8.4
Claudication 16.2 17.9
Diabetes mellitus (%) 23.1 24.2




Predialysis care (%) 76.1 55.3
< 65 years 79.9 46.4
≥ 65 to 75 years 73.0 61.9
≥ 75 years 72.9 62.8
Serum albumin (g/L) 37.0 (33.3-40.0) 35.0 (32.0-38.0)
Cholesterol (mmol/L) 4.8  ± 1.2 4.5  ± 1.2
CRP (mg/L) 6.0 (3.0-12.5) 7.6 (3.0-13.0)
GFR (ml/min per 1.73 m2) 3.1 (1.5-4.9) 2.9 (1.1-4.5)
Hemodialysis Kt/Vurea (week) 2.8  ± 0.8 2.8  ± 0.9
All-cause mortality 
Of the 190 patients with a catheter, 72 patients died within two years. Of the 919 patients with 
an arteriovenous access, 217 died within two years. Figure 1 shows the Kaplan-Meier curves 
for all-cause mortality in young and elderly patients with an arteriovenous access or catheter for 
the first two years of follow-up. Table 2 shows the HRs for 2-year mortality for both age groups: 
young patients with a catheter as compared to young patients with an arteriovenous access 
and elderly patients with a catheter as compared to elderly patients with an arteriovenous 
access. The mortality rate was lowest for young arteriovenous access users and was highest 










































patients with a catheter as compared to young patients with an arteriovenous access after 
adjustment for age, sex, primary kidney disease, Davies comorbidity score, angina pectoris, 
myocardial infarction, heart failure, ischemic stroke, claudication, predialysis care, GFR, 
CRP, cholesterol, BMI, serum albumin levels, and Kt/Vurea delivered by hemodialysis. 
The adjusted HR for 2-year mortality was 1.54 (95% CI 1.13-2.12) in elderly patients with 
a catheter as compared to elderly patients with an arteriovenous access. However, on an 
absolute scale catheter use in elderly patients as compared to arteriovenous access use 
in elderly is associated with more deaths than catheter use in young patients as compared 
to arteriovenous access use in young patients (absolute risk difference of 205 per 1000 
person-years versus 53 per 1000 person-years). As compared to young patients with an 
arteriovenous access, both young patients with a catheter and elderly patients with a catheter 
or arteriovenous access had an increased risk (Table 3); elderly patients with a catheter had 
an almost 6-fold crude and 3-fold adjusted increased mortality risk as compared to young 
patients with an arteriovenous access. 
179 
 
Figure 1. Kaplan-Meier survival curve for arteriovenous access versus catheter in young and elderly  
hemodialysis patients 
 






Shunt < 65 years
Shunt ≥ 65 years
Catheter ≥ 65 years
Catheter < 65 years
Number at risk:
Shunt < 65 years  412                        371                    320                      273                      235
Catheter < 65 years  84                         70                      62                        54                        42
Shunt ≥ 65 years   507                       424                    376                      325                      282

































































Hemodialysis catheters increase mortality as compared to arteriovenous accesses 
131
8







Mortality rate per 1000 py 76 129
Crude HR (95% CI) 1 (reference) 1.70 (0.97-2.99)
Adjusted* HR (95% CI) 1 (reference) 1.74 (0.99-3.08)
Adjusted† HR (95% CI) 1 (reference) 1.54 (0.87-2.74)
Elderly
≥ 65 years
Mortality rate per 1000 py 222 427
Crude HR (95% CI) 1 (reference) 1.93 (95% CI 1.42-2.61)
Adjusted* HR (95% CI) 1 (reference) 1.70 (95% CI 1.25-2.31)
Adjusted† HR (95% CI) 1 (reference) 1.54 (95% CI 1.13-2.12)
py, person-years; HR, hazard ratio; CI, confidence interval. *Adjusted for age, sex, Davies comorbidity 
score, angina pectoris, myocardial infarction, heart failure, ischemic stroke, claudication, and primary 
kidney disease. †Additional adjusted for predialysis care, GFR, CRP, cholesterol, BMI, serum albumin 
levels, and hemodialysis Kt/Vurea.










Arteriovenous access < 65 years 76 1 (reference) 1 (reference) 1 (reference)
Catheter < 65 years 129 1.70 (0.97-2.99) 1.71 (0.97-3.02) 1.49 (0.84-2.66)
Arteriovenous access ≥ 65 years 222 2.93 (2.13-4.02) 2.12 (1.53-2.94) 2.06 (1.48-2.86)
Catheter ≥ 65 years 427 5.64 (3.84-8.27) 3.55 (2.39-5.28) 3.15 (2.09-4.75)
HR, hazard ratio; CI, confidence interval. *Adjusted for sex, Davies comorbidity score, angina pectoris, 
myocardial infarction, heart failure, ischemic stroke, claudication, and primary kidney disease. †Additional 
adjusted for predialysis care, GFR, CRP, cholesterol, BMI, serum albumin levels, and hemodialysis Kt/
Vurea.
Cause-specific mortality
Of the 72 patients with a catheter who died within the first two years of follow-up, 7 died 
because of infections (1 young and 6 elderly patients), 34 because of cardiovascular causes 
(9 young and 25 elderly patients), and 31 died because of other reasons (6 young and 25 
elderly patients). Of the 217 patients with an arteriovenous access who died within 2 years 
of follow-up, 27 died because of infections (7 young and 20 elderly patients), 103 because of 
cardiovascular causes (25 young and 78 elderly patients), and 87 died because of other reasons 
(17 young and 70 elderly patients). Figure 2 shows the adjusted HRs for cause-specific 2-year 
mortality in young and elderly patients. The adjusted HRs in elderly patients with a catheter 
were 1.60 (95% CI 0.62-4.19) for infection-related mortality and 1.67 (95% CI 1.04-2.68) for 
cardiovascular mortality as compared to elderly patients with an arteriovenous access. HRs in 










































were 2.92 (95% CI 0.91-9.37) for infection-related mortality and 3.09 (95% CI 1.70-5.60) for 
cardiovascular mortality after adjustment for sex, primary kidney disease, Davies comorbidity 
score, angina pectoris, myocardial infarction, heart failure, ischemic stroke, claudication, 
predialysis care, GFR, CRP, cholesterol, BMI,  serum albumin levels, and Kt/Vurea delivered 
by hemodialysis. 
Very old patients 
There were 43 very old (aged≥ 75 years) patients with a catheter, 26 patients of whom died 
within two years (11 cardiovascular causes, 3 infection-related causes, and 12 other causes). 
Furthermore, 72 patients of the 203 very old patients with an arteriovenous access died within 
two years (32 cardiovascular causes, 8 infection-related causes, and 32 other causes). The 
mortality rate per 1000 person-years was 244 for very old arteriovenous access users and 
505 for very old catheter users. The adjusted HRs in very old patients were 1.83 (95% CI 
1.14-2.93) for all-cause mortality, 2.32 (95% CI 0.57-9.40) for infection-related mortality, and 




adjusted HRs in very old patients were 1.83 (95% CI 1.14-2.93) for all-cause mortality, 
2.32 (95% CI 0.57-9.40) for infection-related mortality, and 1.96 (95% CI 0.96-4.02) for 
cardiovascular mortality as compared to very old patients with an arteriovenous access. 
 
 
Figure 2. Adjusted hazard ratios with 95% confidence intervals for all-cause and cause- 

























Hazard ratios are adjusted for age, sex, Davies comorbidity score, angina pectoris, myocardial infarction, heart failure,  
ischemic stroke, claudication, primary kidney disease, predialysis care, GFR, CRP, cholesterol, BMI, serum albumin  


















































Elderly (≥ 65 years)
HR
Figure	2.	Adjusted	hazard	ratios	with	95%	confidence	intervals	for	all-cause	and	cause-specific	
mortality for catheter as compared to arteriovenous access in young and elderly hemodialysis 
patients
Hazard ratios are adjusted for age, sex, Davies comorbidity score, angina pectoris, myocardial infarction, 
heart failure, ischemic stroke, claudication, primary kidney disease, predialysis care, GFR, CRP, 












































In this prospective cohort study of incident dialysis patients, we showed that catheter use was 
associated with an increased 2-year all-cause mortality risk as compared to arteriovenous 
access use. Elderly patients (aged ≥ 65 years) with a catheter had a 54% increased risk for 
mortality within 2 years as compared to elderly patients with an arteriovenous access and 
had a 3-fold increased risk for mortality within 2 years as compared to young patients (aged 
< 65 years) with an arteriovenous access. Very old patients with a catheter (aged ≥ 75 years) 
had an 83% increased mortality risk as compared to very old patients with an arteriovenous 
access. Among elderly patients, catheter use increased especially infection-related and 
cardiovascular mortality as compared to arteriovenous access use. The occurrence of 
septicemia or bacteremia has been shown to be associated with subsequent cardiovascular 
morbidity and mortality.26 Our findings provide support to the guidelines which indicate that 
the use of catheters for hemodialysis should be discouraged. We showed that, especially 
in elderly hemodialysis patients, catheter use should be discouraged, since older age and 
catheter use are associated with an even higher increased mortality risk. 
The 1.54-fold increased risk for mortality within two years of follow-up in elderly hemodialysis 
patients in our Dutch cohort is comparable to the increased risk found in cohorts from the United 
States. Three studies have reported a 1.3- to 2.1-fold increased risk for mortality in elderly 
patients with a catheter as compared to elderly patients with an arteriovenous access.16-18 The 
first study used data from the United States Medicare dialysis population from 1995 to 1997.16 
They showed that catheter use was associated with a 1.7-fold increased one-year mortality 
as compared to native fistula use in elderly dialysis patients aged ≥ 67 years. The second 
study used data from the United States Renal Data System.17 They showed in a subgroup 
analysis that catheter use was associated with a 2.1-fold increased mortality as compared 
to native fistula use in elderly dialysis patients aged ≥ 65 years over a mean follow-up of one 
year. Finally, the Choices for Healthy Outcomes in Caring for End-stage renal disease study 
showed in a subgroup analysis that catheter use was associated with a 1.3-fold increased 
mortality as compared to native fistula use in elderly dialysis patients aged ≥ 65 years over a 
follow-up of three years.18 
 
Previous studies have reported that catheter use is associated with sepsis and bacteremia,10-13 
with decreased delivered dose of dialysis due to decreased blood flow rates,27 and higher 
levels of inflammatory factors.28 In addition, several studies have shown an increased infection-
related and cardiovascular mortality risk in patients with a catheter as vascular access, 
especially in the first three months of dialysis.29,30 However, to our knowledge, there are no 










































use in elderly patients. We showed that elderly patients with a catheter had a 60% increased 
risk for infection-related mortality and a 67% increased risk for cardiovascular mortality as 
compared to elderly patients with an arteriovenous access. Including the first three months of 
dialysis would probably have led to an even higher infection-related mortality. Furthermore, 
we showed that very old patients with a catheter had a 2.3-fold increased risk for infection-
related mortality and a 2.0-fold increased risk for cardiovascular mortality as compared to 
very old patients with an arteriovenous access. The confidence intervals for the HR for the 
infection-related 2-year mortality were wide due to a low number of patients with infection-
related mortality. 
Missing values for GFR and serum albumin were imputed. Patients with missing GFR or 
serum albumin used more often catheters and had relatively higher mortality rates. Analyses 
excluding patients who had a missing GFR or serum albumin values would have led to biased 
results, since relative more patients with a catheter with higher mortality rates would have 
been excluded.24 This would have resulted in a decreased mortality risk for catheter use as 
compared to arteriovenous access use. Therefore, imputation of GFR and serum albumin 
using demographic characteristics, mortality, catheter use, and creatinine, serum albumin and 
GFR at different time points leads to more reliable results. 
The comparison between catheter use and arteriovenous access use in an observational 
design makes confounding-by-indication the most important obstacle. It is important to realize 
that these observational studies have limitations to prove causality, since the observed 
increased mortality risk in patients with a catheter may partly reflect the effect of differences 
between arteriovenous access and catheter users. Catheter use has been associated with less 
predialysis care, lower GFR, lower serum albumin levels, and more co-morbidity as compared 
to arteriovenous access users.31-33 In our analyses, we took this into account by correcting 
for these confounders, but this cannot exclude possible residual confounding. Therefore, our 
study shows that catheter use is associated with an increased mortality risk, but this does 
not necessarily prove that catheter use increases mortality risk. However, even additional 
adjustment for diabetes, angina pectoris, myocardial infarction, heart failure, ischemic stroke, 
and claudication did not change the results. Furthermore, we compared catheter use with 
arteriovenous access use and not with native fistula use since this information was lacking 
in our study. Therefore, as according to the literature mortality is higher in patients with a 
graft compared to patients with a native fistula,18,30 patients with catheters in our study would 
have had even higher relative mortality risks. Moreover, we had no information about the 
type of catheters (tunneled or non-tunneled), the insertion place of the catheters, and the 
use of antimicrobial locks for catheters to investigate differences in mortality risk in patients 
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were interested in the association between mortality and initial vascular access treatment 
in elderly dialysis patients. This is important, since guidelines especially discourage catheter 
use as initial vascular access treatment.14,15 In addition, an intention-to-treat analysis also 
avoids bias caused by transferring patients with an arteriovenous access with complications 
to the catheter group. An as-treated design would therefore overestimate the mortality-risk for 
patients with a catheter.  
In conclusion, our study shows that catheter compared to arteriovenous access use is 
associated with an increased mortality, especially among elderly patients. Our findings are 
consistent with the guidelines which indicate that the use of catheters for hemodialysis should 
be discouraged. We showed that this is especially true for the elderly hemodialysis population.
ACKNOWLEDGEMENTS
We thank the investigators and study nurses of the participating dialysis centers an the data 
managers of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) 
for collection and management of data. The members of the Netherlands Cooperative Study 
on the Adequacy of Dialysis (NECOSAD) Study Group include A.J. Apperloo, J.A. Bijlsma, M. 
Boekhout, W.H. Boer, P.J.M. van der Boog, H.R. Büller, M. van Buren, F.Th. de Charro, C.J. 
Doorenbos, M.A. van den Dorpel, A. van Es, W.J. Fagel, G.W. Feith, C.W.H. de Fijter, L.A.M. 
Frenken, W. Grave, J.A.C.A. van Geelen, P.G.G. Gerlag, J.P.M.C. Gorgels, R.M. Huisman, 
K.J. Jager, K. Jie, W.A.H. Koning-Mulder, M.I. Koolen, T.K. Kremer Hovinga, A.T.J. Lavrijssen, 
A.J. Luik, J. van der Meulen, K.J. Parlevliet, M.H.M. Raasveld, F.M. van der Sande, M.J.M. 
Schonck, M.M.J. Schuurmans, C.E.H. Siegert, C.A. Stegeman, P. Stevens, J.G.P. Thijssen, 
R.M. Valentijn, G.H. Vastenburg, C.A. Verburgh, H.H. Vincent, and P.F. Vos. We thank the 
nursing staff of the participating dialysis centers and the staff of the NECOSAD trial office for 
their invaluable assistance in the collection and management of data for this study. This work 
was supported in part by an unrestricted grant from the Dutch Kidney Foundation. The funding 
source was involved in neither the collection, interpretation, and analysis of the data nor the 











































 1.  Carlson DM, Duncan DA, Naessens JM, Johnson WJ. Hospitalization in dialysis patients. Mayo 
Clin Proc. 1984;59:769-775.
 2.  Fan PY, Schwab SJ. Vascular access: concepts for the 1990s. J Am Soc Nephrol. 1992;3:1-11.
 3.  Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA. Hemodialysis vascular 
access morbidity in the United States. Kidney Int. 1993;43:1091-1096.
 4.  Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc 
Nephrol. 1996;7:523-535.
 5.  Ifudu O, Mayers JD, Cohen LS, Paul H, Brezsnyak WF, Avram MM, Herman AI, Friedman EA. 
Correlates of vascular access and nonvascular access-related hospitalizations in hemodialysis 
patients. Am J Nephrol. 1996;16:118-123.
 6.  Mayers JD, Markell MS, Cohen LS, Hong J, Lundin P, Friedman EA. Vascular access surgery 
for maintenance hemodialysis. Variables in hospital stay. ASAIO J. 1992;38:113-115.
 7.  Schwab SJ, Buller GL, McCann RL, Bollinger RR, Stickel DL. Prospective evaluation of a 
Dacron cuffed hemodialysis catheter for prolonged use. Am J Kidney Dis. 1988;11:166-169.
 8.  Suhocki PV, Conlon PJ, Jr., Knelson MH, Harland R, Schwab SJ. Silastic cuffed catheters for 
hemodialysis vascular access: thrombolytic and mechanical correction of malfunction. Am J 
Kidney Dis. 1996;28:379-386.
 9.  Schwab SJ. Assessing the adequacy of vascular access and its relationship to patient outcome. 
Am J Kidney Dis. 1994;24:316-320.
 10.  Taylor GD, McKenzie M, Buchanan-Chell M, Caballo L, Chui L, Kowalewska-Grochowska K. 
Central venous catheters as a source of hemodialysis-related bacteremia. Infect Control Hosp 
Epidemiol. 1998;19:643-646.
 11.  Kairaitis LK, Gottlieb T. Outcome and complications of temporary haemodialysis catheters. 
Nephrol Dial Transplant. 1999;14:1710-1714.
 12.  Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, 
risk factors, and prognosis. Kidney Int. 1999;55:1081-1090.
 13.  Oliver MJ, Rothwell DM, Fung K, Hux JE, Lok CE. Late creation of vascular access for 
hemodialysis and increased risk of sepsis. J Am Soc Nephrol. 2004;15:1936-1942.
 14.  Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48 
Suppl 1:S2-90.
 15.  Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini 
L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG on Vascular 
Access. Nephrol Dial Transplant. 2007;22 Suppl 2:ii88-117.
 16.  Xue JL, Dahl D, Ebben JP, Collins AJ. The association of initial hemodialysis access type with 
mortality outcomes in elderly Medicare ESRD patients. Am J Kidney Dis. 2003;42:1013-1019.
 17.  Foley RN, Chen SC, Collins AJ. Hemodialysis access at initiation in the United States, 2005 to 
2007: still “catheter first”. Hemodial Int. 2009;13:533-542.
 18.  Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J. Type of vascular access and 
survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for 
ESRD (CHOICE) Study. J Am Soc Nephrol. 2005;16:1449-1455.
 19.  Drechsler C, Grootendorst DC, Boeschoten EW, Krediet RT, Wanner C, Dekker FW. Changes 
in parathyroid hormone, body mass index and the association with mortality in dialysis patients. 








































Hemodialysis catheters increase mortality as compared to arteriovenous accesses 
137
8
 20.  van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, Gronhagen-Riska C, 
Kramar R, Leivestad T, Simpson K, Briggs JD. Renal replacement therapy in Europe: the 
results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. 
Nephrol Dial Transplant. 2001;16:1120-1129.
 21.  Davies SJ, Russell L, Bryan J, Phillips L, Russell GI. Comorbidity, urea kinetics, and appetite 
in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of 
survival. Am J Kidney Dis. 1995;26:353-361.
 22.  Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an 
analysis of error. J Am Soc Nephrol. 1993;4:1205-1213.
 23.  Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. 
Relative contribution of residual renal function and different measures of adequacy to survival 
in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of 
Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004;15:1061-1070.
 24.  Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to 
imputation of missing values. J Clin Epidemiol. 2006;59:1087-1091.
 25.  van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure 
covariates in survival analysis. Stat Med. 1999;18:681-694.
 26.  Ishani A, Collins AJ, Herzog CA, Foley RN. Septicemia, access and cardiovascular disease in 
dialysis patients: the USRDS Wave 2 study. Kidney Int. 2005;68:311-318.
 27.  Cortez AJ, Paulson WD, Schwab SJ. Vascular access as a determinant of adequacy of dialysis. 
Semin Nephrol. 2005;25:96-101.
 28.  Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Parrinello G, 
Cancarini GC. The kind of vascular access influences the baseline inflammatory status and 
epoetin response in chronic hemodialysis patients. Blood Purif. 2006;24:387-393.
 29.  Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among 
hemodialysis patients. Kidney Int. 2002;62:620-626.
 30.  Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and 
mortality in U.S. hemodialysis patients. Kidney Int. 2001;60:1443-1451.
 31.  Stehman-Breen CO, Sherrard DJ, Gillen D, Caps M. Determinants of type and timing of initial 
permanent hemodialysis vascular access. Kidney Int. 2000;57:639-645.
 32.  Wasse H, Speckman RA, Frankenfield DL, Rocco MV, McClellan WM. Predictors of delayed 
transition from central venous catheter use to permanent vascular access among ESRD 
patients. Am J Kidney Dis. 2007;49:276-283.
 33.  Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W, Jr. Delayed 
nephrologist referral and inadequate vascular access in patients with advanced chronic kidney 
failure. J Clin Epidemiol. 2002;55:711-716.

Chapter 9
Type of arteriovenous vascular access and 




Frits R. Rosendaal 
Raymond T. Krediet
Elisabeth W. Boeschoten
Friedo W. Dekker 
Marion Verduijn 











































Background: There are only a few risk factors known for primary patency loss in patients with 
an arteriovenous graft or fistula. Furthermore, a limited number of studies have investigated the 
association between arteriovenous access modality and primary patency loss and mortality. 
The aim of this study was to investigate risk factors for patency loss and to investigate the 
association between graft versus fistula use and outcomes (patency loss and mortality). 
Methods: We prospectively followed 919 incident hemodialysis patients and calculated 
hazard ratios (HRs) for putative risk factors of primary patency loss using Cox regression. 
Furthermore, HRs were calculated to study the association between graft versus fistula use 
and two-year primary patency loss and two-year mortality. 
Results: Cardiovascular disease, prior catheter use, lowest tertile of albumin, highest tertile 
of hsCRP, and lowest tertile of fetuin-A were associated with primary patency loss in both 
patients with grafts and fistulas. Increased age, female sex, and diabetes mellitus were 
only associated with primary patency loss in patients with a fistula. We did not observe 
an association between primary patency loss and BMI, residual GFR, levels of calcium, 
phosphorus, and total cholesterol. Furthermore, graft use as compared with fistula use was 
associated with an 1.4-fold (95%CI 1.0-1.9) increased risk of primary patency loss and with 
an 1.5-fold (95%CI 1.0-2.2) increased mortality risk. 
Conclusion: Cardiovascular disease, prior catheter use, albumin, hsCRP, and fetuin-A are 
risk factors for patency loss. Graft use as compared with fistula use was associated with an 












































Preservation of adequate vascular access is of vital importance for patients undergoing chronic 
hemodialysis. Vascular access-related morbidity accounts for 20% of all hospitalizations in 
hemodialysis patients leading to high costs.1,2  
Several studies have shown that graft use as compared with fistula use was associated with 
an increased risk of patency loss.3 However, few studies have investigated whether risk factors 
for patency loss are different for fistula use and graft use. The vast majority of arteriovenous 
access failure is caused by thrombosis, secondary to disproportionate intimal hyperplasia in 
the venous outflow tract.4-7 The mechanisms that are responsible for this localized hyperplastic 
response are incompletely understood. The prevailing opinion is that local hemodynamic 
factors such as flow turbulence, vascular inflammation as well as the prothrombotic milieu 
that results from endothelial damage play a role in the formation of stenotic lesions.8,9 Factors 
associated with atherosclerotic vascular disease and inflammation might play a different role 
in the formation of stenotic lesions in fistulas and graft. CRP and fetuin-A are both markers for 
inflammation and cardiovascular disease that could be associated with patency loss.
Moreover, a limited number of studies have investigated the association between fistula use 
versus graft use and mortality.10,11 These studies found a moderately increased mortality 
risk for graft use as compared with fistula use.10,11 The National Kidney Foundation Kidney 
Disease Outcome Quality Initiative guidelines12 and the European Best Practice Guidelines13 
recommend the use of a fistula instead of grafts for vascular access in all hemodialysis 
patients. To date, it is unknown whether the graft use versus fistula use is associated with 
both patency loss and mortality.
In the present study, we investigated risk factors for primary patency loss (i.e. any intervention 
in the arteriovenous access after the first successful cannulation) in a large Dutch cohort of 
919 incident hemodialysis patients.14 In addition, we investigated the association between 
graft use versus fistula use and two-year patency loss and mortality.
METHODS
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospective 
multicenter cohort study in which incident adult end-stage renal disease patients from 38 
dialysis centers in the Netherlands were included. The study was approved by all local 










































Sint Lucas Andreas Hospital Amsterdam, Dianet Dialysis Center Academic Medical Center 
Amsterdam, Maxima Medical Center Veldhoven, Catharina Hospital Eindhoven, Medical 
Center Haaglanden Den Haag, University Medical Center Groningen, Kennemer Gasthuis 
Haarlem, Atrium Medical Center Heerlen, Medical Center Leeuwarden, Leiden University 
Medical Center Leiden, Elisabeth Hospital Tilburg, University Medical Center Utrecht, Antonius 
Ziekenhuis Nieuwegein, Hospital Gelderse Vallei Ede, Haga Hospital Leyenburg Den Haag, 
Academic Hospital Maastricht, Jeroen Bosch Hospital Den Bosch, Medisch Spectrum Twente 
Enschede, Albert Schweitzer Hospital Dordrecht, Alysis Zorggroep Rijnstate Hospital Arnhem, 
Dianet Dialysis Center Lunetten Utrecht, Canisius Wilhelmina Hospital Nijmegen, Vie Curi 
Medical Center Venlo, Leveste Scheper Hospital Emmen, Dianet Dialysis Center Holendrecht 
Amsterdam, Hage Hospital Rode Kruis Den Haag, Rijnland Hospital Leiderdorp, Admiraal 
de Ruyter ziekenhuis Goes, Medical Center Alkmaar, Laurentius Ziekenhuis Roermond, 
Dialysis Center ’t Gooi Hilversum, Groene Hart Hospital Gouda, Westfries Gasthuis Hoorn, 
Tergooiziekenhuizen Hospital Hilversum, Martini Ziekenhuis Groningen, Zaans Medical Center 
Zaandam). We followed patients until death or censoring, i.e. transfer to a nonparticipating 
dialysis center, withdrawal from the study, transplantation, or end of the follow-up period (April 
2006). We did not censor for patency loss when investigating the effect of fistula versus graft 
use on mortality.
Eligibility included age older than 18 years, no previous renal replacement therapy, and 
survival of the initial three months of dialysis. For the current analyses, we used data from 
incident hemodialysis patients included between January 1997 and April 2004 with a functional 
arteriovenous access (native fistulas or grafts) within three months after the first dialysis 
session. Information about graft use or fistula use was collected from the medical records of 
patients. All patients gave informed consent.
Demographic and clinical data
Data on age, sex, body mass index (BMI), primary kidney disease, cardiovascular disease 
(angina pectoris, myocardial infarction, heart failure, ischemic stroke, or claudication), and 
diabetes mellitus were collected at the start of dialysis treatment. BMI was calculated as 
weight in kilograms divided by height in meters squared. Primary kidney disease was classified 
according to the codes of the European Renal Association-European Dialysis and Transplant 
Association (ERA-EDTA).15 We grouped patients into four classes of primary kidney disease: 
glomerulonephritis, diabetes mellitus, renal vascular disease, and other kidney diseases. 
Other kidney diseases consisted of patients with interstitial nephritis, polycystic kidney 
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The following biochemical parameters were routinely measured in blood samples obtained 
from patients at 3 months after the start of dialysis: creatinine, urea, calcium, phosphorus, 
albumin, total cholesterol. Renal function, expressed as glomerular filtration rate (GFR), 
was calculated as the mean of creatinine and urea clearance corrected for body surface 
area (ml/min per 1.73 m2). Moreover, circulating fetuin-A serum levels and high-sensitivity 
C-reactive protein (hsCRP) were measured at 3 months after the start of dialysis as described 
elsewhere.16 
Primary patency loss and mortality
Time to primary patency loss was defined as the interval from time of first successful 
cannulation of the vascular access for hemodialysis treatment (first dialysis session) to surgery, 
percutaneous endovascular intervention, or abandonment of the vascular access in the first 
two years on dialysis. Information about surgery, percutaneous endovascular intervention, 
or abandonment of the vascular access was obtained from the standard data collection of 
NECOSAD. Two-year mortality was recorded according to the codes of the ERA-EDTA.15 
Statistical analysis
Continuous variables are presented as median and interquartile range (IQR). Categorical 
variables are presented as number with percentages. We calculated hazard ratios (HRs) with 
95% confidence intervals (95% CIs) using Cox regression analysis. HRs were calculated for 
primary patency loss within two-years of follow-up for previous catheter use, factors associated 
with atherosclerotic vascular disease (age, sex, diabetes mellitus, body mass index, residual 
glomerular filtration rate (GFR), calcium levels corrected for albumin, phosphorus levels, 
cholesterol levels, and fetuin-A levels), and factors associated with inflammation (hsCRP and 
albumin) stratified for patients with a fistula and patients with a graft use. Confounders were 
defined as variables that could be associated with exposure and with outcome, based on 
previous literature, without being an intermediate variable in the causal pathway between 
exposure and outcome.17 Therefore, each investigated variable could have a different set of 
variables that were adjusted for. For the same reason, the effect of sex was not adjusted for 
other variables.
Survival curves for primary patency loss and mortality were determined with the Kaplan–Meier 
method stratified for fistula use and graft use. We calculated crude and adjusted hazard ratios 
(HRs) with 95% confidence intervals (95% CIs) for primary patency loss and mortality within 
2 years of follow-up for patients with a fistula and patients with a graft using Cox regression 












































A total of 919 incident hemodialysis patients with an arteriovenous access were included in 
NECOSAD. Of the 919 patients, 727 had a fistula, 146 had a graft, and 46 patients had an 
unknown type of arteriovenous access. Patients with a graft were older, were more often 
female, had a higher body mass index, had more often diabetes mellitus as primary kidney 
disease, had lower residual GFR and had higher total cholesterol levels than patients with a 






Age (years) (IQR) 65.8 (54.5-73.7) 68.5 (59.4-74.3)
Sex, female (%) 37.4 59.6
BMI (kg/m2) (IQR) 24.0 (22.0-26.7) 24.8 (21.5-27.8)
Primary kidney disease (%)
Diabetes mellitus 14.7 17.8
Glomerulonephritis 12.0 5.5
Renal vascular disease 19.1 28.1
Others 54.2 48.6
Cardiovascular disease (%) 40.0 42.5
Prior catheter use (%) 26.8 32.2
Systolic blood pressure, mmHg 148 (135-162) 144 (133-158)
GFR (ml/min/1.73 m2) (IQR) 3.2 (1.7-5.0) 2.4 (1.1-4.4)
Calcium (mmol/L) (IQR) 2.4 (2.2-2.5) 2.4 (2.2-2.6)
Phosphorus (mmol/L) (IQR) 1.8 (1.5-2.2) 1.8 (1.5-2.2)
Serum cholesterol (mmol/L) (IQR) 4.6 (3.9-5.4) 4.9 (4.1-6.0)
Serum albumin (g/L) (IQR) 37 (34-40) 36 (32-40)
hsCRP* (mg/L) (IQR) 5.3 (2.0-13.8) 6.5 (2.5-16.7)
Fetuin-A* (g/L) (IQR) 0.6 (0.5-0.7) 0.6 (0.5-0.8)
BMI, body mas index; IQR, interquartile range. *Missing in 276 patients with a fistula and 63 patients with 
a graft 
During the two-year follow-up, 287 of the 727 patients with a fistula and 84 of the 146 patients 
with a graft lost primary patency of their vascular access within two years. The cumulative 
incidence at two years for primary patency at two years was 56.8% for patients with a fistula 
and was 36.4% for patients with a graft (Figure 1). Of the 727 patients with a fistula, 149 died 
within 2 years. Of the 146 patients with a graft, 51 died within 2 years. Figure 2 shows the 
Kaplan-Meier survival curve with two-years mortality as outcome for patients with a fistula and 














































Figure 1. Kaplan-Meier survival curve for two-year primary patency loss after first  
successful cannulation 









Graft 146 96 71 54 34















Figure 2. Kaplan-Meier survival curve for two-year mortality  









Graft 146 125 114 94 79













Figure 1. Kaplan- eier survival curve for t o-year pri ary patency loss after first  
successful cannulation 








u ber at risk:
raft 146 96 71 54 34
Fistula 727 532 414 322 261














Figure 2. Kaplan- eier survival curve for t o-year ortality  








u ber at risk:
raft 146 125 114 94 79
Fistula 727 643 554 481 418

















































Table 2 shows the adjusted hazard ratios of the risk factors for primary patency loss stratified 
for patients with a fistula and patients with graft. Increased age ≥65 years (HR 1.3; 95% CI 
1.0-1.7), female sex (HR 1.5; 95% CI 1.2-2.9), and diabetes mellitus (HR 2.0; 1.4-2.7) were 
associated with an increased risk of primary patency loss for patients with a fistula and not 
for patients with a graft. Cardiovascular disease (HR 1.7; 95% CI 1.3-2.2 and HR 1.8; 95% 
CI 1.1-2.9), prior catheter use (HR 1.9; 95% CI 1.5-2.4 and HR 2.1; 95% CI 1.3-3.4), lowest 
tertile of albumin (HR 1.5; 95% CI 1.1-2.1 and HR 2.4; 95% CI 1.3-4.5), highest tertile of 
hsCRP (HR 1.6; 95% CI 1.1-2.3 and HR 2.7; 95% CI 1.2-6.3), and lowest tertile of fetuin-A 
(HR 1.9; 95% CI 1.3-2.9 and HR 3.6; 95% CI 1.7-7.4) were associated with primary patency 
loss after adjustment in both patients with a fistula and graft, respectively. We did not find 
an association between primary patency loss and BMI, GFR, levels of calcium corrected for 
albumin, phosphorus, and cholesterol after adjustment (Table 2). 
 
Graft use as compared with fistula use was associated with an 1.4-fold (95% CI 1.0-1.9) 
increased risk of primary patency loss and with an 1.5-fold (95% CI 1.0-2.2) increased two-
year mortality risk after adjustment for age, sex, BMI, primary kidney disease, cardiovascular 
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Crude Adjusted Crude Adjusted
Age* (years) ≥65 versus <65 1.3 (1.1-1.7) 1.3 (1.0-1.7) 1.1 (0.7-1.7) 1.1 (0.7-1.7)
Sex† Female versus Male 1.5 (1.2-2.9) 1.5 (1.2-1.9) 0.7 (0.5-1.1) 0.7 (0.5-1.1)
BMI‡ (kg/m2) ≥25 versus <25 1.0 (0.8-1.2) 0.9 (0.7-1.1) 0.8 (0.5-1.3) 0.8 (0.5-1.3)
Primary kidney disease§ Diabetes mellitus 2.1 (1.6-2.9) 2.0 (1.4-2.7) 1.4 (0.8-2.5) 1.2 (0.7-2.1)
Glomerulonephritis 0.8 (0.6-1.3) 0.9  (0.6-1.3) 1.1 (0.4-3.1) 1.2 (0.4-3.5)
Vascular disease 1.0 (0.8-1.4) 0.9 (0.7-1.3) 0.9 (0.5-1.5) 0.7 (0.4-1.2)
Others 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Cardiovascular disease¶ Yes versus No 1.7  (1.4-2.2) 1.7  (1.3-2.2) 1.8 (1.2-2.8) 1.8 (1.1-2.9)
Prior catheter use** Yes versus No 1.9 (1.5-2.4) 1.9 (1.5-2.4) 2.2 (1.4-3.4) 2.1 (1.3-3.4)
Systolic blood pressure** Low <139 0.9 (0.7-1.2) 0.9 (0.7-1.2) 1.7 (1.0-2.9) 1.5 (0.8-2.6)
(mmHg) Median 139-155 1.0 (0.8-1.4) 1.1 (0.8-1.4) 1.0 (0.6-1.8) 1.1 (0.6-2.0)
High >155 1 (reference) 1 (reference) 1 (reference) 1 (reference)
GFR** >10 1 (reference) 1 (reference) 1 (reference) 1 (reference)
(ml/min/1.73 m2) 5-10 1.1 (0.5-2.3) 1.0 (0.5-2.1) 0.5 (0.1-1.6) 0.6 (0.2-2.1)
<5 0.9 (0.5-1.9) 0.9 (0.4-1.7) 0.4 (0.1-1.3) 0.4 (0.1-1.4)
Calcium** (mmol/L), Low <2.30 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tertiles Median 2.30-2.49 1.3 (0.9-1.7) 1.3 (1.0-1.7) 1.0 (0.6-1.8) 1.1 (0.6-1.9)
High >2.49 1.0 (0.8-1.4) 1.0 (0.8-1.4) 1.4 (0.8-2.3) 1.5 (0.9-2.5)
Phosphorus** (mmol/L), Low <1.57 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tertiles Median 1.57-2.02 0.9 (0.7-1.2) 0.9 (0.7-1.2) 0.7 (0.4-1.2) 0.8 (0.4-1.3)
High >2.02 0.9 (0.7-1.2) 0.9 (0.7-1.2) 0.9 (0.5-1.5) 0.9 (0.5-1.5)
Cholesterol** (mmol/L), Low <4.20 1 (reference) 1  reference) 1 (reference) 1 (reference)
Tertiles Median 4.20-5.10 0.7 (0.5-0.9) 0.7 (0.5-1.0) 0.9 (0.5-1.6) 0.9 (0.5-1.6)
High >5.10 0.8 (0.6-1.1) 0.8 (0.6-1.1) 0.7 (0.4-1.2) 1.0 (0.5-1.7)
Albumin** (g/L), Low <35.0 1.8 (1.3-2.4) 1.5 (1.1-2.1) 3.1 (1.7-5.5) 2.4 (1.3-4.5)
Tertiles Median 35.0-38.9 1.3 (1.0-1.8) 1.2 (0.9-1.7) 2.1 (1.1-4.0) 2.4 (1.2-4.6)
High >38.9 1 (reference) 1 (reference) 1 (reference) 1 (reference)
hsCRP** (mg/L), Low <2.95 1 (reference) 1 (reference) 1 (reference) 1 (reference)
Tertiles Median 2.95-9.94 1.1 (0.7-1.6) 1.1 (0.7-1.6) 2.5 (1.1-5.5) 2.6 (1.0-6.5)
High >9.94 1.6 (1.1-2.4) 1.6 (1.1-2.3) 2.5 (1.1-5.6) 2.7 (1.2-6.3)
Fetuin-A** (g/L), 
Tertiles
Low <0.55 1.9 (1.3-2.9) 1.9 (1.3-2.9) 3.6 (1.4-6.7) 3.6 (1.7-7.4)
Median 0.55-0.64 1.5 (1.0-2.3) 1.5 (1.0-2.3) 3.1 (1.8-7.3) 3.3 (1.5-7.5)
High >0.64 1 (reference) 1 (reference) 1 (reference) 1 (reference)
*Adjusted for sex, †Unadjusted, ‡Adjusted for age, sex, primary kidney disease, and cardiovascular 
disease, §Adjusted for age, sex, BMI, and cardiovascular disease, ¶Adjusted for age, sex, BMI, and 















































Total Fistula (N=727) 1 (reference) 1 (reference)
Graft (N=146) Crude 1.6 (1.3-2.0) 1.7 (1.3-2.4)
Adjusted* 1.4 (0.9 -2.1) 1.5 (1.0-2.2)
HR, hazard ratio; CI, confidence interval. *Adjusted for age, sex, BMI, primary kidney disease, 
cardiovascular disease, prior catheter use, GFR, calcium corrected for albumin, phosphorus, and 
cholesterol
DISCUSSION
In this prospective cohort study of 919 incident hemodialysis patients with an arteriovenous 
access, we showed that cardiovascular disease, prior catheter use, levels of albumin, hsCRP, 
and fetuin-A were associated with primary patency loss in both patients with a fistula and a 
graft. Increased age, female sex, and diabetes mellitus was only associated with an increased 
risk of primary patency loss in patients with a fistula. We did not find an association between 
primary patency loss and BMI, GFR, and levels of calcium, phosphorus, and cholesterol. 
Furthermore, we showed that graft use as compared with fistula use was associated with an 
1.4-fold (95% CI 1.0-1.9) increased risk of primary patency loss and with an 1.5-fold (95% CI 
1.0-2.2) increased two-year mortality risk. 
Previous smaller studies on risk factors of arteriovenous dysfunction have shown conflicting 
results.18-25 Increased age has been associated in previous studies with vascular access 
morbidity,18,19,21 but not in other studies.20,22,23 Similar inconsistencies have been observed 
in previous studies on gender as a risk factor for arteriovenous access dysfunction.20-23,25 
In our large study using incident hemodialysis patients with an arteriovenous access, we 
have showed that increased age, female gender, and diabetes mellitus were associated with 
primary patency loss in patients with a fistula and not in patients with a graft. Since patients 
with a graft are a group of selected dialysis patients with an increased mortality risk and an 
increased risk of patency loss as compared with patients with a fistula, selection bias could 
explain the differences in the association between patency loss and age, sex, and presence 
of diabetes mellitus. Another reason could be that graft patency is less influenced by age, sex, 
and diabetes mellitus than fistula patency. Furthermore, we had less power in the graft group 
than in the fistula group for the investigation of risk factors for patency loss. In line with our 
study, cardiovascular disease18,21 and prior catheter use24 have been shown to be important 
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Limited studies have investigated the association between arteriovenous access dysfunction 
and BMI, GFR, calcium, phosphorus, and cholesterol. In concordance with the results of 
previous studies,19-21 these potential risk factors were not associated with arteriovenous 
access dysfunction in our study. Fetuin-A, hsCRP, and albumin levels have been associated 
with mortality in dialysis patients.25-28 However, a new observation in our study was that levels 
of fetuin-A, hsCRP, and albumin levels were associated with vascular access dysfunction in 
patients with a fistula and in patients with a graft. 
The pathogenic mechanisms for arteriovenous dysfunction are incompletely understood, 
but it is thought that thrombosis resulting from stenosis due to neointimal hyperplasia is the 
main cause of arteriovenous dysfunction.7-9 The stimuli responsible for this localized intimal 
hyperplastic response in the venous outflow tract are multifactorial and include hemodynamic 
factors such as turbulent flow, endothelial damage as well as repetitive strain injury and 
vascular inflammation that might relate to compliance mismatch between the anastomosed 
blood vessels.7-9 The stenotic vascular lesions that arise from this intimal hyperplastic 
response mainly consist of vascular smooth muscle cells, myofibroblasts and extracellular 
matrix proteins such as collagen.7-9 A recent study showed that the stenotic vascular lesions 
are already present prior to dialysis access placement.29 Morphologically, these lesions 
differ substantially from atherosclerotic lesions that mainly consist of lipid-rich foam cells 
and activated T-cells 30,31. Interestingly, our study suggests that well-known risk factors for 
atherosclerosis (cardiovascular disease and fetuin-A levels) and factors associated with 
inflammation (C-reactive protein and albumin) might play an important role in the development 
of stenotic lesions in arteriovenous fistulas in dialysis patients as well.   
In the present study, graft use as compared with fistula use was associated with an 1.4-fold 
(95% CI 1.0-1.9) increased risk of primary patency loss and with an 1.5-fold (95% CI 1.0-2.2) 
increased two-year mortality risk. Previous studies found also an increased risk of patency los 
in patients with a graft as compared with patients with a fistula. However, limited studies have 
investigated the association between type of arteriovenous access and mortality.10,11 These 
studies suggested an increased mortality risk for graft use as compared with fistula use.10,11 
Although National Kidney Foundation Kidney Disease Outcome Quality Initiative guidelines12 
and the European Best Practice Guidelines13 recommend the use of a fistulas instead of grafts 
for vascular access in all hemodialysis patients, it could be that for special subgroups, such as 
elderly patients, grafts are good alternatives as first option for a vascular access, especially 
when we take into account that failure of vascular access before successful cannulation for 











































Our study has several potential limitations. We had no information on several vascular access 
characteristics (anatomic location, flow, vessel diameter, and intervention prior to cannulation) 
that are associated with vascular access dysfunction. Moreover, type of arteriovenous access 
was unknown in 46 patients. However, when unknown type of vascular access was either 
classified as graft use or fistula, the influence of these unknown type of vascular accesses 
in the association between graft use versus fistula use and patency loss or mortality was 
minimal (data not shown). Another limitation is that confounding-by-indication could occur 
when comparing different outcomes for graft use versus fistula use in an observational 
design. The observed increased mortality risk and patency loss of graft use versus fistula 
use may partly reflect the effect of other differences between graft and fistula users. In our 
analyses, we took this into account by correcting for many confounders, but this cannot 
exclude possible residual confounding. Therefore, randomized controlled trials are needed 
when comparing outcomes between graft use and fistula use. However, there might be ethical 
and practical problems to conduct this kind of a randomized controlled trial. In view of the 
clinical importance in combination with the small differences in outcomes between graft use 
and fistula use in elderly patients, ethical objections against such a randomized controlled 
trial seem exaggerated. Furthermore, we had no information about failure of arteriovenous 
accesses before the successful first cannulation. However, this would probably result in an 
underestimation of the point estimates for the investigated risk factors. The general strength 
of this study was the large and well-defined Dutch cohort of incident hemodialysis patients 
with an arteriovenous access with available data on many patient characteristics, laboratory 
measurements, and death. 
In conclusion, we showed that cardiovascular disease, prior catheter use, levels of albumin, 
hsCRP, and fetuin-A were associated with primary patency loss in both patients with a fistula 
and a graft. Current guidelines for prevention of vascular access failure recommend uniform 
surveillance of all patients.33 The results of our study might lead to a more directed approach 
for surveillance techniques. The observed risk factors for primary patency loss could be used 
to focus on specific patient groups for more intensive surveillance. Furthermore, we showed 
that graft use as compared with fistula use was associated with an increased risk of primary 
patency and an increased mortality risk. 
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Chapter 10
Single nucleotide variants in the protein C 



























































Background: The protein C pathway plays an important role in the maintenance of endothelial 
barrier function and in the inflammatory and coagulant processes that are characteristic 
of patients on dialysis. We investigated whether common single nucleotide variants (SNV) 
in genes encoding protein C pathway components were associated with all-cause 5 years 
mortality risk in dialysis patients. 
Methods: Single nucleotides variants in the factor V gene (F5 rs6025; factor V Leiden), 
the thrombomodulin gene (THBD rs1042580), the protein C gene (PROC rs1799808 and 
1799809) and the endothelial protein C receptor gene (PROCR rs867186, rs2069951, and 
rs2069952) were genotyped in 1070 dialysis patients from the NEtherlands COoperative 
Study on the Adequacy of Dialysis (NECOSAD) cohort) and in 1243 dialysis patients from the 
German 4D cohort. 
Results: Factor V Leiden was associated with a 1.5-fold (95% CI 1.1-1.9) increased 5-year 
all-cause mortality risk and carriers of the AG/GG genotypes of the PROC rs1799809 had a 
1.2-fold (95% CI 1.0-1.4) increased 5-year all-cause mortality risk. The other SNVs in THBD, 
PROC, and PROCR were not associated with 5-years mortality. 
Conclusion: Our study suggests that factor V Leiden and  PROC rs1799809 contributes to 












































The protein C pathway plays an important role in endothelial barrier function and in inflammatory 
and anticoagulant processes.1 Protein C activation occurs on the endothelial cell membrane 
by thrombin bound to thrombomodulin and this is enhanced when protein C is bound to 
the endothelial protein C receptor. Activated protein C together with its cofactor protein S 
inactivates the procoagulant factors Va and VIIIa. Activated protein C resistance is often 
caused by a variant of factor V  (factor V Leiden), that abrogates one of the inactivation sites 
in factor Va.2 Besides anticoagulant properties, activated protein C has direct cytoprotective 
effects on endothelial cells that include anti-inflammatory actions, anti-apoptotic activities, 
and stabilization of endothelial barriers. These effects are largely mediated by activation of 
protease activated receptors.3-7 
The crucial role of the protein C pathway in endothelial function, coagulation, and 
inflammation became evident in several studies.8-12 The importance of the protein C system 
is most clearly demonstrated by the massive thrombotic complications occurring in infants 
with severe homozygous or compound heterozygous protein C deficiency8 and the increased 
risk of venous thrombosis in haploinsufficient adults.9 In severe sepsis patients with a high 
mortality risk treatment with activated protein C reduced mortality, probably through its anti-
inflammatory and anticoagulant activities.10 In addition, low plasma protein C levels have been 
shown to increase the risk of ischemic stroke.11 Finally, particular combinations of variants in 
the thrombomodulin, protein C, and factor V genes seem to increase the risk of cardiovascular 
events in the general population.12
Patients on dialysis have a high mortality risk due to endothelial damage and subsequent 
cardiovascular diseases.13 Dialysis patients also have a high risk of dying from dialysis 
treatment failure,13 which is associated with thrombotic events (i.e. vascular access thrombosis 
and catheter thrombosis) and infections.13 Genetic variation in the protein C pathway could 
influence the mortality risk by changing processes related to endothelial damage, by influencing 
inflammatory response, and by increasing or decreasing the chance of thrombotic events 
associated with treatment failure. We hypothesized that genetic mutations in genes encoding 
protein C pathway components or targets might influence mortality rates in dialysis patients.
We selected seven single nucleotide variants (SNVs) that are known to influence levels or 
activity of proteins in the protein C pathway or have been associated with venous thrombosis, 
arterial thrombosis or mortality in the general population: factor V (F5) rs6025 (factor V Leiden),2 
thrombomodulin (THBD) rs1042580,12,14 protein C (PROC) rs1799809 and rs1799808,15 and 










































association between these SNVs and all-cause and cause-specific (cardiovascular and non-
cardiovascular) mortality in the NEtherlands COoperative Study on the Adequacy of Dialysis 
(NECOSAD) cohort and the German Diabetes Dialysis Study (4D-study). 
          
METHODS
Patients
The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a prospective 
multicenter cohort study in which incident adult dialysis patients from 38 dialysis centers 
in the Netherlands were included. The Medical Review Ethics Committee of the Leiden 
University Medical Center approved the study. All patients gave written informed consent. 
Eligibility criteria included age older than 18 years, and no previous renal replacement therapy 
(transplantation or dialysis). For the current analyses, we used data from patients who were 
included between June 1997 and June 2007 in 23 dialysis centers that approved DNA analysis. 
Information was gathered from patients until date of death or date of censoring, i.e. transfer 
to a nonparticipating dialysis center, withdrawal from the study, transplantation, or end of the 
follow-up period in June 2009, whichever occurred first. 
Demographic and clinical data
Data on age, sex, primary kidney disease, and cardiovascular disease were collected at the 
start of dialysis treatment. Pre-existing cardiovascular disease was defined as a history of 
angina pectoris, myocardial infarction, heart failure, ischemic stroke, or claudication at the 
time of inclusion. 
Single nucleotide variants
Blood samples were collected for DNA analysis. We genotyped one SNV in the factor V 
gene (F5 rs6025; factor V Leiden), one SNV in the thrombomodulin gene (THBD rs1042580), 
two SNVs in the protein C gene (PROC rs1799809 and rs1799808), and three SNVs in the 
protein C receptor gene (PROCR rs867186, rs2069951, and rs2069952) using TaqMan SNV 
Genotyping Assays (Applied Biosystems, Foster City, CA, USA) as described previously.14-17 
Mortality
We classified causes of death according to the codes of the European Renal Association-
European Dialysis and Transplantation Association (ERA-EDTA) which is a standardized 
classification of death causes in dialysis patients.18 We grouped death causes into 
cardiovascular and non-cardiovascular mortality. Cardiovascular mortality was defined as 
death due to myocardial ischemia and infarction (code 11); cardiac arrest/ sudden death 
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hypokalemia (code 12,17); pulmonary embolism (code 21); cerebrum-vascular accident (code 
22); hemorrhage from ruptured vascular aneurysm (code 26); mesenteric infarction (code 
29); cause of death uncertain/unknown (code 0). All other deaths were designated as non-
cardiovascular mortality. 
Replication
For independent replication of the results of the NECOSAD study, we analyzed data from the 
German Diabetes Dialysis Study (4D-study). Methods of the 4D-study have been described 
in detail previously.19 Briefly, the 4D-study was a double-blind, randomized trial on the effect 
of atorvastatin in hemodialysis patients with type 2 diabetes mellitus who had less than two 
years of previous hemodialysis treatment. The primary endpoint was a composite of cardiac 
death, non-fatal myocardial infarction and stroke, whichever occurred first. Patients were 
randomly assigned to either 20 mg of atorvastatin or placebo once daily until the date of death, 
censoring, or the end of study in March 2004. Atorvastatin showed no effect on the composite 
primary endpoint.19 The genotyping of the SNV in the factor V gene (F5 rs6025; factor V 
Leiden), the SNV in the thrombomodulin gene (THBD rs1042580), the two SNVs in the protein 
C gene (PROC rs1799809 and rs1799808), and the three SNVs in the protein C receptor 
gene (PROCR rs867186, rs2069951, and rs2069952) were the same as described above 
for the NECOSAD cohort. The SNV in the factor V gene (F5 rs6025; factor V Leiden), the 
SNV in the thrombomodulin gene (THBD rs1042580), and the SNV in the protein C receptor 
gene (PROCR rs867186) were genotyped earlier than the other SNVs, therefore the numbers 
vary for these SNVs as compared with the other SNVs. Mortality was also categorized into 
cardiovascular and non-cardiovascular deaths.
Statistical analysis
The baseline characteristics are presented as median and 5th-95th percentiles for continuous 
variables, and as percentages for categorical variables. Distributions of genotypes were 
compared by the chi-square test to test for Hardy-Weinberg equilibrium. We calculated pooled 
hazard ratios (HRs) with 95% confidence intervals (95% CIs) for all-cause, cardiovascular, 
and non-cardiovascular mortality by Cox’s regression analysis to study the effect of the seven 
SNVs on 5-year mortality from start of dialysis in the NECOSAD and 4D-study together. 
Furthermore, we calculated HRs with 95% CIs separately for the NECOSAD cohort and 
4D-study. In addition, we repeated the analyses in the NECOSAD cohort for only hemodialysis 
patients with diabetes mellitus, since the 4D-study consists of only hemodialysis patients with 
diabetes mellitus. HRs were calculated for homozygous or heterozygous carriers of the rare 
alleles (except for rs2069952 for which the risk allele was the common major allele) of the 
SNVs compared to non-carriers. We reported unadjusted HRs, since adjustment in genetic 










































bias through overadjustment.20 We used SPSS statistical software (version 17.0; SPSS, 
Chicago) for all statistical analyses. 
RESULTS
A total of 1070 patients from the NECOSAD cohort and 1243 patients from the 4D cohort 
were genotyped for the seven SNVs. Baseline characteristics of the 1070 patients from the 
NECOSAD cohort and 1243 patients from the 4D cohort are shown in Table 1. In contrast to 
the NECOSAD cohort, the 4D cohort consisted only of hemodialysis patients with diabetes 
mellitus. In the NECOSAD cohort, 140 hemodialysis patients (20.7%) had diabetes mellitus.





Age (years), median (5th-95th percentile) 62.2 (33.0- 80.2) 66.0 (51.0-78.0)
Males, % 62.9 54.1
Body mass index (kg/m2), median (5th-95th percentile) 24.3 (19.2-33.2) 26.7 (20.7-36.3)
Dialysis duration (months), median (5th-95th percentile) 0 6.0 (1.1-22.5)
Dialysis modality,%
Hemodialysis 63.4 100
Peritoneal dialysis 36.6 0
History of diabetes mellitus, % 20.7 100
Cardiovascular disease,% 35.2 29.5
Table 2 shows the genotype and allele frequencies for the seven SNVs. All SNVs in the 
NECOSAD cohort were in Hardy-Weinberg equilibrium, except PROC rs1799809 (p-value 
0.002). In the 4D cohort, F5 rs6025 (factor V Leiden) (p-value <0.001), PROC rs1799808 
(p-value <0.036), and PROCR rs2069952 (p-value 0.001) were not in Hardy-Weinberg 
equilibrium (Table 2).
Of the 1070 patients from the NECOSAD cohort, 401 died within 5 years of follow-up; 185 
patients due to cardiovascular causes and 216 due to non-cardiovascular causes. In the 
4D cohort, 594 patients died within 5 years of follow-up (297 patients due to cardiovascular 
causes and 297 due to non-cardiovascular causes).
Factor V (Leiden) rs6025
Factor V Leiden was associated with a 1.5-fold (95% CI 1.1-1.9) increased 5-year all-cause 
mortality risk in the pooled results. The hazard ratios were 1.4 (95% CI 0.9-2.1) in the total 
NECOSAD cohort and 1.6 (95% CI 1.1-2.2) in the 4D-study (Table 3). Restricting the analyses 
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only includes diabetic hemodialysis patients), factor V Leiden was associated with a 2.1-fold 
(95% CI 1.0-4.5) increased 5-year all-cause mortality risk (Table 3). 
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Thrombomodulin, protein C and protein C receptor variants
As compared to the AA genotype in PROC rs1799809, carriers of the AG/GG genotypes 
had a 1.2-fold (95% CI 1.0-1.4) increased 5-year all-cause mortality risk (Table 3). PROC 
rs1799809, THBD rs1042580, PROC rs1799808, PROCR rs867186, PROCR rs2069951, 
and PROCR rs2069952 were not associated with all-cause mortality in the NECOSAD and 





















































Gene/SNV Genotype Mortality HR (95%	CI) HR (95%	CI) HR (95%	CI) HR (95%	CI)



























































































































































































































































*hemodialysis patients with diabetes mellitus
DISCUSSION
This candidate-gene study assessed the 5-year mortality risk while on dialysis treatment for 
seven genetic variants that influence levels or activity of proteins in the protein C pathway: one 
SNV in the factor V gene (factor V Leiden), two SNVs in the protein C gene (PROC), one SNV 
in the thrombomodulin gene (THBD) and three SNVs (tagging three haplotypes) in the protein 
C receptor gene (PROCR). We found that factor V Leiden was associated with a 1.5-fold (95% 
CI 1.1-1.9) increased 5-year all-cause mortality risk and that PROC rs1799809 was associated 
with a 1.2-fold (95% CI 1.0-1.4) increased 5-year all-cause mortality risk. Furthermore, we 
showed that THBD rs1042580, PROC rs1799808, PROCR rs867186, PROCR rs2069951, 
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Studies in the general population have shown an association between factor V Leiden and 
an increased risk of different adverse outcomes, including venous thrombosis,17 ischemic 
stroke,21 and myocardial infarction.22 We showed in the current study that factor V Leiden 
was associated with increased all-cause mortality in dialysis patients. Other studies did not 
find an increased all-cause mortality risk for factor V Leiden in the general population and in 
thrombophilic families.23,24 However, it could be that an interaction between dialysis and factor 
V Leiden leads to an increased mortality risk in dialysis patients. Previous studies on factor V 
in the dialysis population have been focused on arteriovenous access failure. A recent study 
showed that a factor V gene SNV (rs6019) was associated with arteriovenous graft failure in 
dialysis patients suggesting an association between factor V SNVs and adverse outcomes in 
dialysis patients,25 which is in line with our study. 
Several mechanisms might provide plausible explanations for the higher mortality risk in dialysis 
patients associated with factor V Leiden. First, factor V Leiden in combination with pre-existing 
and highly prevalent endothelial damage could lead to excess mortality from cardiovascular 
events. Second, factor V Leiden has been associated with venous thrombosis.14,16,17,26 
The excess mortality could have been caused by fatal pulmonary embolisms due to the 
procoagulant changes due to factor V Leiden in combination with the start of dialysis which 
is also associated with an increased risk of venous thrombosis.27,28 Arguing against this 
explanation is that in our study confirmed pulmonary embolism was the cause of death in only 
three patients, but pulmonary embolisms as cause of death might have gone undetected or 
misclassified as for example sudden cardiac death. Third, one of the main complications in 
dialysis therapy is clot formation and thrombosis in vascular accesses.29 Factor V Leiden is 
associated with procoagulant changes and could therefore lead to treatment failure in dialysis 
patients. Previous studies have reported an increased risk of arteriovenous access failure in 
patients with factor V SNVs.30,31 
THBD rs1042580 AG/GG genotypes have been associated with venous thrombosis in the 
general population.14 In addition, the combination of THBD rs1042580 with different Factor V 
SNVs was associated with an increased risk of cardiovascular events.12 Other THBD SNVs 
have also been associated with cardiovascular outcomes when combined with PROC SNVs or 
factor V Leiden in the general population.12 However, we did not find an association between 
THBD rs1042580 AG/GG genotypes and mortality in dialysis patients. 
In contrast to previous studies in sepsis patients, we found no association between the PROC 
rs1799808 and mortality. However, we found that PROC rs1799809 was associated with a 
small increased (hazard ratio 1.2, 95% CI 1.0-1.4) mortality risk. Haplotypes tagged by these 










































severe sepsis patients.32,33 An earlier study found that PROC rs1799808 was less important in 
the determination of protein C levels, indicating that the effect on protein C levels was mainly 
mediated by the PROC rs1799809.15 Studies in the general population on PROCR rs867186, 
PROCR rs2069951, and PROCR rs2069952 have been inconsistent in the risk of venous 
thrombosis15,16,26 and arterial thrombosis.34,35 We did not find an association between these 
SNVs and mortality. 
The genotype distribution of PROC rs1799809 deviated from Hardy-Weinberg equilibrium 
in the NECOSAD study and the genotype distribution of F5 rs6025 (factor V Leiden), PROC 
rs1799808, and PROCR rs2069952 were not in Hardy-Weinberg equilibrium in the 4D cohort. 
It is likely that in diseased populations, such as dialysis patients, selection could have resulted 
in deviations from Hardy-Weinberg equilibrium. 
A potential limitation of our study is that we replicated our results in a dialysis population 
consisting of hemodialysis patients with diabetes mellitus. For most of the SNVs this was 
not a problem, since there were no large differences when we restricted the NECOSAD 
cohort to hemodialysis patients with diabetes mellitus. However, in the 4D-study, we could not 
investigate the association between mortality and the protein C SNVs in peritoneal dialysis 
patients and in patients without diabetes mellitus. Furthermore, although we included more 
than 2000 dialysis patients, our study could be underpowered to detect small differences.
In conclusion, our study suggests that factor V Leiden and PROC rs1799809 contributes to an 
increased mortality risk in dialysis patients. This study is the first to investigate the association 
between protein C pathway SNVs and mortality in large cohorts of dialysis patients. 
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The main objectives of this thesis were to:
•	 investigate the association between kidney disease and venous and arterial thrombosis
•	 provide insight in the mechanism of the association between kidney disease and 
thrombosis
•	 investigate the mortality risks for hemodialysis patients with catheter, fistula  or graft 
vascular accesses
•	 investigate the association between genetic risk factors for arterial and venous thrombosis 
and mortality in dialysis patients
In this chapter, the main findings are summarized and strengths and limitations of our studies 
are discussed. In addition, clinical implications, recommendations for future research and 
main conclusions are provided.
11.1 Main findings
In chapter 2, we investigated the association between self-reported liver disease, kidney 
disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke and arterial 
thrombosis in a large case-control study (MEGA study). We showed that self-reported kidney 
disease was associated with an almost 4-fold increased risk of venous thrombosis. Liver 
disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke and arterial 
thrombosis were also associated with an increased risk of venous thrombosis. Furthermore, 
we showed that combinations of these major illnesses with immobilization, increased factor 
VIII levels, increased factor IX levels, increased von Willebrand factor levels, factor V Leiden, 
and blood group non-O further increased the risks of venous thrombosis. 
In chapter 3, we investigated the association between the early stages of kidney disease 
and venous thrombosis in a large cohort including 8495 subjects (PREVEND study). Most 
individuals with early stages of kidney disease are asymptomatic and unaware of their 
decreased kidney function or the presence of albuminuria. The incidence rate of venous 
thrombosis for patients with chronic kidney disease stages 1–3 was 3.7 per 1000 person-
years. Patients with chronic kidney disease stages 1–3 had an almost 2-fold increased risk of 
venous thrombosis as compared with subjects without chronic kidney disease.
As kidney disease appeared to be associated with venous thrombosis in chapters 2 and 
3, we investigated in the MEGA study (chapter	4)	whether the association between kidney 
disease and venous thrombosis could be explained by body mass index, immobilization, 










































prothrombin G20210A, and coagulation factors levels. We showed that a moderately to severely 
decreased kidney function (estimated glomerular filtration rate <60 ml/min) was associated 
with an almost 3-fold increased risk of venous thrombosis as compared with normal kidney 
function. Furthermore, we found that factor VIII levels and von Willebrand factor levels were 
increased in patients with a moderately to severely decreased kidney function. Adjustment for 
factor VIII or von Willebrand factor in the association between decreased kidney function and 
venous thrombosis attenuated the risk of venous thrombosis indicating an effect of kidney 
function on thrombosis through these factors. In contrast, adjustments for body mass index, 
factor V Leiden, prothrombin G20210A, diabetes mellitus, malignancy, arterial disorders, 
immobilization, surgery or corticosteroid use did not affect the risks of venous thrombosis. 
In chapter 2 and 3, kidney disease was associated with venous thrombosis. In chapter 
5, we wanted to identify high-risk groups with kidney disease that may benefit from 
thromboprophylaxis. Therefore, we investigated joint effects of reduced kidney function and 
common risk factors for venous thrombosis in the MEGA study. Moderately and severely 
reduced kidney function in combination with arterial thrombosis resulted in a 5-fold increased 
risk of venous thrombosis, with malignancy in a 6-fold increased risk, with surgery in a 14-
fold increased risk, with immobilization in a 17-fold increased risk, with the factor V Leiden 
mutation in a 4-fold increased risk and with the prothrombin G20210A mutation in a 10-fold 
increased risk of venous thrombosis. The risks of venous thrombosis increased further in the 
presence of more than one risk factor of venous thrombosis in combination with moderately 
and severely decreased kidney function.
Chapter 2 to 4 specifically focused on non-dialysis patients. In chapter 6, we assessed the 
absolute risk of venous thrombosis, myocardial infarction and ischemic stroke in a cohort 
of end-stage renal disease patients receiving dialysis treatment (NECOSAD). The incidence 
rate of venous thrombosis was 12 per 1000 person-years. The incidence rate of myocardial 
infarction was 62 per 1000 person-years. For ischemic stroke, we found an incidence rate of 28 
per 1000 person-years. The incidence rates in dialysis patients as compared with the general 
population were 6-fold increased for venous thrombosis, 12-fold increased for myocardial 
infarction, and 8-fold increased for ischemic stroke after adjustment for age and sex.
In the previous chapter, we mainly investigated non-fatal cases of venous thrombosis, 
myocardial infarction and stroke. In chapter 7, we evaluated mortality rate ratios for pulmonary 
embolism, myocardial infarction and stroke in dialysis patients from the ERA-EDTA registry 
as compared with the general population. The age- and sex-standardized mortality rate from 
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For myocardial infarction and stroke, we showed that dialysis patients had, respectively, an 
11-fold and 8-fold increased mortality risk as compared with the general population after 
adjustment for age and sex. 
In chapters 8 and 9, we focused on vascular access related complications in hemodialysis 
patients. We found that the mortality rate was 1.5-fold higher in patients with a catheter for 
hemodialysis than in those with an arteriovenous access for hemodialysis. Especially elderly 
patients with a catheter as vascular access had high mortality rates on dialysis. Furthermore, 
we showed that graft use as compared with fistula use in hemodialysis patients with a vascular 
access was associated with a 1.4-fold increased risk of primary patency loss and with a 1.5-
fold increased mortality risk.  
In chapters 6 to 9, we showed that dialysis patients were at increased risk of vascular access 
related complications and venous and arterial thrombosis. In chapter 10, we investigated 
whether polymorphisms in the protein C pathway (factor V Leiden, THBD rs1042580, PROC 
rs1799808 and 1799809 and PROCR rs867186, rs2069951, and rs2069952) were associated 
with mortality in dialysis patients in the NECOSAD cohort and the German 4D cohort. The 
protein C pathway plays an important role in endothelial barrier function and anticoagulant 
processes and abnormalities in this pathway are associated with venous or arterial thrombosis 
or vascular access related complications. Factor V Leiden was associated with a 1.5-fold 
increased 5-year all-cause mortality risk and carriers of the AG/GG genotypes of the PROC 
rs1799809 had a 1.2-fold increased 5-year all-cause mortality risk in the pooled cohorts. The 
other genotyped single nucleotide variants in the thrombomodulin gene (THBD rs1042580), 
the protein C gene (PROC rs1799808 and 1799809), and the endothelial protein C receptor 
gene (PROCR rs867186, rs2069951, and rs2069952) were not associated with 5-year all-
cause mortality.
11.2 Strengths and limitations
In this section, the strengths and limitations of our studies in the MEGA study, PREVEND 
study, NECOSAD study, 4D study and the ERA-EDTA registry are discussed.
11.2.1 MEGA study
The studies described in chapter 2, 4 and 5 are based on data collected from the MEGA 
study. The MEGA study is a large, population-based case-control study on risk factors for 
venous thrombosis. The major strengths of the MEGA study include the large patient sample, 
the detailed information about established risk factors in both patients and controls, and the 










































A limitation of the MEGA study is that blood samples were collected after the thrombotic event. 
Therefore, we cannot exclude the possibility that differences in creatinine levels between 
cases and controls resulted from the thrombotic event itself. However, it is not likely that 
thrombotic events influence creatinine levels. Furthermore, we showed that there were no 
major differences in estimated glomerular filtration rates when patients were tested within 3-6 
months, 6-12 months or after 12 months suggesting that creatinine levels were not influenced 
by a temporally raised effect. 
Another limitation was that those who died soon after a first venous thrombotic event (4% of 
the patient population) could not participate as a case in the MEGA study. This has probably 
led to an underestimation of our risk estimates, as patients with chronic kidney disease are 
more likely to die from venous thrombosis than patients without a major illness.1,2 
In addition, we had no information about proteinuria. It would be useful to explore whether 
proteinuria is associated with an increased risk of venous thrombosis and whether the 
association between decreased kidney function and venous thrombosis can be explained by 
the presence of proteinuria. Proteinuria, especially in the nephrotic range (defined as proteinuria 
of more than 3 grams per 24 hours), has been associated with venous thrombosis, which may 
be caused by changes in the plasma levels of some proteins involved in coagulation.3-6
Moreover, we cannot provide risk estimates by the primary kidney disease. This is because 
most of the subjects with impaired kidney function in our study had no symptoms and were 
never, or not yet diagnosed with impaired kidney function. It would certainly be useful to study 
the risks of thrombosis for the various types of primary kidney disease, since the thrombosis 
risk could be elevated for only specific primary kidney diseases.  
A final aspect of the MEGA study was the presence of two separate control groups (partner 
controls and random digital dialing). While both may serve a slightly different purpose, results 
pointed in the same direction and were roughly similar when both control groups were 
analyzed separately.
11.2.2 PREVEND study
Major strengths of the PREVEND study as compared with the MEGA study are the presence 
of  data on albuminuria which was assessed in 24-h urine samples and the presence of 
follow-up data to calculate absolute risks. Therefore, in the PREVEND study, absolute risks of 
venous thrombosis could be calculated for chronic kidney disease stages 1 and 2, since both 








































Summary and general discussion
175
11
An important limitation of this cohort study was that the kidney function and the presence 
of albuminuria were assessed long before the occurrence of the disease (mean 4.0 years), 
resulting in a possible dilution of the effect. 
Another limitation was that venous thrombotic events were identified through anticoagulation 
clinic databases and registers for hospital discharge diagnoses and death certificates, which 
could lead to an underestimation of the incidence rates of venous thrombosis by missing 
patients who had venous thrombosis. However, the incidence rates for venous thrombosis 
in the PREVEND cohort (i.e. 1.4 per 1000 person-years) correspond well to those found in 
previous studies.7 
Furthermore, there were only 52 subjects in the PREVEND study with an estimated glomerular 
filtration rate below 45 ml/min. Therefore, we had a limited power to investigate the association 
between venous thrombosis and an estimated glomerular filtration rate below 45 ml/min. 
Previous studies suggested that especially these patients had increased risks of adverse 
outcomes, such as cardiovascular diseases and mortality.8,9 
11.2.3 NECOSAD study
The NECOSAD study is a large and well-defined Dutch cohort of incident hemodialysis 
patients with available data on many patient characteristics, laboratory measurements, and 
death. 
Our studies in the NECOSAD cohort have some potential limitations that should be addressed. 
A limitation of our studies is that comparisons between types of vascular access (catheter, 
fistula or graft) in an observational design could be a problem due to confounding by indication. 
Differences in outcomes for different treatment modalities in dialysis patients may reflect the 
different prognosis at baseline. In our analyses, we took this into account by correcting for 
these confounders, but this cannot exclude possible residual confounding. 
Another limitation of this study is that there were missing values for several laboratory values, 
such as the kidney function and serum albumin. Analyses excluding patients who had a 
missing values could lead to biased results in case missing is influenced by the treatment 
or outcome.10 Therefore, imputation could lead to more reliable results than excluding the 
patients with missing data.10,11
Moreover, we had no detailed information about the type of vascular access. Data about 
the type of catheters (tunnelled or non-tunnelled), the insertion place of the catheters and 










































several arteriovenous access characteristics (anatomic location, flow, vessel diameter, and 
intervention prior to cannulation) that are associated with vascular access dysfunction.  
Furthermore, we had no information about failure of arteriovenous access before the first 
dialysis session. Failure of vascular access before successful cannulation for dialysis is 
higher for fistulas than for grafts.12 Therefore, it could be that graft use as compared with 
fistula use could be beneficial in specific subgroups in terms of morbidity, including number 
of hospitalizations, and quality of life when we take into account the time period between 
creation of a vascular access and the first dialysis session. 
11.2.4 4D-study
We investigated the association between seven single nucleotide variants and all-cause and 
cause-specific mortality in the NECOSAD cohort and replicated these findings in the German 
Diabetes Dialysis Study.  
A potential limitation of this study is that we replicated our results in a dialysis population 
consisting of hemodialysis patients with diabetes mellitus. The NECOSAD cohort also includes 
non-diabetic patients and patients treated with peritoneal dialysis. Therefore, in the 4D-study, 
we could not investigate the association between mortality and singe nucleotide variants in 
peritoneal dialysis patients and in patients without diabetes mellitus. 
11.2.5 ERA-EDTA Registry
The study cohort consisted of more than 100 000 incident dialysis patients derived from the 
European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) 
Registry.13 An important strength of this study, besides its large size, is the presence of data 
on renal replacement therapy, including date of birth, sex, primary kidney disease, date of 
start of renal replacement therapy, dialysis modality at baseline and during follow-up, and date 
and cause of death. 
A potential limitation of our study was that the cause of death was unknown in approximately 
14% of the dialysis patients compared with 2.0% of the general population. This difference 
can be explained by the different method for assigning the cause of death in dialysis patients 
as compared with the general population. Causes of death among patients on dialysis were 
recorded by the primary nephrologist. When a patient died at home or elsewhere outside the 
hospital, the nephrologist will have been dependent on information from others, and may more 
likely report a cause of death as unknown. Conversely, causes of death within the general 
population are, according to law, recorded by the physician who confirmed the death and 
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11.3 Clinical implications and future research
Vascular complications such as venous and arterial thrombosis and vascular access (fistula, 
graft or catheter) related complications are associated with many hospitalizations and deaths 
in chronic kidney disease patients, especially in dialysis patients.14-20
In chapter 2, we showed that self-reported kidney disease was associated with a 3.7-fold 
increased risk of venous thrombosis. Furthermore, we showed that self-reported rheumatoid 
arthritis, multiple sclerosis, heart failure, hemorrhagic stroke and arterial thrombosis in these 
patients were associated with an increased risk of venous thrombosis varying from a 1.5-
fold increased risk for a history of arterial thrombosis and rheumatoid arthritis to a 4.9-fold 
increased risk for hemorrhagic stroke. Also other studies found an association between venous 
thrombosis and including liver disease,21,22 kidney disease,5,6,23 rheumatoid arthritis,21,24 multiple 
sclerosis,25 heart failure,21,26,27 hemorrhagic stroke,28 and arterial thrombosis.21,29,30 Based on 
these estimates, thromboprophylaxis in patients with a major illness seems unjustified, since 
the number needed to treat would be excessively high, while introducing a considerable risk 
of major bleeding. However, risks increased in the presence of immobilization or trombophilia. 
In chapter 3, we showed that patients with chronic kidney disease stage 1 and 2, and 
patients with chronic kidney disease stage 3 in the presence of albuminuria had increased 
risks of venous thrombosis. Patients with chronic kidney disease stage 3 without albuminuria 
had no increased risk of venous thrombosis. These findings are in line with several other 
studies suggesting a higher risk for chronic kidney disease stage 3 subjects with albuminuria 
than for CKD stage 3 subjects without albuminuria for different adverse outcomes, such as 
cardiovascular disease and the development of end-stage renal disease.9,31-33 Based on the 
weak associations between early stages of chronic kidney disease and venous thrombotic 
risk (the incidence rate of subjects without chronic kidney disease was 1.3 per 1000 person-
years and the incidence rate of subjects with chronic kidney disease stages 1-3 was 3.7 
per 1000 person-years), the number needed to treat (approximately 400) will be too high to 
justify thromboprophylaxis for all patients with chronic kidney disease stages 1-3. Further 
studies are needed to show whether venous thrombosis prophylaxis in subgroups of patients 
with early stages of chronic kidney disease in the presence of albuminuria will be safe and 
cost-effective, especially as the high risk of anticoagulant treatment-related major bleeding 
episodes applies to chronic kidney disease stages 4 and 5, and not to the early stages of 
chronic kidney disease.34 
In chapter 4, it was found that impaired kidney function affected venous thrombosis risk 
via concurrently raised factor VIII and von Willebrand factor levels. An increased body mass 










































arterial thrombosis,41,42 immobilization,38 surgery,38 and corticosteroid use43 could not explain 
the association between an impaired kidney function and venous thrombosis. However, the 
exact mechanism through which chronic kidney disease leads to venous thrombosis via 
procoagulant changes (especially increases in factor VIII and von Willebrand factor levels) 
cannot be determined from these data with certainty. As von Willebrand factor and factor VIII 
are markers of endothelial damage,44 it might be that endothelial damage, which is associated 
with chronic kidney disease, leads to increased factor VIII and von Willebrand factor levels 
and eventually to venous thrombosis. According to this view, chronic kidney disease would 
be an epiphenomenon to the risk of venous thrombosis, and the endothelial damage that 
leads to a procoagulant shift would be the underlying cause. Alternatively, the endothelial 
damage could be caused by the chronic kidney disease, which leads to a procoagulant state 
and finally to venous thrombosis. The exact mechanism could be of clinical importance, since 
targeting the actual risk factor could also influence the risk of venous thrombosis. Targeting 
epiphenomena would not influence the risk of venous thrombosis.  
In chapter 5, kidney function showed an inverse association with venous thrombosis risk with 
a nearly 6-fold increased risk for those with severely decreased kidney function (estimated 
glomerular filtration rate <30 ml/min). Those with additional risk factors had an even higher 
risk of thrombosis, particularly patients who were immobilized or underwent surgery (around 
15-fold increased risk). Furthermore, there was a cumulative effect when several risk factors 
were present simultaneously with renal function impairment, with over 50-fold increased risks. 
Furthermore, we showed that a high glomerular filtration rate of more than 125 ml/min was 
also associated with an increased risk of venous thrombosis (odds ratio 1.4; 95% CI 1.0-1.9). 
A high glomerular filtration rate has been shown to be an indicator for early kidney disease and 
a predictor of cardiovascular disease.45-48 Based on the odds ratios of venous thrombosis for 
decreased kidney function ranging from 1.1 for mildly decreased kidney function (estimated 
glomerular filtration rate 60-90 ml/min) to 5.5 for severely decreased kidney function 
(estimated glomerular filtration rate <30 ml/min), thromboprophylaxis is probably not justified 
in all patients with decreased kidney function since it does not seem to outweigh the increased 
bleeding risk associated with decreased kidney function.49,50 Randomized clinical trials are 
needed to investigate whether prophylaxis with anticoagulant medication is beneficial for 
specific subgroups of patients with chronic kidney disease.
In chapter 6 and 7, it was found that dialysis patients have an increased risk for non-fatal and 
fatal myocardial infarction, stroke and venous thrombosis.51,52 This finding was in contrast to 
autopsy studies that showed that venous thrombosis was less common in dialysis patients 
than in non-dialysis patients.53-56 However, autopsy studies are likely to be biased for this kind 
of comparisons. Clinicians should be aware of the increased risk of this disorder in dialysis 
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In chapter 8 and 9, we showed that catheter use compared with arteriovenous access use 
was associated with increased mortality. Furthermore, we showed that graft use as compared 
with fistula use was associated with an increased risk of primary patency loss and with an 
increased mortality risk. Our findings are consistent with the National Kidney Foundation 
Kidney Disease Outcome Quality Initiative guidelines58 and the European Best Practice 
Guidelines59 which recommend the use of a fistulas instead of grafts or catheters for vascular 
access. However, it could be that for subgroups grafts are good alternatives as first option 
for a vascular access, especially when we take into account that failure of vascular access 
before successful cannulation for dialysis is higher for fistulas than for grafts which we did not 
investigate in our studies.12  
In chapter 10, our study showed that factor V Leiden was associated with an increased 
mortality risk in dialysis patients. Further studies are needed to explore the role of coagulation 
abnormalities in dialysis patients and to investigate the pathologic mechanisms of coagulation 
abnormalities in dialysis patients that leads to adverse outcomes. Recent studies also showed 
that single nucleotide variants in the factor V gene were associated with arteriovenous graft 
failure in dialysis patients.60,61 However, the association between factor V Leiden and adverse 
outcomes in dialysis patients are weak and the prevalence of factor V Leiden is too low to 
decide on a strategy to screen all dialysis patients for factor V Leiden. Furthermore, it is 
unknown what the therapeutic consequence should be in case factor V Leiden is found in a 
dialysis patient.   
11.4 Conclusions
The main conclusions of this thesis are:
•	 Kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic 
stroke and arterial thrombosis are associated with an increased risk of venous 
thrombosis.
•	 Patients with chronic kidney disease stages 1–3 had an almost 2-fold increased risk 
of venous thrombosis as compared with subjects without chronic kidney disease.
•	 Impaired kidney function affects venous thrombosis risk via concurrently raised 
factor VIII and von Willebrand factor levels.
•	 Kidney function is inversely associated with venous thrombosis risk with a nearly 
6-fold increased risk for those with severely decreased kidney function (estimated 
glomerular filtration rate <30 ml/min). 
•	 Dialysis patients have an increased risk of fatal and non-fatal venous thrombosis, 
myocardial infarction and ischemic stroke
•	 Catheter use as compared with arteriovenous access use is associated with an 










































•	 Graft use as compared with fistula use is associated with an increased risk of primary 
patency loss and with an increased mortality risk.
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Vasculaire complicaties in nierziekte
Het aantal patiënten met een chronische nierziekte is de afgelopen jaren sterk toegenomen. 
Chronische nierziekte wordt vastgesteld op grond van het niveau van nierfunctie en 
nierschade. Het aantal volwassenen met een chronische nierinsufficiëntie in de Nederlandse 
bevolking wordt geschat op 10%. Chronische nierinsufficiëntie wordt in vijf stadia ingedeeld 
op basis van de nierfunctie en de aanwezigheid van nierschade (albuminurie). Individuen met 
stadium 5 chronische nierinsufficiëntie komen in aanmerking voor dialyse of transplantatie. 
Dialysepatiënten die dialyseren door middel van hemodialyse hebben een vaattoegang in de 
vorm van een fistel (de verbinding tussen ader en slagader zonder een kunststof prothese), 
een graft (de verbinding tussen ader en slagader met een kunststof prothese) of een catheter 
(kunststof slang die in een grote ader in de lies, de hals of onder het sleutelbeen wordt 
ingebracht). 
Een groot gezondheidsprobleem bij patiënten met een nierziekte zijn stolselvormingen in 
slagaders (arteriële trombose), aders (veneuze trombose) en vaatproblemen gerelateerd 
aan vaattoegang bij patiënten op hemodialyse. Deze verschillende vaatproblemen leiden 
tot veel opnamen in het ziekenhuis, tot blijvende gezondheidsschade, tot een verminderde 
kwaliteit van leven en tot een hogere sterfte bij patiënten met een nierziekte. Het doel van 
het onderzoek beschreven in dit proefschrift was meer inzicht te krijgen in de relatie tussen 
nierziekte en trombose en om de mechanismen die leiden tot trombosevorming in patiënten 
met nierziekte te achterhalen. Verder werd de relatie onderzocht tussen bepaalde genetische 
varianten die een rol spelen in het ontwikkelen van veneuze en arteriële trombosen en sterfte 
van dialysepatiënten. Daarnaast werden de sterfterisico’s voor dialysepatiënten met een 
fistel, graft en catheter bestudeerd.
In hoofdstuk 2 werd het risico op veneuze trombose voor zelfgerapporteerde nierziekten 
onderzocht in de MEGA studie (Multiple Environmental and Genetic Assessment of risk 
factors for venous thrombosis). Patiënten met een nierziekte bleken een 4 keer hoger risico 
op veneuze trombose te hebben dan personen zonder een nierziekte. 
Hoofdstuk 3 beschrijft de resultaten van een onderzoek naar de vroege stadia (stadium 1, 2 
en 3) van nierziekte en de relatie met veneuze trombose in de PREVEND studie (Prevention 
of Renal and Vascular Disease). Er werd aangetoond dat patiënten met een nierziekte in 










































Hoofdstuk 4 doet verslag van een onderzoek in de MEGA studie waarin werd onderzocht of 
de relatie tussen nierziekte en veneuze trombose verklaard kon worden door stollingsfactoren, 
body mass index, factor V Leiden, prothrombin G20210A, diabetes mellitus, maligniteit, 
arteriële trombose, immobilisatie of corticosteroid gebruik. We vonden dat verhoogde factor 
VIII en Von Willebrand factorwaarden de relatie tussen nierziekten en veneuze trombosen 
verklaarden.
In hoofdstuk 5 onderzochten we de associatie tussen veneuze trombose en de combinatie 
van nierziekte met andere risicofactoren voor veneuze trombose in de MEGA studie om hoog-
risico groepen te identificeren die baat zouden kunnen hebben van tromboseprofylaxe. Het 
bleek dat vooral patiënten met een nierziekte die geopereerd werden of immobiel waren een 
sterk verhoogd risico hadden op veneuze trombosen. 
Hoofdstuk 6 rapporteert over een onderzoek waarin de risico’s op veneuze trombose, 
myocardinfarct en herseninfarct werden bestudeerd voor dialysepatiënten in de NECOSAD 
studie (Netherlands Cooperative Study on the Adequacy of Dialysis). We toonden aan dat 
dialysepatiënten een 6 keer verhoogd risico hadden op veneuze trombose, een 12 keer 
verhoogd risico op een myocardinfarct en een 8 keer verhoogd risico op een herseninfarct.
In hoofdstuk 7 werden de overlijdensrisico’s op veneuze trombose, myocardinfarct en 
beroerte (herseninfarct of hersenbloeding) onderzocht voor dialysepatiënten in de ERA-EDTA 
database (European Renal Association-European Dialysis and Transplant Association). 
Het bleek dat dialysepatiënten een 12 keer verhoogd risico hadden op overlijden door een 
veneuze trombose, een 11 keer verhoogd risico op overlijden door myocardinfarct en een 
8 keer verhoogd risico op overlijden door een beroerte in vergelijking met de algemene 
bevolking.
    
Hoofdstuk 8 en 9 beschrijft de resultaten van een onderzoek in de NECOSAD studie waarin 
vaattoegangsproblemen werden onderzocht in dialysepatiënten. Het bleek dat patiënten met 
een catheter een hogere sterftekans hadden dan patiënten met een fistel of graft. Daarnaast 
toonden we aan dat patiënten met een graft in vergelijking met patiënten met een fistel een 
hogere kans hadden op het niet functioneren van de vaattoegang en een hogere kans op 
overlijden.
In hoofdstuk 10 onderzochten we de relatie tussen genetische varianten in de ‘Protein C 
pathway’ (factor V Leiden, THBD rs1042580, PROC rs1799808 and 1799809 and PROCR 
rs867186, rs2069951, and rs2069952) en overlijden in dialysepatiënten in de NECOSAD 










































een belangrijke rol in stollingsprocessen en in de vaten. Genetische varianten hierin zijn 
geassocieerd  met arteriële en veneuze trombose. In deze studie bleek dat factor V Leiden was 
gerelateerd met  een verhoogd overlijdensrisico in dialysepatiënten. De andere onderzochte 
genetische varianten waren niet geassocieerd met een verhoogd overlijdensrisico in 
dialysepatiënten.
In de verschillende studies in dit proefschrift kwam naar voren dat patiënten met een 
nierziekte een hoge kans hebben op veneuze trombose, arteriële trombose en op 
vaattoegangsproblemen. Deze bevindingen zouden tot klinische consequenties kunnen 
leiden. Gebaseerd op onze studies die aantoonden dat patiënten met een nierziekte een 
hoger risico hebben op veneuze trombose, zouden bepaalde patiënten met een nierziekte 
baat kunnen hebben van antistollingsmiddelen. Echter, de huidige antistollingsmiddelen 
geven een dermate hoog risico op ernstige bijwerkingen (bloedingen) dat tromboseprofylaxe 
in de vorm van anticoagulantia in alle patiënten met chronische nierziekte waarschijnlijk 
geen netto klinisch voordeel met zich zal meebrengen. Verder toonden we aan dat vooral 
dialysepatiënten met een catheter nadelige uitkomsten ondervinden in vergelijking met 
patiënten met een fistel of graft. Dit zou kunnen suggereren dat een catheter vermeden moet 
worden als vaattoegang. Grote, gecontroleerde, gerandomiseerde studies ontbreken echter. 
Verder onderzoek naar vasculaire complicaties in patiënten met een nierziekte is noodzakelijk 
voor het optimaliseren van de preventie en de behandeling van vasculaire complicaties in 
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